CA2359650A1 - Pharmaceutical preparations and methods for inhibiting tumors - Google Patents
Pharmaceutical preparations and methods for inhibiting tumors Download PDFInfo
- Publication number
- CA2359650A1 CA2359650A1 CA002359650A CA2359650A CA2359650A1 CA 2359650 A1 CA2359650 A1 CA 2359650A1 CA 002359650 A CA002359650 A CA 002359650A CA 2359650 A CA2359650 A CA 2359650A CA 2359650 A1 CA2359650 A1 CA 2359650A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- amino acid
- polypeptide analog
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 138
- 238000000034 method Methods 0.000 title claims abstract description 77
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 53
- 239000000825 pharmaceutical preparation Substances 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 826
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 822
- 229920001184 polypeptide Polymers 0.000 claims abstract description 818
- 239000000203 mixture Substances 0.000 claims abstract description 76
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 74
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 67
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 62
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 50
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 48
- 230000012010 growth Effects 0.000 claims abstract description 39
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims abstract description 35
- 230000028327 secretion Effects 0.000 claims abstract description 31
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 30
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 30
- 230000002357 endometrial effect Effects 0.000 claims abstract description 30
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 30
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 30
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 29
- 230000002611 ovarian Effects 0.000 claims abstract description 29
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 26
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 26
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 26
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract description 22
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 21
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims abstract description 21
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229930192392 Mitomycin Natural products 0.000 claims abstract description 21
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims abstract description 21
- 229940009456 adriamycin Drugs 0.000 claims abstract description 21
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 21
- 229960004316 cisplatin Drugs 0.000 claims abstract description 21
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 21
- 229960000908 idarubicin Drugs 0.000 claims abstract description 21
- 229960000485 methotrexate Drugs 0.000 claims abstract description 21
- 229960004857 mitomycin Drugs 0.000 claims abstract description 21
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims abstract description 20
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims abstract description 20
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims abstract description 20
- 150000004579 taxol derivatives Chemical class 0.000 claims abstract description 20
- 239000002552 dosage form Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims description 296
- 235000001014 amino acid Nutrition 0.000 claims description 170
- 229940024606 amino acid Drugs 0.000 claims description 166
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 114
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 110
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 106
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 104
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 104
- 108010093516 tigapotide Proteins 0.000 claims description 96
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 55
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 53
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 49
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 48
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 48
- 239000004473 Threonine Substances 0.000 claims description 48
- 235000009582 asparagine Nutrition 0.000 claims description 48
- 229960001230 asparagine Drugs 0.000 claims description 48
- 235000003704 aspartic acid Nutrition 0.000 claims description 48
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 48
- 235000013922 glutamic acid Nutrition 0.000 claims description 47
- 239000004220 glutamic acid Substances 0.000 claims description 47
- 108091033319 polynucleotide Proteins 0.000 claims description 45
- 102000040430 polynucleotide Human genes 0.000 claims description 45
- 239000002157 polynucleotide Substances 0.000 claims description 44
- 239000003937 drug carrier Substances 0.000 claims description 42
- 210000004899 c-terminal region Anatomy 0.000 claims description 32
- 150000004676 glycans Chemical class 0.000 claims description 32
- 239000002502 liposome Substances 0.000 claims description 32
- 229920001282 polysaccharide Polymers 0.000 claims description 32
- 239000005017 polysaccharide Substances 0.000 claims description 32
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 26
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 25
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 25
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 25
- 235000018417 cysteine Nutrition 0.000 claims description 25
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 25
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- PNJSAKBBGRRTHL-RBUYSXEJSA-N tigapotide triflutate Chemical compound OC(=O)C(F)(F)F.C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@@H](NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 PNJSAKBBGRRTHL-RBUYSXEJSA-N 0.000 claims 10
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 168
- 125000003275 alpha amino acid group Chemical group 0.000 description 156
- ZRXXHPDJLAQCPC-SFJRRRFZSA-N tigapotide Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@@H](NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 ZRXXHPDJLAQCPC-SFJRRRFZSA-N 0.000 description 73
- 108010020169 beta-microseminoprotein Proteins 0.000 description 71
- 102100025142 Beta-microseminoprotein Human genes 0.000 description 66
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 53
- 108020004414 DNA Proteins 0.000 description 46
- 238000007792 addition Methods 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 45
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 34
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 32
- 238000000338 in vitro Methods 0.000 description 31
- 238000003556 assay Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 25
- 230000004614 tumor growth Effects 0.000 description 23
- 210000002307 prostate Anatomy 0.000 description 22
- 230000009467 reduction Effects 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 21
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 19
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 19
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000011580 nude mouse model Methods 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 229960004679 doxorubicin Drugs 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- -1 paclitaxel) Chemical compound 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 14
- 229940098773 bovine serum albumin Drugs 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 238000000719 MTS assay Methods 0.000 description 13
- 231100000070 MTS assay Toxicity 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 238000002513 implantation Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 238000012762 unpaired Student’s t-test Methods 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 206010053759 Growth retardation Diseases 0.000 description 8
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000011613 copenhagen rat Methods 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 238000011194 good manufacturing practice Methods 0.000 description 8
- 231100000001 growth retardation Toxicity 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000000582 semen Anatomy 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 241000235058 Komagataella pastoris Species 0.000 description 7
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 208000017497 prostate disease Diseases 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 229940123237 Taxane Drugs 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 229960003668 docetaxel Drugs 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 5
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 102000009732 beta-microseminoprotein Human genes 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 230000009422 growth inhibiting effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 4
- 101710182846 Polyhedrin Proteins 0.000 description 4
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- 208000023958 prostate neoplasm Diseases 0.000 description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 239000013585 weight reducing agent Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000013392 nude mouse xenograft model Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000002100 tumorsuppressive effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 101150061183 AOX1 gene Proteins 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 101100045709 Aspergillus terreus (strain NIH 2624 / FGSC A1156) terG gene Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 101100046806 Citrus sinensis TPS1 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 101800002913 Decapeptide 1 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- XIPZDANNDPMZGQ-WHFBIAKZSA-N Gln-Cys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O XIPZDANNDPMZGQ-WHFBIAKZSA-N 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000009021 linear effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof.
In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
Description
PHARMACEUTICAL PREPARATIONS AND METHODS
FOR INHIBITING TUMORS
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate hyperplasia (BPH).
BACKGROUND OF THE INVENTION
The prostate gland, which is found exclusively in male mammals, produces several components of semen and blood and several regulatory peptides. The prostate gland comprises stroma and epithelium cells, the latter group consisting of columnar secretory cells and basal nonsecretory cells. A proliferation of these basal cells as well as stroma cells gives rise to benign prostatic hyperplasia (BPH), which is one common prostate disease. Another common prostate disease is prostatic adenocarcinoma (CaP), which is the most common of the fatal pathophysiological prostate cancers, and involves a malignant transformation of epithelial cells in the peripheral region of the prostate gland. Prostatic adenocarcinoma and benign prostatic hyperplasia are two common prostate diseases, which have a high rate of incidence in the aging human male population. Approximately one out of every four males above the age of 55 suffers from a prostate disease of some form or another. Prostate cancer is the second most common cause of cancer related death :in elderly men, with approximately 96,000 cases diagnosed and about 26,000 deaths reported annually in the United States.
Studies of the various substances synthesized and secreted by normal, benign and cancerous prostates carried out in order to gain an understanding of the pathogenesis of the various prostate diseases reveal that certain c>f these substances may be used as immunohistochemical tumor markers in the diagnosis of prostate disease. The three predominant proteins or polypeptides secreted by a normal prostate gland are: (1) Prostatic Acid Phosphatase (PAP);
FOR INHIBITING TUMORS
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate hyperplasia (BPH).
BACKGROUND OF THE INVENTION
The prostate gland, which is found exclusively in male mammals, produces several components of semen and blood and several regulatory peptides. The prostate gland comprises stroma and epithelium cells, the latter group consisting of columnar secretory cells and basal nonsecretory cells. A proliferation of these basal cells as well as stroma cells gives rise to benign prostatic hyperplasia (BPH), which is one common prostate disease. Another common prostate disease is prostatic adenocarcinoma (CaP), which is the most common of the fatal pathophysiological prostate cancers, and involves a malignant transformation of epithelial cells in the peripheral region of the prostate gland. Prostatic adenocarcinoma and benign prostatic hyperplasia are two common prostate diseases, which have a high rate of incidence in the aging human male population. Approximately one out of every four males above the age of 55 suffers from a prostate disease of some form or another. Prostate cancer is the second most common cause of cancer related death :in elderly men, with approximately 96,000 cases diagnosed and about 26,000 deaths reported annually in the United States.
Studies of the various substances synthesized and secreted by normal, benign and cancerous prostates carried out in order to gain an understanding of the pathogenesis of the various prostate diseases reveal that certain c>f these substances may be used as immunohistochemical tumor markers in the diagnosis of prostate disease. The three predominant proteins or polypeptides secreted by a normal prostate gland are: (1) Prostatic Acid Phosphatase (PAP);
(2) Prostate Specific Antigen (PSA); and, (3) Prostate Secretory Protein of 94 amino acids (PSP94), which is also known as Prostatic Inhibin Peptide (PIP), Human Seminal Plasma Inhibin (HSPI), or (3-microseminoprotein (R-MSP), and which i.s hereinafter referred to as PSP94.
PSP94 is a simple non-glycosylated cysteine-rich protein, and constitutes one of three predominant proteins found in human seminal fluid along with Prostate Specific Antigen (PSA) and Prostate Acid Phosphatase (PAP). PSP94 has a molecular weight of 10.7 kiloDaltaon (kDa), and the complfte amino acid sequence of this protein has already been determined (SEQ ID N0:1). The cDNA and gene for PSP94 have been cloned and characterized (Ulvsback, et al., Biochem.
Biophys. Res. Comm., 164:1310, 1989; Green, et al., Biochem. Biophys.
Res. Comm., 167:1184, 1990). Immunochemical and in situ hybridization techniques have shown that PSP94 is located predominantly in prostate epithelial cells. It is also present, however, in a variety of other secretory epithelial cells (Weiber, et al., Am. J. Pathol., 137:593, 1990). PSP94 has been shown to be expressed in prostate adenocarcinoma cell line, LNCap (Yang, et al., J. Urol., 160:2240, 1998). As well, an inhibitory effect of exogenous PSP94 on t~.zmor cell growth has been observed both in vivo and in vitro (Garde, et al., Prostate, 22:225, 1993; Lokeshwar, et al., Cancer Res., 53:4855, 1993), suggesting that PSP94 could be a negative regulator for prostate carcinoma growth via interaction with cognate receptors on tumor cells.
Native PSP94 has been shown to have a therapeutic modality in treating hormone refractory prostate ~~ancer (and potentially other prostate indications).
Metabolic and immunohistochemical studies have shown that the prostate is a major source of PSP94. PSP94 is involved in the feedback control of, and acts to suppress secretion of, circulating follicle-stimulating hormone (FSH) both in-vitro and in-vivo in adult male rats. PSP94 acts both at the pituitary as well as at the prostate site since both are provided with receptor sites for PSP94.
It has been demonstrated to suppress the biosynthesis and release of FSH from the rat pituitary as well as to possibly affect the synthesis/secretion of an FSH-like peptide by the prostate. These findings suggest that the effects of PSP-94 on tumor growth in vivo, could be attributed to the reduction :in serum FSH levels.
Both PSA and PAP have been studied as tumor markers in the detection of prostate disease, but since both exhibit elevated levels in prostates having benign prostatic hyperplasia (BPH), neither marker is specific and therefore they are of limited utility.
PSP94 is a simple non-glycosylated cysteine-rich protein, and constitutes one of three predominant proteins found in human seminal fluid along with Prostate Specific Antigen (PSA) and Prostate Acid Phosphatase (PAP). PSP94 has a molecular weight of 10.7 kiloDaltaon (kDa), and the complfte amino acid sequence of this protein has already been determined (SEQ ID N0:1). The cDNA and gene for PSP94 have been cloned and characterized (Ulvsback, et al., Biochem.
Biophys. Res. Comm., 164:1310, 1989; Green, et al., Biochem. Biophys.
Res. Comm., 167:1184, 1990). Immunochemical and in situ hybridization techniques have shown that PSP94 is located predominantly in prostate epithelial cells. It is also present, however, in a variety of other secretory epithelial cells (Weiber, et al., Am. J. Pathol., 137:593, 1990). PSP94 has been shown to be expressed in prostate adenocarcinoma cell line, LNCap (Yang, et al., J. Urol., 160:2240, 1998). As well, an inhibitory effect of exogenous PSP94 on t~.zmor cell growth has been observed both in vivo and in vitro (Garde, et al., Prostate, 22:225, 1993; Lokeshwar, et al., Cancer Res., 53:4855, 1993), suggesting that PSP94 could be a negative regulator for prostate carcinoma growth via interaction with cognate receptors on tumor cells.
Native PSP94 has been shown to have a therapeutic modality in treating hormone refractory prostate ~~ancer (and potentially other prostate indications).
Metabolic and immunohistochemical studies have shown that the prostate is a major source of PSP94. PSP94 is involved in the feedback control of, and acts to suppress secretion of, circulating follicle-stimulating hormone (FSH) both in-vitro and in-vivo in adult male rats. PSP94 acts both at the pituitary as well as at the prostate site since both are provided with receptor sites for PSP94.
It has been demonstrated to suppress the biosynthesis and release of FSH from the rat pituitary as well as to possibly affect the synthesis/secretion of an FSH-like peptide by the prostate. These findings suggest that the effects of PSP-94 on tumor growth in vivo, could be attributed to the reduction :in serum FSH levels.
Both PSA and PAP have been studied as tumor markers in the detection of prostate disease, but since both exhibit elevated levels in prostates having benign prostatic hyperplasia (BPH), neither marker is specific and therefore they are of limited utility.
Recently, it has been shown that. PSP94 concentrations in serum of patients with BPH or CaP are significantly higher than normal.
The highest serum concentration of PSP94 observed in normal men is approximately 40 ng/ml, while in men with either BPH or CaP, serum concentrations of PSP94 have been observed in the range from 300-400 ng/ml. Because there exists some overlap in the concentrations of PSP94 in subjects having normal prostates and patients exhibiting either BPH or CaP, serum levels in and of themselves are of little value.
A major therapy in the treatment of prostate cancer is androgen-ablation. While most patients respond initially to this treatment, its effectiveness decreases over time, possibly because of the presence of a het:erogenous population of androgen-dependant and androgen-independent cells to the androgen treatment, while any androgen insensitive cells present would continue to proliferate unabated.
Other forms of cancer, which are currently exacting a heavy toll on population are breast cancer :in women and cancer of the gastrointestinal traces. Currently, the use of various cancer drugs such as mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin and daunomyc:in form part of the therapy for treating such cancers. One drawback to such a therapeutic treatment is the presence of adverse side effects due to the drugs in the concentration ranges required for effective treatment.
Accordingly, it would be advantageous to find a more effective means of arresting ttve growth of prostate, breast and gastrointestinal cancer cells and tumors, which may be used effectively against both androgen sensitive and androgen insensitive cells.
In previous work, described in United States Patent No.
5,428,011, we provided pharmaceutical preparations (i.e., compositions) of native human seminal plasma PSP94 for inhibiting in-vitro and in-vivo cancerous prostate, gastrointestinal and breast tumors. The pharmaceutical preparations included native human seminal plasma PSP94 which could be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from prostate cancer. In another embodiment, the pharmaceutical preparation included a mixture of human seminal plasma PSP94 and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example gastrointestinal cancer.
PSP94 sourced from human seminal fluid carries with it significant risk of contamination with infectious agents (e. g., HIV, hepatitis (a, b, or c), and other viruses and/or prions). Even with the use of harsh chemical treatment, total eradication of such agents cannot be guaranteed. Additionally, human seminal fluid is found in limited supply, thus making bulk production of PSP94 very difficult.
Therefore, the acceptability of human or even xenogeneic sourced PSP94 may be very difficult for both the regulatory authorities and the marketplace.
Therefore, the use of recombinant technology for producing PSP94 would represent a significant advancement, as recombinant PSP94 could be produced both free of pathogens and in an unlimited supply.
Furthermore, the material would be homogeneous from a single lot source, avoiding batch variation.
SU1~IARY OF THE INVENTION
In its first aspect the present invention relates to a polypeptide or a polypeptide analog selected from the group consisting of the polypeptide as set :forth in SEQ ID N0: 3, the polypeptide as set fc>rth in SEQ ID N0: 4, the polypeptide as set forth in SEQ ID N0: 5, and the polypeptide as set forth in SEQ ID N0:
6, a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID NO: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ
ID N0: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q XZ D X1 C X1 XZ C XZ C X3 X1 XZ as set forth in SEQ ID N0: 89, wherein X1 is either gl.utamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X~ is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ
ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5. 'The polypeptide analog mentionned herein may be capable of inhibiting the growth of a tumor or more precisely may be capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelia:L secretion, or benign prostate hyperplasia (BPH).
In a second aspect, the present invention relates to the use of a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID
N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID N0:
5 (PCK3145), and the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID N0: 3, of SEQ ID NO: 4, of SEQ
ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: ?, of SEQ ID N0: 3, of SEQ ID
N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q XZ D X1 C X1 Xz C Xz C X3 X1 XZ as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ :ID NO: 5, a polypeptide analog comprising two to terG units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two t=o fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 °. of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 ° of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 °, of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5 and mixtures) thereof, for inhibiting the growth of a tumor or more precisely for inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
In one embodiment of the second aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug, such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexat:e, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an additional embodiment of the second aspect of the present invention, the polypeptide or polypeptide analog may be used with a pharmaceutically acceptable carrier.
In a further embodiment of the second aspect of the present invention the polypeptide or polypeptide analog may be used with a time-release means such as, for examp:Le, liposomes and polysaccharides for effecting continual dosing of said polypeptide or polypeptide analog.
It other embodiments of the second aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug and a pharmaceutically acceptable carrier, with an anticancer drug and a time-release means, with a pharmaceutically acceptable carrier and a time-release means, or with an anticancer drug, a pharmaceutically acceptable and a time-release means. Some examples of an anticancer drug, a pharmaceutically acceptable carrier and a time-release means are described herein.
In a third aspect, the present :invention relates to a method for treating a patient with a tumor o:r more precisely with prostatic adenocarcinoma, stomach cancer, breast. cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94), a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID
N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ
ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID NO: 9, of SEQ ID N0: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q Xz D X, C X1 Xz C X2 C X3 X1 X~ as set forth in SEQ ID N0:
89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X~ is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ
ID N0: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID
N0: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID
N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID
N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0:
5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 a of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5 and mixtures thereof. The polypeptide analog mentionned herein may be capable of inhibiting the growth of a tumor or more precisely may be capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast= cancer, endometrial, ovarian _g_ or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
The method for treating a patient as described above may result, for example, in the inhibition (e. g., reduction, control, atenuation, prohibition) of the growth of a tumors) in a patient suffering for example from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). The method described above may be performed, for example, by administering to the patient a pharmaceutical composition comprising a polypeptide, a polypeptide analog, or mixtures thereof of the present invention.
In one embodiment of the third aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug, such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an additional embodiment of the third aspect of the present invention, the polypeptide or polypeptide analog may be used with a pharmaceutically acceptable carrier.
In a further embodiment of the third aspect of the present invention the polypeptide or polypeptide analog may be used with a time-release means such as for example, liposomes and polysaccharides for effecting continual dosing of said polypeptide or polypeptide analog.
It other embodiments of the third aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug and a pharmaceutically acceptable carrier, with an anticancer drug and a time-release means, with a pharmaceutically acceptable carrier and a time-release means, or with an anticancer drug, a pharmaceutically acceptable and a time-release means. Some examples of an anticancer drug, a pharmaceutically acceptable carrier and a time-release means are described herein.
In a fourth aspect, the present invention relates to a method for treating a patient with a tumor or more precisely with prostatic adenocarcinoma, stomach cancer, breast. cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition including a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier or a pharmaceutical composition comprising a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID N0: 9, and a polynucleotide having at least 10 to 50 contiguous residues of SEQ ID
N0: 9, and a pharmaceutically acceptable carrier.
In one embodiment of the fourth aspect of the present invention, the vector or the polynucleotide may be used with an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an additional embodiment of t:he fourth aspect of the present invention, the vector or the polynucleotide may be used with a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of said vector.
In further embodiment of the fourth aspect of the present invention, the vector or the polynucle otide may be used with an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof and with a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of said vector or polynucleotide.
In a fifth aspect, the present invention relates to a pharmaceutical composition for inhibiting (e. g., recuding, controling, atenuating, prohibiting) l.he growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperpl<3sia (BPH), comprising:
a) a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID NO: 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0: 6 (Polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID NO: 4, of SEQ
ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D X1 X2 C X3 X1 X: as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ
ID N0: 88, a polypeptide analog comprising SEQ ID N0:
and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine ('ryr), a polypeptide analog having at least of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least '70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and mixtures) thereof, and;
b) an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
In one embodiment of the fifth aspect of the present invention the pharmaceutical composition may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
In a sixth aspect, the present invention relates to a pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:
a) a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID
N0:
2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (Polypeptide 21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0:
(Polypeptide 76-94), a polypeptide analog of at least five cont:.iguous amino acids of SEQ IL> N0: 2, of SEQ
ID
N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID
N0:
6, a polypeptide analog o.f at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0:
4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C Xz C X3 X1 X~ as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), XZ is either t.hreonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide <~nalog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID
N0:
5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ
ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 °s of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and mixtures) thereof, and;
b) a pharmaceutically acceptable carrier.
In one embodiment of the sixth aspect of the present invention the pharmaceutical composition may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
1$ In a second embodiment of the sixth aspect of the present invention the pharmaceutical composition may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
In a third embodiment of the sixth aspect of the present invention, the pharmaceutical composition may further comprise a time-release means and an anticancer drug. Examples of time-release means and anticancer drug are described herein.
In a seventh aspect, the present invention relates to a pharmaceutical composition comprising:
a) A polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID NO: 4, of SEQ
ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D X1 C X1 X2 C
XZ C X3 X1 X:, as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ
ID N0: 88, a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), aspara.gine (Asn), cysteine (Cys), or tyrosine ('ryr), a polypeptide analog having at least 90 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and mixtures) thereof, in a therapeutically effective amount, and;
b) an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof in a therapeutically effective amount.
In one embodiment of the seventh aspect of the present invention the pharmaceutical composit_Lon may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
In an eighth aspect, the present invention relates to a pharmaceutical composition comprising:
a) a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ
ID NO: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID
NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 Xz C X~ C X3 X1 X~ as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine ('Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino a~~id to its amino-terminus wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID
N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID
N0: 5, and rnixture(s) thereof, in a therapeutically effective amount, and;
b) a pharmaceutically acceptable carrier.
In one embodiment of the eighth aspect of the present invention the pharmaceutical composition may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
In a second embodiment of the eight aspect of the present invention, the pharmaceutical composit=ion may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
In a third embodiment of the eight aspect of the present invention, the pharmaceutical composii=i.on may further comprise a time-release means and an anticancer drug. Examples of time-release means and anticancer drug are described herein.
In a ninth aspect, the present invention relates to a pharmaceutical composition for inhibiting (reducing, controling, atenuating, prohibiting) the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising a vector comprising the nucleotide sequence of SEQ ID N0: 9 and a pharmaceutically acceptable carrier, or a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ
ID N0: 9 and a polynucleotide having <~t least 10 to 50 contiguous residues of SEQ ID NO: 9, and a pharmaceutically acceptable carrier.
In one embodiment of the ninth aspect of the present invention, the pharmaceutical composition may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an tenth aspect, the present invention relates to a pharmaceutical composition for inhibiting the grc>wth of a tumor in a patient, comprising a vector comprising the nucleotide sequence of SEQ ID N0: 9 and a pharmaceutically acceptable carrier, or a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID N0: 9 and a polynucleotide having at least 10 to 50 contiguous residues of SEQ ID
N0: 9, and a pharmaceutically acceptable carrier.
In one embodiment of the tenth aspect of the present invention, the pharmaceutical composition may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,do cetaxel, taxane), and mixtures thereof.
In an eleventh aspect, the present invention relates to a method for treating patients with a disease characterized by elevated levels of FSH comprising administering a pharmaceutical composition in an appropriate dosage form, the pharmaceutical composition comprising a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4, the polypeptide as set forth in SEQ ID NO: 5, and the polypeptide as set forth in SEQ ID N0: 6, a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID
NO: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ I:D N0: 5, or of SEQ
ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D X1 C X1 Xz C Xz C X3 X1 X, as set forth in SEQ ID N0: 89, wherein Xl is either glutamic acid (Gl.u), asparagine (Asn) or aspartic acid (Asp), X~ is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ
ID N0: 59 to SEQ ID N0: 88, a polypepti_de analog comprising SEQ ID
NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID
N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID
N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID N0:
5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 °s of its amino a<:id sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5, and mixtures thereof, and a pharmaceutically acceptable carrier in a human dose.
In a twelfth aspect, the present. invention relates to the use of a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID
N0: 4 (polypeptide 7-21), the polypepi=ide as set forth in SEQ ID N0:
5 (PCK3145), and the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ
ID NO: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID
N0: 4, of SEQ ID N0: 5, or of SEQ ID tQO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D Xi C X1 X~ C Xz C X3 X1 X2 as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ :ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a palypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 °. of its amino acid sequence identical to the amino acid sequence .set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 °-<; of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 ° of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixtures) thereof, for treating patients with a disease characterized by elevated levels of FSH.
The use of a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP99 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-'Z1), the polypeptide as set forth in SEQ ID N0: 5 (PCK3145), the polypeptide as set forth in SEQ
ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID
N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q Xz D X1 C X1 X~ C Xz C X3 X1 Xz as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide an<3l.og comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID IJ0:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 ° of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 °. of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 ~ of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5 and mixtures thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.
In accordance with the present invention, rHuPSP94 may be used in a dosage range from about 10 micrograms/kg/day to about 4 milligrams/kg/day, in a dosage range .from about 500 picograms/kg/day to about 1 milligram/kg/day, in a dosage range from about 5 nanograms/kg/day to about 10 micrograms/kg/day or in a dosage range from about 5 nanograms/kg/day to about. 500 nanograms/kg/day.
In accordance with the present invention, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0:
4, the polypeptide as set forth in SEQ ID N0: 5, the polypeptide as set forth in SEQ ID N0: 6, and mixtures thereof may be used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
In accordance with the present invention, the anticancer drug may be mixed or not with a polypeptide=_ or polypeptide analog or mixtures thereof or it may be given separately, by a different route, or even in a different administration schedule (e. g., a different time or day).
In accordance with the present invention administration of the composition may be performed by any suitable routes including administration by injection via the intra-muscular (IM), subcutaneous (SC), intra-dermal (ID), intra-venous (IV) or intra-peritoneal (IP) routes or administration at the mucosal membranes including the oral and nasal cavity membranes using any suitable means.
In accordance with the present invention, the composition may be used to treat gastrointestinal cancer.
It is known in the art that the proteins or polypeptides of the present invention may be made according to methods present in the art. The polypeptides of the present. invention may be prepared for example, from bacterial cell extracts, or through the use of recombinant techniques. Polypeptides of the present invention may, for example, be produced by transformation (transfection, transduction, or infection) of a host cell with all or part of a rHuPSP94 (SEQ ID NO: 2), the decapeptide as set forth in SEQ ID N0:
3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID N0: 5 (PCK3145), and the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94) encoding DNA sequence in a suitable expression vehicle. Examples of suitable expression vehicles comprise for example, plasmids, viral particles, artificial chromosomes and phages. The entire expression vehicle, or a part thereof, may be integrated into the host cell genome. In some circumstances, it is desirable to employ an inducible expression vector.
Any of a wide variety of expression syst=ems may be used to provide the recombinant protein. The precise host cell used is not critical to the invention. Polypeptides of the present invention may be produced in a prokaryotic host (e.g., E. col.i or B. subtilis) or in a eukaryotic host (yeast e.g., Saccharomyces or Pichia Pastoris;
mammalian cells, e.g., monkey COS ce:Ll_s, mouse 3T3 cells (Todaro GJ
and Green H., J. Cell Biol. 17: 299-313, 1963), Chinese Hamster Ovary cells (CHO) (Puck TT et al., J. Exp. Med. 108: 945-956, 1958), BHK, human kidney 293 cells (ATCC: CRL-1573), or human HeLa cells (ATCC:CCL-2); or insect cells).
In a yeast cell expression system such as Pichia Pastoris (P.
Pastoris), DNA sequence encoding polypeptides of the present invention may be clor:ed into a suitable expression vector such as the pPIC9 vector (Invitrogen). Upon introduction of a vector containing the DNA sequence encoding all or part of the polypetides of the present invention into the P. Pastoris host cells, recombination event may occur for example in the AOX1 locus. Such recombination event may place the DNA sequence of the various polypetides of the present invention under the dependency of the AOX1 gene promoter.
Successful insertion of a gene (DNA sequence) encoding polypeptides of the present invention may result in an expression of such polypeptides that is regulated and/or induced by methanol added in the growth media of the host cell (for reference see Buckholz, R.G.
and Gleeson, M.A.G., Biotechnology, 9:1067-1072,1991; Cregg, J.M., et al., Biotechnology, 11:905-910, 1993; Sreekrishna, K., et al., J.Basic Microbiol., 28:265-278, 1988; Wegner, G.H., FEMS Microbiology Reviews, 87:279-284, 1990).
In mammalian host cells, a number of viral-based expression systems may be utilized. For example, in the event where an adenovirus is used as an expression vector for the polypeptides of the present invention, nucleic acid sequence may be ligated to an adenovirus transcript_ion/translation control complex (e. g., the late promoter and tripartite leader sequence). This chimeric gene may be inserted into the adenovirus genome, for example, by in vitro or in vivo recombination. Insertion into a non-essential region of the viral genome (e. g., region E1 or E3) may result in a recombinant virus that is viable and capable of expressing polypeptides of the present invention in infected hosts.
Proteins and polypeptides of the present invention may also be produced by plant cells. Expression vectors such as cauliflower mosaic virus and tobacco mosaic virus and plasmid expression vectors (e.g., Ti plasmid) may be used for the expression of polypeptides in plant cells. Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Rockland, Md.). The methods of transformation or transfection and the choice of expression vehicle are of course to be chosen ac<:ordingly to the host cell selected.
In an insect cell expression system such as Autographa californica nuclear polyhedrosis virus (AcNPV), which grows in Spodoptera frugiperda cells, AcNPV may be used as a vector to express foreign genes. For example, DNA sequence coding for all or part of the polypeptides of the present invention may be cloned into non-essential regions of the virus (for example the polyhedrin gene) and placed under control of an AcNPV promoter, (e. g., the polyhedrin promoter). Successful insertion of a gene (i.e.,DNA sequence) encoding polypeptides of the present invention may result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat encoded by the polyhedrin gene). These recombinant viruses may be used to infect spodoptera frugiperda cells in which the inserted gene is expressed.
In addition, a host cell may be chosen for its ability to modulate the expression of the inserted sequences, or to modify or process the gene product in a specific, desired fashion. Such modifications (e. g., glycosylation) and processing (e. g., cleavage) of protein products may be important for the function of the protein.
Different host cells have characteristics and specific mechanisms for posttranslational processing and modification of proteins and gene products. Of course, cell lines or host systems may be chosen to ensure desired modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.
Such mammalian host cells comprise for example, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, and 3T3.
Alternatively, polypeptides of the present invention may be produced by a stably transfected mammalian cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public; methods for constructing such cell lines are also publicly available. In one example, cDNA encoding the rHuPSP94 protein may be cloned into an expression vector that includes the dihydrofolate reductase (DHFR) gene. Integration of the plasmid and, therefore, DNA sequence of polypeptides of the present invention, into the host cell chromosome may be selected for by including methotrexate in the cell culture media. This selection may be accomplished in most cell types.
Specific initiation signals may also be required for the efficient translation of DNA sequences inserted in a suitable expression vehicle as described above. These signals may include the ATG initiation codon and adjacent sequences. For example, in the event where gene or cDNA encoding polypeptides of the present invention, would not have their own initiation codon and adjacent sequences, additional translational control signals may be needed.
For example, exogenous translational control signals, including, perhaps, the ATG initiation codon, may be needed. It is known in the art that the initiation codon must be in phase with the reading frame of the polypeptide sequence to ensure proper translation of the desired polypeptide. Exogenous translational control signals and initiation codons may be of a variety of origins, including both natural and synthetic.. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators.
As may be appreciated, a number of modifications may be made to the polypeptides and fragments of the present invention without deleteriously affecting the biological activity of the polypeptides or fragments. Polypeptides of the present invention comprises for example, those containing amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are known in the art.
Modifications may occur anywhere in a polypeptide including the polypeptide backbone, the amino acid side-chains and the amino or carboxy termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypepti_des may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications comprise for example, without limitation, acetylation, acylation, addition of acetomidomethyl (Acm) group, ADP-ribosylation, amidation, covalent attachment to fiavin, covalent attachment to a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachmc>nt of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of c:ystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI
anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylat:ion, sulfation, transfer-RNA
mediated addition of amino acids to proteins such as arginylation and ubiquitination (for reference see, Protein-structure and molecular proterties, 2°d Ed., T.E. Creighton, W.H. Freeman and Company, New-York, 1993).
Other type of polypeptide modification may comprises for example, amino acid insertion (i.e., addition), deletion and substitution (i.e., replacement), either conservative or non-conservative (e. g., D-amino acids, desamino acids) in the polypeptide sequence where such changes do not substantially alter the overall biological activity of the polypeptide. Polypeptides of the present invention comprise for example, biologically active mutants, variants, fragments, chimeras, and analogs; fragments encompass amino acid sequences having truncations of one or more amino acids, wherein the truncation may originate from the amino terminus (N-terminus), carboxy terminus (C-terminus), or from the interior of the protein.
Analogs of the invention involve an insertion or a substitution of one or more amino acids. Variants, mutants, fragments, chimeras and analogs may have the biological property of polypeptides of the present invention which is to inhibit growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
Example of substitutions may be those, which are conservative (i.e., wherein a residue is replaced by another of the same general type). As is understood, naturally occurring amino acids may be sub-classified as acidic, basic, neutral and polar, or neutral and non-polar. Furthermore, three of the encoded amino acids are aromatic.
It may be of use that encoded polypepti.des differing from the determined polypeptide of the present invention contain substituted codons for amino acids, which are from the same group as that of the amino acid be replaced. Thus, in some cases, the basic amino acids Lys, Arg and His may be interchangeable; the acidic amino acids Asp and Glu may be interchangeable; the neutral polar amino acids Ser, Thr, Cys, Gln, and Asn may be interchangeable; the non-polar aliphatic amino acids Gly, Ala, Val, Cl.e, and Leu are interchangeable but because of size Gly and Ala are more closely related and Val, Ile and Leu are more closely related to each other, and the aromatic amino acids Phe, Trp and Tyr may be interchangeable.
It should be further noted that if the polypeptides are made synthetically, substitutions by amino acids, which are not naturally encoded by DNA may also be made. For example, alternative residues include the omega amino acids of the .formula NH2(CH2)nCOOH wherein n is 2-6. These are neutral nonpolar amino acids, as are sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleuci_ne, and norleucine.
Phenylglycine may substitute for Trp, Tyr or Phe; citrulline and methionine sulfoxide are neutral nonpolar, cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.
It is known in the art that mutants or variants may be generated by substitutional mutagenesis and retain the biological activity of the polypeptides of the present invention. These variants have at least one amino acid residue in the protein molecule removed and a different residue inserted in its place. For example, one site of interest for substitutional_ mutagenesis may include but are not restricted to sites identified as the active site(s), or immunological site(s). Other sites o.f interest may be those, for example, in which particular residues obtained from various species are identical. These positions may be important for biological activity. Examples of substitutions identified a~> "conservative substitutions" are shown in table 1. If such substitutions result in a change not desired, then other type of substitutions, denominated "exemplary substitutions" in table 1, or as further described herein in reference to amino acid classes, are introduced and the products screened.
In some cases it may be of interest to modify the biological activity of a polypeptide by amino acid substitution, insertion, or deletion. For example, modification of= a polypeptide may result in an increase in the polypeptide's biological activity, may modulate its toxicity, may result in changes in bioavailability or in stability, or may modulate its immunological activity or immunological identity. Substantial modifications in function or immunolo gical identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone i.n the area of the substitution, for example, as a sheet or helical conformation. (b) the charge or hydrophobicity of the molecule at t:he target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties:
(1) hydrophobic: norleucine, methionine (Met), Alanine (Ala), S Valine (Val), Leucine (Leu), I,soleucine (Ile) (2) neutral hydrophilic: Cysteine (Cys), Serine (Ser), Threonine (Thr) (3) acidic: Aspartic acid (Asp), G:Lutamic acid (Glu) (4) basic: Asparagine (Asn), Glutamine (Gln), Histidine (His), Lysine (Lys), Arginine (Arg) (5) residues that influence chain orientation: Glycine (Gly), Proline (Pro); and (6) aromatic: Tryptophan (Trp), Tyrosine (Tyr), Phenylalanine (Phe) Non-conservative substitutions will entail exchanging a member of one of these classes for another.
TABLE 1. Preferred amino acid substitution Original Exemplary substitutionConservative residue substitution Ala(A) Val,Leu, Ile Val Arg(R) Lys,Gln, Asn Lys Asn(N) Gln,His, Lys, Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro Pro His(H) Asn,Gln, Lys, Arg Arg Ile(I) Leu,Val, Leu Phe,Met, Ala, norleucine Leu(L) Norleucine, Ile Ile, Val, Met, Ala, Phe Lys(K) Arg,Gln, Asn Arg Met(M) Leu,Phe, Ile Leu Phe(F) Leu,Val, Ile, Ala Leu Pro(P) Gly Gly Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr Tyr Tyr(Y) Trp,Phe, Phe Val(V) Ile,Thr, Leu Ala,Ser Leu, Met, Phe, norleucine Example of analogs of PCK3145 (SEQ ID NO: 5) exemplified by amino acid substitutions has been illustrated below.
Position 1 5 10 15 SEQ ID NO: 89 X, W Q XZ D X, C X, Xz C X, C X3 X, XZ
For example, X1 could be glutamic acid (i.e., glutamate) (Glu), aspartic acid (aspartate) (Asp), or asparagine (Asn), X~ could be threonine (Thr) or serine (Ser) and X_; could be tyrosine (Tyr) or phenylalanine (Phe).
Amino acids sequence insertions (e. g., additions) include amino and/or carboxyl-terminal fusions ranging in length from one residues to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
Other insertional variants include the fusion of the N- or C-terminus of the protein to a homologous or heterologous polypeptide forming a chimera. Chimeric polypeptides (i.e., chimeras, polypeptide analog) comprise sequence of the polypeptides of the present invention fused to homologous or heterologous sequence. Said homologous or heterologous sequence encompass those which, when formed into a chimera with the polypeptides of the px-esent invention retain one or more biological or in~nunological properties. Examples of homologous sequences fused to PCK3145 (SEQ ID N0: 5) are illustrated below (1 to 79). Such homologous sequences are de_ri.ved as it is the case for PCK3145, from rHuPSP94 (SEQ ID N0: 2).
1) EWQTDNCETCTCYETE (SEQ ID NO: 10) 2) EWQTDNCETCTCYETEI (SEQ ID NO: 11) 3) EWQTDNCETCTCYETEIS (SEQ ID NO: 12) 4) EWQTDNCETCTCYETEISC (SEQ ID NO: 13) 5) EWQTDNCETCTCYETEISCC (SEQ ID NO: 14) 6) EWQTDNCETCTCYETEISCCT (SEQ ID NO: 15) 7) EWQTDNCETCTCYETEISCCTL (SEQ ID NO: 16) 8) EWQTDNCETCTCYETEISCCTLV (SEQ ID NO: 17) 9) EWQTDNCETCTCYETEISCCTLVS (SEQ ID NO: 18) 10) EWQTDNCETCTCYETEISCCTLVST (SEQ ID NO: 19) 11) EWQTDNCETCTCYETEISCCTLVSTP (SEQ ID NO: 20) 12) EWQTDNCETCTCYETEISCCTLVSTPV (SEQ ID NO: 21) 13) EWQTDNCETCTCYETEISCCTLVSTPVG (SEQ ID NO: 22) 14) EWQTDNCETCTCYETEISCCTLVSTPVGY (SEQ ID NO: 23) 15) EWQTDNCETCTCYETEISCCTLVSTPVGYD (SEQ ID NO: 24) 16) EWQTDNCETCTCYETEISCCTLVSTPVGYDK (SEQ ID NO: 25) 17) EWQTDNCETCTCYETEISCCTLVSTPVGYDKD (SEQ ID NO: 26) 18) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDN (SEQ ID NO: 27) 19) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNC (SEQ ID NO: 28) 20) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQ (SEQ ID NO: 29) 21) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQR (SEQ ID NO: 30) 22) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRI (SEQ ID NO: 31) 23) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIF (SEQ ID NO: 32) 24) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFK (SEQ ID NO: 33) 25) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKK (SEQ ID NO: 34) 26) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKE (SEQ ID NO: 35) 27) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKED (SEQ ID NO: 36) 28) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDC (SEQ ID NO: 37) 29) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCK (SEQ ID NO: 38) 30) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKY (SEQ ID NO: 39) 31) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYI (SEQ ID NO: 40) 32) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIV
(SEQ ID NO: 41) 33) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVV
(SEQ ID NO: 42) 34) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVE
(SEQ ID NO: 43) 35) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEK
(SEQ ID NO: 44) 36) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKK
(SEQ ID NO: 45) 37) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKD
(SEQ ID NO: 46) 38) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDP
(SEQ ID NO: 47) 39) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPK
(SEQ ID NO: 48) 40) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKK
(SEQ ID NO: 49) 41) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
(SEQ ID NO: 50) 42) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKTC
(SEQ ID NO: 51) 43) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKTCS
(SEQ ID NO: 52) 44) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSV (SEQ ID NO: 53) 45) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVS (SEQ ID NO: 54) 46) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSE (SEQ ID NO: 55) 47) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSEW (SEQ ID NO: 56) 48) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSEWI (SEQ ID NO: 57) 49) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSEWII (SEQ ID NO: 58) 50) SCYFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 88) 51) CYFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 87) 52) YFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 86) 53) FIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 85) 54) IPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 84) 55) PNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 83) 56) NEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 82) 57) EGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 81) 58) GVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 80) 59) VPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 79) 60) PGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 78) 61) GDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 77) 62) DSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 76) 63) STRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 75) 64) TRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 74) 65) RKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 73) 66) KCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 72) 67) CMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 71) 68) MDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 70) 69) DLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 69) 70) LKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 68) 71) KGNKHPINSEWQT'DNCETCTCYET (SEQ ID NO: 67) 72) GNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 66) 73) NKHPINSEWQTDNCETCTCYET (SEQ ID NO: 65) 74) KHPINSEWQTDNCETCTCYET (SEQ ID NO: 64) 75) HPINSEWQTDNCETCTCYET (SEQ ID NO: 63) 76) PINSEWQTDNCETCTCYET (SEQ ID NO: 62) 77) INSEWQTDNCETCTCYET (SEQ ID NO: 61 ) 78) NSEWQTDNCETCTCYET (SEQ ID NO: 60) 79) SEWQTDNCETCTCYET (SEQ ID NO: 59) Other type of chimera generated by homologous fusion includes new polypeptides formed by the repetition of two or more polypeptides of the present invention. The number of repeat may be, for example, between 2 and 50 units (i.e., repeats). In some instance, it may be useful to have a new polypeptide with a number of repeat greater than 50. Examples of new polypeptides formed by the repetition of PCK3145 (SEQ ID N0: 5) are illustrated below (80 to 82). In some instance, SEQ ID NO: 5 units may be separated by a linker or an adaptor of variable length.
The highest serum concentration of PSP94 observed in normal men is approximately 40 ng/ml, while in men with either BPH or CaP, serum concentrations of PSP94 have been observed in the range from 300-400 ng/ml. Because there exists some overlap in the concentrations of PSP94 in subjects having normal prostates and patients exhibiting either BPH or CaP, serum levels in and of themselves are of little value.
A major therapy in the treatment of prostate cancer is androgen-ablation. While most patients respond initially to this treatment, its effectiveness decreases over time, possibly because of the presence of a het:erogenous population of androgen-dependant and androgen-independent cells to the androgen treatment, while any androgen insensitive cells present would continue to proliferate unabated.
Other forms of cancer, which are currently exacting a heavy toll on population are breast cancer :in women and cancer of the gastrointestinal traces. Currently, the use of various cancer drugs such as mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin and daunomyc:in form part of the therapy for treating such cancers. One drawback to such a therapeutic treatment is the presence of adverse side effects due to the drugs in the concentration ranges required for effective treatment.
Accordingly, it would be advantageous to find a more effective means of arresting ttve growth of prostate, breast and gastrointestinal cancer cells and tumors, which may be used effectively against both androgen sensitive and androgen insensitive cells.
In previous work, described in United States Patent No.
5,428,011, we provided pharmaceutical preparations (i.e., compositions) of native human seminal plasma PSP94 for inhibiting in-vitro and in-vivo cancerous prostate, gastrointestinal and breast tumors. The pharmaceutical preparations included native human seminal plasma PSP94 which could be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from prostate cancer. In another embodiment, the pharmaceutical preparation included a mixture of human seminal plasma PSP94 and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example gastrointestinal cancer.
PSP94 sourced from human seminal fluid carries with it significant risk of contamination with infectious agents (e. g., HIV, hepatitis (a, b, or c), and other viruses and/or prions). Even with the use of harsh chemical treatment, total eradication of such agents cannot be guaranteed. Additionally, human seminal fluid is found in limited supply, thus making bulk production of PSP94 very difficult.
Therefore, the acceptability of human or even xenogeneic sourced PSP94 may be very difficult for both the regulatory authorities and the marketplace.
Therefore, the use of recombinant technology for producing PSP94 would represent a significant advancement, as recombinant PSP94 could be produced both free of pathogens and in an unlimited supply.
Furthermore, the material would be homogeneous from a single lot source, avoiding batch variation.
SU1~IARY OF THE INVENTION
In its first aspect the present invention relates to a polypeptide or a polypeptide analog selected from the group consisting of the polypeptide as set :forth in SEQ ID N0: 3, the polypeptide as set fc>rth in SEQ ID N0: 4, the polypeptide as set forth in SEQ ID N0: 5, and the polypeptide as set forth in SEQ ID N0:
6, a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID NO: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ
ID N0: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q XZ D X1 C X1 XZ C XZ C X3 X1 XZ as set forth in SEQ ID N0: 89, wherein X1 is either gl.utamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X~ is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ
ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5. 'The polypeptide analog mentionned herein may be capable of inhibiting the growth of a tumor or more precisely may be capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelia:L secretion, or benign prostate hyperplasia (BPH).
In a second aspect, the present invention relates to the use of a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID
N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID N0:
5 (PCK3145), and the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID N0: 3, of SEQ ID NO: 4, of SEQ
ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: ?, of SEQ ID N0: 3, of SEQ ID
N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q XZ D X1 C X1 Xz C Xz C X3 X1 XZ as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ :ID NO: 5, a polypeptide analog comprising two to terG units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two t=o fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 °. of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 ° of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 °, of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5 and mixtures) thereof, for inhibiting the growth of a tumor or more precisely for inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
In one embodiment of the second aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug, such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexat:e, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an additional embodiment of the second aspect of the present invention, the polypeptide or polypeptide analog may be used with a pharmaceutically acceptable carrier.
In a further embodiment of the second aspect of the present invention the polypeptide or polypeptide analog may be used with a time-release means such as, for examp:Le, liposomes and polysaccharides for effecting continual dosing of said polypeptide or polypeptide analog.
It other embodiments of the second aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug and a pharmaceutically acceptable carrier, with an anticancer drug and a time-release means, with a pharmaceutically acceptable carrier and a time-release means, or with an anticancer drug, a pharmaceutically acceptable and a time-release means. Some examples of an anticancer drug, a pharmaceutically acceptable carrier and a time-release means are described herein.
In a third aspect, the present :invention relates to a method for treating a patient with a tumor o:r more precisely with prostatic adenocarcinoma, stomach cancer, breast. cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94), a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID
N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ
ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID NO: 9, of SEQ ID N0: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q Xz D X, C X1 Xz C X2 C X3 X1 X~ as set forth in SEQ ID N0:
89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X~ is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ
ID N0: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID
N0: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID
N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID
N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0:
5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 a of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5 and mixtures thereof. The polypeptide analog mentionned herein may be capable of inhibiting the growth of a tumor or more precisely may be capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast= cancer, endometrial, ovarian _g_ or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
The method for treating a patient as described above may result, for example, in the inhibition (e. g., reduction, control, atenuation, prohibition) of the growth of a tumors) in a patient suffering for example from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). The method described above may be performed, for example, by administering to the patient a pharmaceutical composition comprising a polypeptide, a polypeptide analog, or mixtures thereof of the present invention.
In one embodiment of the third aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug, such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an additional embodiment of the third aspect of the present invention, the polypeptide or polypeptide analog may be used with a pharmaceutically acceptable carrier.
In a further embodiment of the third aspect of the present invention the polypeptide or polypeptide analog may be used with a time-release means such as for example, liposomes and polysaccharides for effecting continual dosing of said polypeptide or polypeptide analog.
It other embodiments of the third aspect of the present invention, the polypeptide or polypeptide analog may be used with an anticancer drug and a pharmaceutically acceptable carrier, with an anticancer drug and a time-release means, with a pharmaceutically acceptable carrier and a time-release means, or with an anticancer drug, a pharmaceutically acceptable and a time-release means. Some examples of an anticancer drug, a pharmaceutically acceptable carrier and a time-release means are described herein.
In a fourth aspect, the present invention relates to a method for treating a patient with a tumor or more precisely with prostatic adenocarcinoma, stomach cancer, breast. cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition including a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier or a pharmaceutical composition comprising a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID N0: 9, and a polynucleotide having at least 10 to 50 contiguous residues of SEQ ID
N0: 9, and a pharmaceutically acceptable carrier.
In one embodiment of the fourth aspect of the present invention, the vector or the polynucleotide may be used with an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an additional embodiment of t:he fourth aspect of the present invention, the vector or the polynucleotide may be used with a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of said vector.
In further embodiment of the fourth aspect of the present invention, the vector or the polynucle otide may be used with an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof and with a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of said vector or polynucleotide.
In a fifth aspect, the present invention relates to a pharmaceutical composition for inhibiting (e. g., recuding, controling, atenuating, prohibiting) l.he growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperpl<3sia (BPH), comprising:
a) a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID NO: 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0: 6 (Polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID NO: 4, of SEQ
ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D X1 X2 C X3 X1 X: as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ
ID N0: 88, a polypeptide analog comprising SEQ ID N0:
and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine ('ryr), a polypeptide analog having at least of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least '70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and mixtures) thereof, and;
b) an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
In one embodiment of the fifth aspect of the present invention the pharmaceutical composition may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
In a sixth aspect, the present invention relates to a pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:
a) a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID
N0:
2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (Polypeptide 21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0:
(Polypeptide 76-94), a polypeptide analog of at least five cont:.iguous amino acids of SEQ IL> N0: 2, of SEQ
ID
N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID
N0:
6, a polypeptide analog o.f at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0:
4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C Xz C X3 X1 X~ as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), XZ is either t.hreonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide <~nalog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID
N0:
5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ
ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 °s of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and mixtures) thereof, and;
b) a pharmaceutically acceptable carrier.
In one embodiment of the sixth aspect of the present invention the pharmaceutical composition may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
1$ In a second embodiment of the sixth aspect of the present invention the pharmaceutical composition may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
In a third embodiment of the sixth aspect of the present invention, the pharmaceutical composition may further comprise a time-release means and an anticancer drug. Examples of time-release means and anticancer drug are described herein.
In a seventh aspect, the present invention relates to a pharmaceutical composition comprising:
a) A polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID NO: 4, of SEQ
ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D X1 C X1 X2 C
XZ C X3 X1 X:, as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ
ID N0: 88, a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), aspara.gine (Asn), cysteine (Cys), or tyrosine ('ryr), a polypeptide analog having at least 90 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and mixtures) thereof, in a therapeutically effective amount, and;
b) an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof in a therapeutically effective amount.
In one embodiment of the seventh aspect of the present invention the pharmaceutical composit_Lon may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
In an eighth aspect, the present invention relates to a pharmaceutical composition comprising:
a) a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ
ID NO: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID
NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 Xz C X~ C X3 X1 X~ as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine ('Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino a~~id to its amino-terminus wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID
N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID
N0: 5, and rnixture(s) thereof, in a therapeutically effective amount, and;
b) a pharmaceutically acceptable carrier.
In one embodiment of the eighth aspect of the present invention the pharmaceutical composition may further comprise a time-release means such as, for example, liposomes and polysaccharides for effecting continual dosing of the composition.
In a second embodiment of the eight aspect of the present invention, the pharmaceutical composit=ion may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
In a third embodiment of the eight aspect of the present invention, the pharmaceutical composii=i.on may further comprise a time-release means and an anticancer drug. Examples of time-release means and anticancer drug are described herein.
In a ninth aspect, the present invention relates to a pharmaceutical composition for inhibiting (reducing, controling, atenuating, prohibiting) the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising a vector comprising the nucleotide sequence of SEQ ID N0: 9 and a pharmaceutically acceptable carrier, or a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ
ID N0: 9 and a polynucleotide having <~t least 10 to 50 contiguous residues of SEQ ID NO: 9, and a pharmaceutically acceptable carrier.
In one embodiment of the ninth aspect of the present invention, the pharmaceutical composition may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,docetaxel, taxane), and mixtures thereof.
In an tenth aspect, the present invention relates to a pharmaceutical composition for inhibiting the grc>wth of a tumor in a patient, comprising a vector comprising the nucleotide sequence of SEQ ID N0: 9 and a pharmaceutically acceptable carrier, or a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID N0: 9 and a polynucleotide having at least 10 to 50 contiguous residues of SEQ ID
N0: 9, and a pharmaceutically acceptable carrier.
In one embodiment of the tenth aspect of the present invention, the pharmaceutical composition may further comprise an anticancer drug such as, for example, mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol (i.e., paclitaxel), taxol derivative (e.g.,do cetaxel, taxane), and mixtures thereof.
In an eleventh aspect, the present invention relates to a method for treating patients with a disease characterized by elevated levels of FSH comprising administering a pharmaceutical composition in an appropriate dosage form, the pharmaceutical composition comprising a polypeptide or polypeptide analog selected from the group consisting of rHuPSP94 as set forth SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4, the polypeptide as set forth in SEQ ID NO: 5, and the polypeptide as set forth in SEQ ID N0: 6, a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID
NO: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ I:D N0: 5, or of SEQ
ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D X1 C X1 Xz C Xz C X3 X1 X, as set forth in SEQ ID N0: 89, wherein Xl is either glutamic acid (Gl.u), asparagine (Asn) or aspartic acid (Asp), X~ is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ
ID N0: 59 to SEQ ID N0: 88, a polypepti_de analog comprising SEQ ID
NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID
N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID
N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID N0:
5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 °s of its amino a<:id sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 0 of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID N0: 5, and mixtures thereof, and a pharmaceutically acceptable carrier in a human dose.
In a twelfth aspect, the present. invention relates to the use of a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID
N0: 4 (polypeptide 7-21), the polypepi=ide as set forth in SEQ ID N0:
5 (PCK3145), and the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID NO: 3, of SEQ ID N0: 4, of SEQ
ID NO: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID
N0: 4, of SEQ ID N0: 5, or of SEQ ID tQO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X~ D Xi C X1 X~ C Xz C X3 X1 X2 as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID N0: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID N0: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ :ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a palypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 °. of its amino acid sequence identical to the amino acid sequence .set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 °-<; of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 ° of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixtures) thereof, for treating patients with a disease characterized by elevated levels of FSH.
The use of a polypeptide or a polypeptide analog selected from the group consisting of rHuPSP99 as set forth in SEQ ID N0: 2, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-'Z1), the polypeptide as set forth in SEQ ID N0: 5 (PCK3145), the polypeptide as set forth in SEQ
ID N0: 6 (polypeptide 76-94), a polypeptide analog of at least five contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID
N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID N0: 2, of SEQ ID N0: 3, of SEQ ID N0: 4, of SEQ ID N0: 5, or of SEQ ID N0: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q Xz D X1 C X1 X~ C Xz C X3 X1 Xz as set forth in SEQ ID N0: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), Xz is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide an<3l.og comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID N0:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID N0: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID IJ0:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID N0: 58, a polypeptide analog comprising two to fifty units of SEQ ID N0: 5, a polypeptide analog comprising two to ten units of SEQ ID N0: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 ° of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, a polypeptide analog having at least 70 °. of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5, and a polypeptide analog having at least 50 ~ of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID N0: 5 and mixtures thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.
In accordance with the present invention, rHuPSP94 may be used in a dosage range from about 10 micrograms/kg/day to about 4 milligrams/kg/day, in a dosage range .from about 500 picograms/kg/day to about 1 milligram/kg/day, in a dosage range from about 5 nanograms/kg/day to about 10 micrograms/kg/day or in a dosage range from about 5 nanograms/kg/day to about. 500 nanograms/kg/day.
In accordance with the present invention, the decapeptide as set forth in SEQ ID N0: 3, the polypeptide as set forth in SEQ ID N0:
4, the polypeptide as set forth in SEQ ID N0: 5, the polypeptide as set forth in SEQ ID N0: 6, and mixtures thereof may be used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
In accordance with the present invention, the anticancer drug may be mixed or not with a polypeptide=_ or polypeptide analog or mixtures thereof or it may be given separately, by a different route, or even in a different administration schedule (e. g., a different time or day).
In accordance with the present invention administration of the composition may be performed by any suitable routes including administration by injection via the intra-muscular (IM), subcutaneous (SC), intra-dermal (ID), intra-venous (IV) or intra-peritoneal (IP) routes or administration at the mucosal membranes including the oral and nasal cavity membranes using any suitable means.
In accordance with the present invention, the composition may be used to treat gastrointestinal cancer.
It is known in the art that the proteins or polypeptides of the present invention may be made according to methods present in the art. The polypeptides of the present. invention may be prepared for example, from bacterial cell extracts, or through the use of recombinant techniques. Polypeptides of the present invention may, for example, be produced by transformation (transfection, transduction, or infection) of a host cell with all or part of a rHuPSP94 (SEQ ID NO: 2), the decapeptide as set forth in SEQ ID N0:
3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID N0: 5 (PCK3145), and the polypeptide as set forth in SEQ ID N0: 6 (polypeptide 76-94) encoding DNA sequence in a suitable expression vehicle. Examples of suitable expression vehicles comprise for example, plasmids, viral particles, artificial chromosomes and phages. The entire expression vehicle, or a part thereof, may be integrated into the host cell genome. In some circumstances, it is desirable to employ an inducible expression vector.
Any of a wide variety of expression syst=ems may be used to provide the recombinant protein. The precise host cell used is not critical to the invention. Polypeptides of the present invention may be produced in a prokaryotic host (e.g., E. col.i or B. subtilis) or in a eukaryotic host (yeast e.g., Saccharomyces or Pichia Pastoris;
mammalian cells, e.g., monkey COS ce:Ll_s, mouse 3T3 cells (Todaro GJ
and Green H., J. Cell Biol. 17: 299-313, 1963), Chinese Hamster Ovary cells (CHO) (Puck TT et al., J. Exp. Med. 108: 945-956, 1958), BHK, human kidney 293 cells (ATCC: CRL-1573), or human HeLa cells (ATCC:CCL-2); or insect cells).
In a yeast cell expression system such as Pichia Pastoris (P.
Pastoris), DNA sequence encoding polypeptides of the present invention may be clor:ed into a suitable expression vector such as the pPIC9 vector (Invitrogen). Upon introduction of a vector containing the DNA sequence encoding all or part of the polypetides of the present invention into the P. Pastoris host cells, recombination event may occur for example in the AOX1 locus. Such recombination event may place the DNA sequence of the various polypetides of the present invention under the dependency of the AOX1 gene promoter.
Successful insertion of a gene (DNA sequence) encoding polypeptides of the present invention may result in an expression of such polypeptides that is regulated and/or induced by methanol added in the growth media of the host cell (for reference see Buckholz, R.G.
and Gleeson, M.A.G., Biotechnology, 9:1067-1072,1991; Cregg, J.M., et al., Biotechnology, 11:905-910, 1993; Sreekrishna, K., et al., J.Basic Microbiol., 28:265-278, 1988; Wegner, G.H., FEMS Microbiology Reviews, 87:279-284, 1990).
In mammalian host cells, a number of viral-based expression systems may be utilized. For example, in the event where an adenovirus is used as an expression vector for the polypeptides of the present invention, nucleic acid sequence may be ligated to an adenovirus transcript_ion/translation control complex (e. g., the late promoter and tripartite leader sequence). This chimeric gene may be inserted into the adenovirus genome, for example, by in vitro or in vivo recombination. Insertion into a non-essential region of the viral genome (e. g., region E1 or E3) may result in a recombinant virus that is viable and capable of expressing polypeptides of the present invention in infected hosts.
Proteins and polypeptides of the present invention may also be produced by plant cells. Expression vectors such as cauliflower mosaic virus and tobacco mosaic virus and plasmid expression vectors (e.g., Ti plasmid) may be used for the expression of polypeptides in plant cells. Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Rockland, Md.). The methods of transformation or transfection and the choice of expression vehicle are of course to be chosen ac<:ordingly to the host cell selected.
In an insect cell expression system such as Autographa californica nuclear polyhedrosis virus (AcNPV), which grows in Spodoptera frugiperda cells, AcNPV may be used as a vector to express foreign genes. For example, DNA sequence coding for all or part of the polypeptides of the present invention may be cloned into non-essential regions of the virus (for example the polyhedrin gene) and placed under control of an AcNPV promoter, (e. g., the polyhedrin promoter). Successful insertion of a gene (i.e.,DNA sequence) encoding polypeptides of the present invention may result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat encoded by the polyhedrin gene). These recombinant viruses may be used to infect spodoptera frugiperda cells in which the inserted gene is expressed.
In addition, a host cell may be chosen for its ability to modulate the expression of the inserted sequences, or to modify or process the gene product in a specific, desired fashion. Such modifications (e. g., glycosylation) and processing (e. g., cleavage) of protein products may be important for the function of the protein.
Different host cells have characteristics and specific mechanisms for posttranslational processing and modification of proteins and gene products. Of course, cell lines or host systems may be chosen to ensure desired modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.
Such mammalian host cells comprise for example, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, and 3T3.
Alternatively, polypeptides of the present invention may be produced by a stably transfected mammalian cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public; methods for constructing such cell lines are also publicly available. In one example, cDNA encoding the rHuPSP94 protein may be cloned into an expression vector that includes the dihydrofolate reductase (DHFR) gene. Integration of the plasmid and, therefore, DNA sequence of polypeptides of the present invention, into the host cell chromosome may be selected for by including methotrexate in the cell culture media. This selection may be accomplished in most cell types.
Specific initiation signals may also be required for the efficient translation of DNA sequences inserted in a suitable expression vehicle as described above. These signals may include the ATG initiation codon and adjacent sequences. For example, in the event where gene or cDNA encoding polypeptides of the present invention, would not have their own initiation codon and adjacent sequences, additional translational control signals may be needed.
For example, exogenous translational control signals, including, perhaps, the ATG initiation codon, may be needed. It is known in the art that the initiation codon must be in phase with the reading frame of the polypeptide sequence to ensure proper translation of the desired polypeptide. Exogenous translational control signals and initiation codons may be of a variety of origins, including both natural and synthetic.. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators.
As may be appreciated, a number of modifications may be made to the polypeptides and fragments of the present invention without deleteriously affecting the biological activity of the polypeptides or fragments. Polypeptides of the present invention comprises for example, those containing amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are known in the art.
Modifications may occur anywhere in a polypeptide including the polypeptide backbone, the amino acid side-chains and the amino or carboxy termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypepti_des may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications comprise for example, without limitation, acetylation, acylation, addition of acetomidomethyl (Acm) group, ADP-ribosylation, amidation, covalent attachment to fiavin, covalent attachment to a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachmc>nt of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of c:ystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI
anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylat:ion, sulfation, transfer-RNA
mediated addition of amino acids to proteins such as arginylation and ubiquitination (for reference see, Protein-structure and molecular proterties, 2°d Ed., T.E. Creighton, W.H. Freeman and Company, New-York, 1993).
Other type of polypeptide modification may comprises for example, amino acid insertion (i.e., addition), deletion and substitution (i.e., replacement), either conservative or non-conservative (e. g., D-amino acids, desamino acids) in the polypeptide sequence where such changes do not substantially alter the overall biological activity of the polypeptide. Polypeptides of the present invention comprise for example, biologically active mutants, variants, fragments, chimeras, and analogs; fragments encompass amino acid sequences having truncations of one or more amino acids, wherein the truncation may originate from the amino terminus (N-terminus), carboxy terminus (C-terminus), or from the interior of the protein.
Analogs of the invention involve an insertion or a substitution of one or more amino acids. Variants, mutants, fragments, chimeras and analogs may have the biological property of polypeptides of the present invention which is to inhibit growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
Example of substitutions may be those, which are conservative (i.e., wherein a residue is replaced by another of the same general type). As is understood, naturally occurring amino acids may be sub-classified as acidic, basic, neutral and polar, or neutral and non-polar. Furthermore, three of the encoded amino acids are aromatic.
It may be of use that encoded polypepti.des differing from the determined polypeptide of the present invention contain substituted codons for amino acids, which are from the same group as that of the amino acid be replaced. Thus, in some cases, the basic amino acids Lys, Arg and His may be interchangeable; the acidic amino acids Asp and Glu may be interchangeable; the neutral polar amino acids Ser, Thr, Cys, Gln, and Asn may be interchangeable; the non-polar aliphatic amino acids Gly, Ala, Val, Cl.e, and Leu are interchangeable but because of size Gly and Ala are more closely related and Val, Ile and Leu are more closely related to each other, and the aromatic amino acids Phe, Trp and Tyr may be interchangeable.
It should be further noted that if the polypeptides are made synthetically, substitutions by amino acids, which are not naturally encoded by DNA may also be made. For example, alternative residues include the omega amino acids of the .formula NH2(CH2)nCOOH wherein n is 2-6. These are neutral nonpolar amino acids, as are sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleuci_ne, and norleucine.
Phenylglycine may substitute for Trp, Tyr or Phe; citrulline and methionine sulfoxide are neutral nonpolar, cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.
It is known in the art that mutants or variants may be generated by substitutional mutagenesis and retain the biological activity of the polypeptides of the present invention. These variants have at least one amino acid residue in the protein molecule removed and a different residue inserted in its place. For example, one site of interest for substitutional_ mutagenesis may include but are not restricted to sites identified as the active site(s), or immunological site(s). Other sites o.f interest may be those, for example, in which particular residues obtained from various species are identical. These positions may be important for biological activity. Examples of substitutions identified a~> "conservative substitutions" are shown in table 1. If such substitutions result in a change not desired, then other type of substitutions, denominated "exemplary substitutions" in table 1, or as further described herein in reference to amino acid classes, are introduced and the products screened.
In some cases it may be of interest to modify the biological activity of a polypeptide by amino acid substitution, insertion, or deletion. For example, modification of= a polypeptide may result in an increase in the polypeptide's biological activity, may modulate its toxicity, may result in changes in bioavailability or in stability, or may modulate its immunological activity or immunological identity. Substantial modifications in function or immunolo gical identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone i.n the area of the substitution, for example, as a sheet or helical conformation. (b) the charge or hydrophobicity of the molecule at t:he target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties:
(1) hydrophobic: norleucine, methionine (Met), Alanine (Ala), S Valine (Val), Leucine (Leu), I,soleucine (Ile) (2) neutral hydrophilic: Cysteine (Cys), Serine (Ser), Threonine (Thr) (3) acidic: Aspartic acid (Asp), G:Lutamic acid (Glu) (4) basic: Asparagine (Asn), Glutamine (Gln), Histidine (His), Lysine (Lys), Arginine (Arg) (5) residues that influence chain orientation: Glycine (Gly), Proline (Pro); and (6) aromatic: Tryptophan (Trp), Tyrosine (Tyr), Phenylalanine (Phe) Non-conservative substitutions will entail exchanging a member of one of these classes for another.
TABLE 1. Preferred amino acid substitution Original Exemplary substitutionConservative residue substitution Ala(A) Val,Leu, Ile Val Arg(R) Lys,Gln, Asn Lys Asn(N) Gln,His, Lys, Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro Pro His(H) Asn,Gln, Lys, Arg Arg Ile(I) Leu,Val, Leu Phe,Met, Ala, norleucine Leu(L) Norleucine, Ile Ile, Val, Met, Ala, Phe Lys(K) Arg,Gln, Asn Arg Met(M) Leu,Phe, Ile Leu Phe(F) Leu,Val, Ile, Ala Leu Pro(P) Gly Gly Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr Tyr Tyr(Y) Trp,Phe, Phe Val(V) Ile,Thr, Leu Ala,Ser Leu, Met, Phe, norleucine Example of analogs of PCK3145 (SEQ ID NO: 5) exemplified by amino acid substitutions has been illustrated below.
Position 1 5 10 15 SEQ ID NO: 89 X, W Q XZ D X, C X, Xz C X, C X3 X, XZ
For example, X1 could be glutamic acid (i.e., glutamate) (Glu), aspartic acid (aspartate) (Asp), or asparagine (Asn), X~ could be threonine (Thr) or serine (Ser) and X_; could be tyrosine (Tyr) or phenylalanine (Phe).
Amino acids sequence insertions (e. g., additions) include amino and/or carboxyl-terminal fusions ranging in length from one residues to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
Other insertional variants include the fusion of the N- or C-terminus of the protein to a homologous or heterologous polypeptide forming a chimera. Chimeric polypeptides (i.e., chimeras, polypeptide analog) comprise sequence of the polypeptides of the present invention fused to homologous or heterologous sequence. Said homologous or heterologous sequence encompass those which, when formed into a chimera with the polypeptides of the px-esent invention retain one or more biological or in~nunological properties. Examples of homologous sequences fused to PCK3145 (SEQ ID N0: 5) are illustrated below (1 to 79). Such homologous sequences are de_ri.ved as it is the case for PCK3145, from rHuPSP94 (SEQ ID N0: 2).
1) EWQTDNCETCTCYETE (SEQ ID NO: 10) 2) EWQTDNCETCTCYETEI (SEQ ID NO: 11) 3) EWQTDNCETCTCYETEIS (SEQ ID NO: 12) 4) EWQTDNCETCTCYETEISC (SEQ ID NO: 13) 5) EWQTDNCETCTCYETEISCC (SEQ ID NO: 14) 6) EWQTDNCETCTCYETEISCCT (SEQ ID NO: 15) 7) EWQTDNCETCTCYETEISCCTL (SEQ ID NO: 16) 8) EWQTDNCETCTCYETEISCCTLV (SEQ ID NO: 17) 9) EWQTDNCETCTCYETEISCCTLVS (SEQ ID NO: 18) 10) EWQTDNCETCTCYETEISCCTLVST (SEQ ID NO: 19) 11) EWQTDNCETCTCYETEISCCTLVSTP (SEQ ID NO: 20) 12) EWQTDNCETCTCYETEISCCTLVSTPV (SEQ ID NO: 21) 13) EWQTDNCETCTCYETEISCCTLVSTPVG (SEQ ID NO: 22) 14) EWQTDNCETCTCYETEISCCTLVSTPVGY (SEQ ID NO: 23) 15) EWQTDNCETCTCYETEISCCTLVSTPVGYD (SEQ ID NO: 24) 16) EWQTDNCETCTCYETEISCCTLVSTPVGYDK (SEQ ID NO: 25) 17) EWQTDNCETCTCYETEISCCTLVSTPVGYDKD (SEQ ID NO: 26) 18) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDN (SEQ ID NO: 27) 19) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNC (SEQ ID NO: 28) 20) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQ (SEQ ID NO: 29) 21) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQR (SEQ ID NO: 30) 22) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRI (SEQ ID NO: 31) 23) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIF (SEQ ID NO: 32) 24) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFK (SEQ ID NO: 33) 25) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKK (SEQ ID NO: 34) 26) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKE (SEQ ID NO: 35) 27) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKED (SEQ ID NO: 36) 28) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDC (SEQ ID NO: 37) 29) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCK (SEQ ID NO: 38) 30) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKY (SEQ ID NO: 39) 31) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYI (SEQ ID NO: 40) 32) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIV
(SEQ ID NO: 41) 33) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVV
(SEQ ID NO: 42) 34) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVE
(SEQ ID NO: 43) 35) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEK
(SEQ ID NO: 44) 36) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKK
(SEQ ID NO: 45) 37) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKD
(SEQ ID NO: 46) 38) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDP
(SEQ ID NO: 47) 39) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPK
(SEQ ID NO: 48) 40) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKK
(SEQ ID NO: 49) 41) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
(SEQ ID NO: 50) 42) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKTC
(SEQ ID NO: 51) 43) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKTCS
(SEQ ID NO: 52) 44) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSV (SEQ ID NO: 53) 45) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVS (SEQ ID NO: 54) 46) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSE (SEQ ID NO: 55) 47) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSEW (SEQ ID NO: 56) 48) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSEWI (SEQ ID NO: 57) 49) EWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKT
CSVSEWII (SEQ ID NO: 58) 50) SCYFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 88) 51) CYFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 87) 52) YFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 86) 53) FIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 85) 54) IPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 84) 55) PNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 83) 56) NEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 82) 57) EGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 81) 58) GVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 80) 59) VPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 79) 60) PGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 78) 61) GDSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 77) 62) DSTRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 76) 63) STRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 75) 64) TRKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 74) 65) RKCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 73) 66) KCMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 72) 67) CMDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 71) 68) MDLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 70) 69) DLKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 69) 70) LKGNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 68) 71) KGNKHPINSEWQT'DNCETCTCYET (SEQ ID NO: 67) 72) GNKHPINSEWQTDNCETCTCYET (SEQ ID NO: 66) 73) NKHPINSEWQTDNCETCTCYET (SEQ ID NO: 65) 74) KHPINSEWQTDNCETCTCYET (SEQ ID NO: 64) 75) HPINSEWQTDNCETCTCYET (SEQ ID NO: 63) 76) PINSEWQTDNCETCTCYET (SEQ ID NO: 62) 77) INSEWQTDNCETCTCYET (SEQ ID NO: 61 ) 78) NSEWQTDNCETCTCYET (SEQ ID NO: 60) 79) SEWQTDNCETCTCYET (SEQ ID NO: 59) Other type of chimera generated by homologous fusion includes new polypeptides formed by the repetition of two or more polypeptides of the present invention. The number of repeat may be, for example, between 2 and 50 units (i.e., repeats). In some instance, it may be useful to have a new polypeptide with a number of repeat greater than 50. Examples of new polypeptides formed by the repetition of PCK3145 (SEQ ID N0: 5) are illustrated below (80 to 82). In some instance, SEQ ID NO: 5 units may be separated by a linker or an adaptor of variable length.
80) EWQTDNCETCTCYETEEWQTDNCETCTCYETE (SEQ ID NO: 90) 81) EWQTDNCETCTCYETEEWQTDNCETCTCYETEEWQTDNCETCTCYETE (SEQ ID
NO: 91) 82) EWQTDNCETCTCYETEEWQTDNCETCTCYETEEWQTDNCETCTCYETEEWQTDNCE
TCTCYETE (SEQ ID NO: 92) Heterologous fusion includes new polypeptides made by the fusion of polypeptides of the present invention with heterologous polypeptides. Such polypeptides may include but are not limited to bacterial polypeptides (e.g., betalactamase, glutathione-S-transferase, or an enzyme encoded by the E.coli trp locus), yeast protein, viral proteins, phage prot=eins, bovine serum albumin, chemotactic polypeptides, immunoglobulin constant region (or other immunoglobulin regions), albumin, or ferritin.
Other type of polypeptide modification includes amino acids sequence deletions (e. g., truncations). Those generally range from about 1 to 30 residues, more preferably about 1 to 10 residues and typically about 1 to 5 residues.
A host cell transformed or transfected with nucleic acids encoding the polypeptides of the present invention (i.e., vector containing the DNA sequence of the polypeptides of the present invention) or chimeric proteins formed with the polypeptides of the present invention are also encompassed by the invention. Any host cell, which produces a polypeptide analog, mutant, variant, fragment, or chimera having at least one of the biological properties of the present invention is encompassed by the present invention. For example, such host cell may include bacterial, yeast, plant, insect or mammalian cells. In addition, the polypeptides of the present invention may be produced in transgenic animals. Transformed or transfected host cells and transgenic animals may be obtained using materials and methods that are routinely available to one skilled in the art.
T17: L'TT7T~PTlIATC
General Molecular Biology Unless otherwise indicated, the recombinant DNA techniques utilized in the present invention are standard procedures, known to those skilled in the art. Example of such techniques are explained in the literature in sources such as J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al ., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), T.A. Brown (editor), Essential Molecular Biology: A
Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present) and are incorporated herein by reference.
"Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA
that is a mixture of single- and doub:Le-stranded regions, hybrid molecules comprising DNA and RNA that may be sin_qle-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "po.lynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus "polynucleotide"
embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic o.f viruses and cells.
"Polynucleotide" includes but is not limited to linear and end-closed molecules. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
"Polypeptides" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds (i.e., peptide isosteres). "Polypeptide" refers to both short chains, commonly referred as peptides, oligopeptides or oligomers, and to longer chains generally referred to as proteins.
As described above, polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
As used herein the term "polypeptide analog" relates to mutants, variants, chimeras, fusions, deletions, additions and any other type of modifications made relative to a given polypeptide.
As used herein, the term "homologous" sequence relates to nucleotide or amino acid sequence derived from the rHuPSP94 DNA
sequence or polypeptide.
As used herein, the term "heterologous" sequence relates to DNA
sequence or amino acid sequence of a heterologous polypeptide and includes sequence other than that of PSP94.
As used herein, the term "tumor" relates to solid or non-solid tumors, metastasic or non-metastasic tumors, tumors of different tissue origin including, but not limited to, tumors originating in the liver, lung, brain, lymph node, bone marrow, adrenal gland, breast, colon, pancreas, prostate, stomach, or reproductive tract (cervix, ovaries, endometrium etc.). The term "tumor" as used herein, refers also to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
As used herein, the term "polysaccharide" refers to a substance made of two or more saccharide unit and comprise, for example, chitosan, pectin, chondroitin sulfate, cyclodextrin, dextrans, guar gum, inulin, amylose, and locust bean gum.
As used herein, the term "vector" refers to an autonomously replicating DNA or RNA molecule into which foreign DNA or RNA
fragments are inserted and then propagated in a host cell for either expression or amplification of the foreign DNA or RNA molecule. The term « vector » comprises and is not limited to a plasmid (e. g., linearized or not) that can be used to transfer DNA sequences from one organism to another.
As used herein, the term "time-release encapsulation means"
refers to controlled or sustained release obtained when a pharmaceutical composition is formulai:ed, for example, with polysaccharides, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, dry powders, or transdermal delivery systems. Other controlled release compositions of the present invention include liquids that, upon administration to a mammal, form a solid or a gel in situ. Furthermore, the term "time-s release encapsulation means" or "time-release means" comprises a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycol.ic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crossli.nked or amphipathic block copolymers of hydrogels.
As used herein, "pharmaceutical composition" means therapeutically effective amounts o.f the agent together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or carriers. A "therapeutically effective amount" as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen.
Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e. g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e. g., Tween 20, Tween 80, Pluronic F68, bile acid salts).
Solubilizing agents (e. g., glycerol, polyethylene glycerol), anti-oxidants (e. g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance. Controlled or sustained release compositions include formulation in lipophilic depots (e. g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral routes. In one embodiment the pharmaceutical composition is administered parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally.
Further, as used herein "pharmaceutically acceptable carrier"
or "pharmaceutical carrier" are known in the art and include, but are not limited to, 0.01-0.1 M and preferably 0.05 M phosphate buffer or 0.8 a saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions.
Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's orfixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the 1_Lke. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and t:he like.
Mutants, variants and analogs proteins Mutant polypeptides will possess one or more mutations, which are deletions (e.g., truncations), insertions (e.g., additions), or substitutions of amino acid residues. Mutants can be either naturally occurring (that is to say, purified or isolated from a natural source) or synthetic (for example, by performing site directed mutagenesis on the encoding DNA or made by other synthetic methods such as chemical synthesis). It is thus apparent that the polypeptides of the invention can be either naturally occurring or recombinant (that is to say prepared from the recombinant DNA
techniques).
A protein at least 50 o identical, as determined by methods known to those skilled in the art (for example, the methods described by Smith, T.F. and Waterman M.S. (198:L) Ad. Appl.Math., 2:482-489, or Needleman, S.B. and Wunsch, C.D. (1970) J.Mol.Biol., 48: 443-453), to those polypeptides of the present invention are included in the invention, as are proteins at least 70 °s or 80 o and more preferably at least 90 % identical to the protein of the present invention.
This will generally be over a region of at least 5, preferably at least 20 contiguous amino acids.
"Variant" as the term used herein, is a polynucleotide or polypeptide that differs from reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusion and truncations in the polypeptide encoded by the reference sequence, as discussed herein. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequence of t:he reference polypeptide and the variant are close:Ly similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid by one or more substitutions, additions, deletions, or any combination therefore. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant polynuclotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenes:is techniques or by direct synthesis.
Amino acid sequence variants may be prepared by introducing appropriate nucleotide changes into DNA, or by in vitro synthesis of the desired polypeptide. Such variant include, for example, deletions, insertions, or substitutions of residues within the amino acid sequence. A combination of deletion, insertion and substitution can be made to arrive at the final construct, provided that the final protein product possesses the desired characteristics. The amino acid changes also may alter posttranslational processes such as changing the number or position of the glycocylation sites, altering the membrane anchoring characteristics, altering the intra-cellular location by inserting, deleting or otherwise affecting the transmembrane sequence of the native protein, or modifying its susceptibility to proteolytic cleavage.
It is to be understood herein, that if a "range" or "group" of substances (e.g. amino acids), substitutents" or the like is mentioned or if other- types of a particular characteristic (e. g.
temperature, pressure, chemical structure, time, etc.) is mentioned, the present invention relates to and explicitly incorporates herein each and every specific member and combination of sub-ranges or sub-groups therein whatsoever. Thus, any specified range or group is to be understood as a shorthand way of referring to each and every member of a range or group individually as well as each and every possible sub-ranges or sub-groups encompassed therein; and similarly with respect to any sub-ranges or sub-groups therein. Thus, for example, - with respect to a pressure greater than atmospheric, this is to be understood as specifically incorporating herein each and every individual pressure state, as well as sub-range, above atmospheric, such as for example 2 psig, 5 psig, 20 psig, 35.5 psig, 5 to 8 psig, 5 to 35, psig 10 to 25 psig, to 40 psig, 35 to 50 psig, 2 to 100 psig, etc..;
with respect to a temperature greater than 100° C, this is 15 to be understood as specifically incorporating herein each and every individual temperature state, as well as sub-range, above 100° C, such as for example 101° C, 105° C
and up, 110° C and up, 115° C and up, 110 to 135° C, 115° c to 135° C, 102° C to 150° C, up to 210° C, etc.;
- with respect to a temperature lower than 100° C, this is to be understood as specifically incorporating herein each and every individual temperature state, as well as sub-range, below 100° C, such as for example 15° C and up, 15° C to 40°
C, 65° C to 95° C, 95° C and lower, etc.;
- with respect to residence or reaction time, a time of 1 minute or more is to be understood as specifically incorporating herein each and every individual time, as well as sub-range, above 1 minute, such as for example 1 minute, 3 to 15 minutes, 1 minute to 20 hours, 1. to 3 hours, 16 hours, 3 hours to 20 hours etc.;
- with respect to polypeptides, a polypeptide analog consisting of at least two contiguous amino acids of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog consisting of amino acid 1 and 2, a polypeptide analog consisting of amino acids 2 and 3, a polypeptide analog consisting of amino acids 3 and 4, a polypeptide analog consisting of amino acids 6 and 7, a polypeptide analog consisting of amino acids 9 and 10, a polypeptide analog consisting of amino acids 36 and 37, a _3~_ polypeptide analog consisting of amino acids 93 and 94, etc.
- with respect to polypeptides, a polypeptide analog consisting of at least five contiguous amino acids of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog consisting of amino acids 1 to 5, a polypeptide analog consisting of amino acids 2 to 6, a polypeptide analog consisting of amino acids 3 to 7, a polypeptide analog consisting of amino acids 6 to 10, a polypeptide analog consisting of amino acids 9 to 13, a polypeptide analog consisting of amino acids 36 to 40, a polypeptide analog consisting of amino acids 90 to 94, etc.
- with respect to polypeptides, a polypeptide analog comprising a particular sequence and having an addition of at least one amino acid to its amino-terminus is to be understood as specifically incorporating each and every individual ~>ossibility, such as for example, a polypeptide analog having an addition of one amino acid to its amino-terminus, a polypeptide analog having an addition of two amino acid to its amino-terminus, a polypeptide analog having an addition of three amino acid to its amino-terminus, a polypeptide analog having an addition of ten amino acid to its amino-terminus, a polypeptide analog having an addition of eighteen amino acid to its amino-terminus, a polypeptide analog having an addition of forty amino acid to its amino-terminus, a polypeptide analog having an addition of two hundred amino acid to its amino-terminus, etc.
- with respect to polypeptides, a polypeptide analog comprising a particular sequence and having an addition of at least one amino acid to its carboxy-terminus is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog having an addition of one amino acid to its carboxy-terminus, a polypeptide analog having an addition of two amino acid to its carboxy-terminus, a polypeptide analog having an addition of five amino acid to its carboxy-terminus, a polypeptide analog having an addition of twenty amino acid to its carboxy-terminus, a polypeptide analog having an addition of fifty-three amino acid to its carboxy-terminus, a polypeptide analog having an addition of three hundred amino acid to its carboxy-terminus, etc.
- with respect to polypeptides, a polypeptide analog comprising two to fifty units of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog comprising two units of that particular sequence, a polypeptide analog comprising three units of that particular sequence, a polypeptide analog comprising six units of that particular sequence, a polypeptide analog comprising thirteen units of that particular sequence, a polypeptide analog comprising thirty-five units of that particular sequence, a polypeptide analog comprising fifty units of that particular sequence, etc.
- with respect to polypeptides, a polypeptide analog comprising two to ten units of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog comprising two units of that particular sequence, a polypeptide analog comprising three units of that particular sequence, a polypeptide analog comprising four units of that particular sequence, a polypeptide analog comprising five units of that particular sequence, a pol.ypeptide analog comprising six units of that particular sequence, a polypeptide analog comprising seven units of that particular sequence, a polypeptide analog comprising eight units of that particular sequence, a polypeptide analog comprising nine units of that particular sequence, and a polypeptide analog comprising ten units of that particular sequence.
- with respect to polypeptides, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog of two amino acid units wherein the amino acids are sequentially; Glu and Trp, a polypeptide analog of two amino acid units wherein the amino acids are sequentially; Trp and Glu, a polypeptide analog of three amino acid units wherein the amino acids are sequentially; Trp, Glu, Trp, a polypeptide analog of three amino acid units wherein the amino acids are sequentially; Trp, Trp, Trp, a polypeptide analog of three amino acid units wherein the amino acids are sequentially; Glu, Glu, Trp, a polypeptide analog of three amino acid units wherein the amino acids are, independently of the order; Tyr, Asp, Glu, a polypepti.de analog of three amino acid units wherein the amino acids are, independently of the order; Thr, Asp, Asn, a polypepti.de analog of three amino acid units wherein the amino acids are, independently of the order; Thr, Thr, Asn, a polypepti.de analog of four amino acid units wherein the amino acids are, independently of the order; Glu, Gln, Cys, Asn, a polypeptide analog of four amino acid units wherein the amino acids are, independently of the order; Gl.n, Gln Cys, Trp, a polypeptide analog of four amino acid units wherein the amino acids are, Cys, Cys, Cys, Cys, a polypeptide analog of fourteen amino acid units wherein the amino acids are, independently of the order; Asn, Asp, Glu, Gln, Trp, Cys, Tyr, Thr, Thr, Asp, Asn, Gln, Thr, Cys, a polypeptide analog of fourteen amino acid units wherein the amino acids are, independently of the order; Asp, Asp, Asp, Asp, Trp, Cys, Cys, Trp, Thr, Thr, Thr, Thr, Thr, Cys, a polypeptide analog of fourteen amino acid units wherein the amino acids are, independently of the order; Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, etc.
with respect to polypeptides, a polypeptide analog having at least 90 0 of its amino acid sequence identical to a particular amino acid sequence is to be understood as specifically incorporating each and every individual possibility (excluding 100 ~), such as for example, a polypeptide analog having 90 °; of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 91 ° of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 93 °. of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 97 ~ of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 99 ° of its amino acid sequence identical to that particular amino acid sequence, etc.
- with respect to polypeptides, a polypeptide analog having at least 70 0 of its amino acid sequence identical to a particular amino acid sequence is to be understood as specifically incorporating each and every individual possibility (excluding 100 oj, such as for example, a polypeptide analog having 70 ~ of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 71 0 of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 73 °, of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 88 ° of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 97 °. of its amino acid sequence identical tc: that particular amino acid sequence, a polypeptide analog having 99 ° of its amino acid sequence identical to that particular amino acid sequence, etc.
with respect to polypeptides, a polypeptide analog having at least 50 s of sequence its amino acid identical to a particular a mino acid sequence to be understood as is specifically incorporating d every individual each an possibility (excluding , h as for example, a 100 ~) suc polypeptide analog having of its amino sequence 50 acid identical to that particularaminoacid sequence,a polypeptide analog having of its amino sequence 51 acid identical to that particularaminoacid sequence,a polypeptide analog having of its amino sequence 54 acid identical to that particularaminoacid sequence,a polypeptide analog having . its amino sequence 66 of acid identical to that particularaminoacid sequence,a polypeptide analog having % its amino sequence 70 of acid identical to that particularaminoacid sequence,a polypeptide analog having a its amino sequence 79 of acid identical to that particularaminoacid sequence,a polypeptide analog having . its amino sequence 82 of acid identical to that particularaminoacid sequence,a polypeptide analog having of its amino sequence 99 acid identical to that particularaminoacid sequence,etc.
and similarly with respect to other parameters such as low pressures, concentrations, elements, etc...
It is also to be understood herein that "g" or "gm" is a reference to the gram weight unit; that "C" is a reference to the Celsius temperature unit; and "psig" is a reference to "pounds per square inch gauge".
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts mass spectrometry analysis of polypeptide 7-21 (SEQ
ID N0: 4).
Figure 2 depicts mass spectrometry analysis of polypeptide PCK3145 (SEQ ID N0: 5).
Figure 3 depicts mass spectrometry analysis of polypeptide 76-94 (SEQ
ID NO: 6) .
Figure 4a is a graph depicting the in-vitro inhibitory activity of the decapeptide of SEQ ID N0: 3 on PC-3 cells after 9 days of culture.
Figure 4b is a graph depicting the in-vitro inhibitory activity of the native PSP94 (nPSP94) on PC-3 cells after 9 days of culture.
Figure 5a is a graph depicting the in-vitro inhibitory activity of the decapeptide of SEQ ID N0: 3 on PC-3 cells after 21 days of culture.
Figure 5b is a graph depicting the in-vitro inhibitory activity of the native PSP94 (nPSP94) on PC-3 cells after 21 days of culture.
Figure 6a is a graph depicting the in-vitro inhibitory activity of the decapeptide of SEQ ID N0: 3 on PC-3 cells after 10 days of culture.
Figure 6b is a graph depicting the in-vitro inhibitory activity of the native PSP94 (nPSP94) on PC-3 cel:Ls after 10 days of culture.
Figure 7 depicts a gel showing DNA fragmentation following treatment of PC-3 cells with polypeptide PCK3145 as set forth in SEQ ID N0: 5.
Figure 8 is a graph depicting the results of an apoptosis assay with an ELISA plus kit following polypeptide treatment of PC-3 cells for 72 hours with various concentration of polypeptide 7-21 (SEQ ID N0:
4), polypeptide PCK3145 (SEQ ID N0: 5), polypeptide 76-94 (SEQ ID NO:
6) or native PSP94 (SEQ ID NO: 1).
Figure 9 is a graph depicting in vitro fibroblast cell growth when exposed for 72 hours to various concentration of native PSP94 (nPSP94) (SEQ ID N0: 1) or various concentration of rHuPSP94 (SEQ ID
NO: 2) or polypeptide 7-21 (SEQ ID N0: 4), polypeptide PCK3145 (SEQ
ID N0: 5), or polypeptide 76-94 (SEQ ID NO: 6).
Figure 10 is a graph depicting the effect of polypeptide 7-21 (SEQ ID
N0: 4), polypeptide PCK3145 (SEQ ID N0: 5), polypeptide 76-94 (SEQ ID
N0: 6), and polypeptide 61-75 on the in vitro growth of PC-3 cells after 72 hours.
Figure 11 is a graph depicting the effect of polypeptide 22-36 and polypeptide PCK3145 (SEQ ID N0: 5) on i.n vitro growth of PC-3 cells after 72 hours.
Figure 12 is a graph depicting results of study no. MLL-1 on the anti-tumor efficacy validation of rHuPSP94 (rPSP99) (SEQ ID N0: 2) against Mat Ly Lu (MLL) tumor implanted in nude mice.
Figure 13 is a graph depicting results of study no. MLL-2 on the anti-tumor efficacy validation of rHuPSP94 (rPSP94) (SEQ ID N0: 2) against Mat Ly Lu (MLL) tumor implanted in nude mice.
Figure 14 is a graph depicting tumor volume (tumor growth reduction) in rHuPSP94-treated nude mice.
Figure 15 is a graph depicting tumor volume (tumor growth reduction) in decapeptide (SEQ ID N0: 3)-treated nude mice.
Figure 16 is a graph depicting tumor volume (tumor growth reduction) in control scrambled polypeptide (PB111)-treated mice.
Figure 17 is a graph depicting tumor volume (tumor growth reduction) in native-PSP94 (nPSP94)-treated mice.
Figure 18 is a graph depicting the in vitro inhibitory activity of PCK3145 (SEQ ID N0: 5) on PC-3 cells, after a 72 hours treatment, as measured by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny_L)-2H-tetrazolium,inner salt) assay.
Figure 19 is a graph depicting the in vitro inhibitory activity of native PSP94 (SEQ ID N0: 1) and PCK3145 (SEQ ID NO: 5) (GMP grade) on PC-3 cells, after 48 hours of treatment, as measured by MTS assay.
Figure 20 is a graph depicting the in vitro inhibitory activity of PCK3145 (SEQ ID N0: 5) (GMP grade) on PC-3 cells (ATCC), after 72 hours of treatment, as measured by the MTS assay.
Figure 21 is a graph depicting the in vitro inhibitory activity of PCK3145 (SEQ ID NO: 5)(GMP grade) on PC:-3 cells (ATCC), after a 48 or 72 hours treatment, as measured by the MTS assay.
Figure 22 is a graph depicting the .in vitro inhibitory activity of decapeptide as set forth in SEQ ID N0: 3, polypeptide 7-21 as set forth in SEQ ID N0: 4, polypeptide PCK3145 as set forth in SEQ ID N0:
5, or polypeptide 76-94 as set forth in SEQ ID N0: 6 on PC-3 cells, measured by [3H]-Thymidine uptake assay.
Figure 23 is a graph depicting the in vitro inhibitory activity of decapeptide as set forth in SEQ ID N0: 3, polypeptide 7-21 as set forth in SEQ ID NO: 4, polypeptide PCK3145 as set forth in SEQ ID N0:
5, or polypeptide 76-94 as set forth in SEQ ID NO: 6 on PC-3 cells, measured by [3H]-Thymidine uptake assay.
Figure 24 is a graph depicting the in vitro inhibitory activity of native PSP94 (SEQ ID NO: 1) on PC-3 cells after 72 hours treatment, measured by [3H]-Thymidine uptake assay.
Figure 25 depicts a gel showing DNA fragmentation following treatment of PC-3 cells with PCK3145 (SEQ ID N0: 5) or doxorubicin.
Figure 26 is a graph depicting the in vivo inhibitory activity of PCK3145 (SEQ ID N0: '.>) (0.1 ~g/kg/day and 10 ~g/kg/day) against human PC-3 tumor xenografted in nude mice.
Figure 27 is a graph depicting the in vivo inhibitory activity of PCK3145 (SEQ ID N0: 5) (10 ~g/kg/day to 1000 ~g/kg/day, administered either via the intra-venous or intra-peritoneal route) against human PC-3 tumor xenografted in nude mice.
Figure 28 is a graph depicting the in vivo inhibitory activity of polypeptide 7-21 (:>EQ ID N0: 4), PCK3145 (SEQ ID N0: 5) or polypeptide 76-94 (SE:Q ID N0: 6), given at doses of 1 ~g/kg/day or 10 ~g/kg/day, in Copenhagen rats implanted with Dunning Mat Ly Lu tumors.
Figure 29 is a graph depicting the in vivo inhibitory activity of PCK3145 (SEQ ID N0: 5) or the scrambled polypeptide given at doses of ~tg/kg/day or 100 ~g/kg/day, in Copenhagen rats implanted with Dunning Mat Ly Lu tumors.
Figure 30 is a graph depicting tumor weight at day 18 following PCK3145 (SEQ ID N0: 5) or scrambled polypeptide treatment (10 ~tg/kg/day or 100~tg/kg/day), in Copenhagen rats implanted with Dunning Mat Ly Lu tumors.
Figure 31 is a graph depicting the efficacy of PCK3145 and taxotere (i.e. docetaxel) combination treatment in Nude mice implanted with PC-3 tumor cells in tumor growth retardation.
DETAILED DESCRIPTION OF THE INVENTION
The recombinant human rHuPSP94 expressed in yeast is non-glycosylated and has 10 cystein residues. The molecular weight of rHuPSP94 was determined to be 11.5 kDa, compared to 10.7 kDa for its native counterpart.
Various experimental studies have been carried out in order to determine the efficacy of rHuPSP94 (SEQ ID N0: 2) relative to the native PSP94 secreted by the diseased prostate as tumor suppressive agent. Studies have also been carried out to determine the efficacy of the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID N0: 5 (PCK3145), and the polypept:ide as set forth in SEQ ID N0: 6 (polypeptide 76-94), as tumor suppressive agents. The tumor suppression activity of the polypeptides of the present invention has been monitored by their ability to reduce or inhibit the growth of prostatic adenocarcinoma both in-vivo and in-vitro.
Those results are sununarized below.
Studies were carried out using PC-3 human prostate adenocarcinoma line, which can be maintained both in vivo as a xenograft in nude mice and in vitro as a cell line. In addition, a rat Dunning Mat LyLu prostate tumor, which is a pre-eminent animal model for the study of CaP, was also used. The Dunning tumor is a fast growing, poorly differentiated, transplantable tumor, which can be maintained both in-vivo in the Copenhagen rat and in-vitro as a cell line.
The following examples are offered by way of illustration and not by way of limitation.
PREPARATION OF rHuPSP94 (SEQ ID NO: 2) and polypeptides (SEQ ID NO:
3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6) Recombinant HuPSP94 was cloned and expressed in Pichia pastoris, and then purified and characterized as follows.
Materials DEAF-cellulose (DE52) was purchased from Whatman (Fairfield, New-Jersey). Dialysis membranes and the electro chemiluminescence (ECL) detection kit were purchased from Biolynx Canada(Pierce Inc.).
Broad-range molecular weight markers and Econo-pack columns fitted with flow adapters were purchased from Bio-Rad Labs Ltd (California).
Pellicon device was purchased from Millipore (Massachusetts). Tris-HC1 was obtained from ICN. MES ((2-[N-Morpholino]ethanesulfonic acid) hydrate)was obtained from Sigma. Swine anti-rabbit IgG alkaline-phosphatase conjugates was purchased from DAKO (Denmark). Pichia Pastoris expression Kit version G was from Invitrogen(Carlsbad, California). Non-Radioactive High Prime DIG labeling kit~ was purchased from Boehringer Mannheim (Indianapolis, Indiana). The MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assays were performed using Cell Titer Aqueous Non radioactive cell proliferation assay kit from Promega (Madison, Wisconsin). MRX microtiter plate reader was from Dynex technologies (Chantillly, Virginia). Rabbit polyclonal antiserum against PSP94 was a gift from the late Dr. A. Sheth. All primers were synthesized by Procyon B:iopharma Inc. London, Ontario, Canada.
Cell line and cell culture P. pastoris host strain GS115 (hiss) and all Pichia related products were obtained from Invitrogen. PC-3 (ATCC-# CRL 1435) cell line was obtained from the American Type Cell Culture (ATCC) and maintained in OPTI MEM (minimum essential media) with 10 o fetal bovine serum (FBS). All cell culture products were obtained from GIBCO BRL.
Cloning TA cloning vector (pCR TM 2.1) containing human PSP94 cDNA
including a 20 amino acid leader sequence described previously (Baijal-Gupta, M., et. al., J. Endocr:inol., 165:425-433, 2000) was used to amplify human PSP94 without its leader sequence using appropriate primers. The primers for the polymerase chain reaction (PCR) were designed to contain an EcoRI restriction sites at either end. The 5' primer used was 5'-GGG AAG AAT TCT CAT GCT ATT TCA TA-3' (SEQ ID NO: 7) and the 3' primer, 5'-TGG ATA TCT GCA GAA TTC GGC-3' (SEQ ID N0: 8). The +1 start site for PSP94 (at a Serine residue) has been underlined in the 5' primer described above.
The PCR included 1 cycle of 12 minutes at 94 °C, followed by 25 cycles of 1 minute at 94 °C, 1 minute at 55 °C, 1 minute at 72 °C and a final step of 1 cycle of 10 minutes at 72 °C. PCR amplification of the product was performed using BM ExpandTM High Fidelity PCR System.
The product was run on a 1.5 o agarose gel and the appropriate PCR
product was isolated using Pharmacia Sehphaglass Kit (Bandprep).
Subcloning of the PSF94 insert was performed in pPIC9 vector (Invitrogen). The EcoRI enzyme was used for the restriction digestion of both the plasmid and the PCR products (thus removing PSP94 signal sequence) followed by ligation and transformation, using DHSa cells. The isolated clones were selected for by ampicillin resistance and inserts were identified by restriction mappings. The constructs were sequenced (Robart's sequencing service, London, Ontario) to identify PSP94 insert with a correct sequence as well as proper orientation and reading frame.
Screening for Clones Expressing rHuPSP94 For Pichia pastoris transformation, the spheroplast method was used according to manufacturer's instructions (Invitrogen) using GS115 and KM71 yeast strains. Plasmid pPIC9 with or without the PSP94 insert were linearized using SalI restriction enzyme. Transformed colonies were screened and selected for their ability to produce their own histidine, hence survived on media without histidine. All GS115 transformants scored as Mut+, whereas all KM71 colonies, which did not grow well in the liquid culture, scored as Muts. Hence a number of GS115 clones were screened for production of the highest levels of rHuPSP94 expression.
About a hundred clones were selected and grown into 2 ml of culture media until an optical density at 600 nm (OD600) of approximately 6 was reached. Total DNA was isolated for rapid dot blot analysis in order to detect multiple integrations by Southern blot that would possibly correspond to high rHuPSP94 expressing clones. Two hundred microliters of each culture specimens were denatured and blotted (in duplicate) to a positively charged nylon membrane, placed in a dot blot apparatus. The membrane was subsequently air-dried. The membrane was soaked between two sheets of Whatman 3MM paper for 15 minutes in a solution containing 50mM
ethylenediaminetetraacetic acid(EDTA), 2.5 % beta-mercaptoethanol (BME), pH 9, followed by an incubation of 24 hours at 37 °C with 1 mg/ml Zymolyase 100T, 5 minutes in O.:L N NaOH, 1.5 M NaCl, 0.015 M
sodium citrate pH 7 and two 5 minutes incubation in 2x saline-sodium citrate (SSC). Finally the membrane was baked at 80 °C for 45 minutes and exposed to ultraviolet light (UV) for 15 minutes. Human PSP94 cDNA probe was labeled with the non-radioactive High Prime DIG
labeling kit~ (Boehringer Mannheim) and was used for hybridization.
Hybridization with digoxigenin labeled cDNA probe (25ng/Ltl) was done for 2 days at 42 °C in Sodium dodecyl sulfate(SDS) buffer (SDS 7 0 (w/v); formamide 50 ='', (v/v); 5 X SSC; 50 mM sodium phosphate, pH 7.0;
N-lauroyl-sarcosine 0.1 % (w/v)) and blocking reagent, CSPD~ 2 (w/v) (Boehringer Mannheim) was used as the chemi.luminescence substrate. All digoxigenin (DIG) labeling procedures were performed according to the manufacturer's instruction. Detection was performed using the Hyper film-ECL product (Amersham Life Science Inc.
Arlington Hts, Illinois).
The clone with the highest signal intensity was used for all flasks shaken cultures.
timization of the Expression of the Protein in Flask Shaken Cultures A clone containing the PSP94 construct was selected for high expression of the protein. Colony was grown in 25m1 of basal minimum growth media (BMG) until an OD600 between 2 and 6 was obtained. This clone was further amplified in Baffled Erlenmeyer flasks in a volume of 1 liter of BMG media until the OD600 reached approximately between 2.0 to 6Ø The culture was centrifuged for 15 minutes at 2500 X g and the pellet was collected. The induction phase (i.e., induction of expression of rHuPSP94) was carried out by inoculating the cell pellet in basal minimum media (BMM). Growth was performed in Baffled flasks for 6 days, as recommended by :Cnvitrogen. The volume of BMM
added varied according to the size of the pellet collected. Five milliliters of 100 °s methanol were added for each liter of culture.
This was performed each day, around the same time, to a final concentration of 0.1 °s of methanol. A plasmid without the PSP94 insert served as a negative control.
To determine the optimum time for harvesting rHuPSP94 secreted in the cell culture media, aliquots were taken every 24 hours for 6 days, starting from the first day of induction. Levels of rHuPSP94 protein expression were determined by measuring OD600 and by performing a 15 o SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) stained with Coomassie Brilliant. blue or by Western blot analysis using polyclonal antibody against PSP94.
Sample Preparation Culture supernatant of clone showing the highest rHuPSP94 expression, post-induction (e.g., after 96 hours), was centrifuged at 2500 X g for 20 minutes. The supernatant was filtered through a 0.8 um filter and concentrated approximately 10-fold using a Pellicon unit (Millipore). The filtered supernatant was dialyzed against 0.05 mM Tris-HCl buffer, pH 8.0, using a 3500 molecular weight cut-off membrane. An aliquot of the dialyzed supernatant was analyzed by SDS-PAGE and Western blot analysis and the rest was submitted to further purification.
Culture Conditions for Fermentation Fermentation was carried out at the Institute for Biological Sciences, National Research Council (NRC) (Ottawa, Ontario Canada), following manufacturer's instruction (Invitrogen). For example, a fermentation procedure was initiated by inoculating 7.5 liter of media with 625 ml of a starting culture. The growth phase was carried out for approximately 2 days :in BMG media until the OD600 reached approximately 0.5. The induction phase was initiated by the addition of methanol (100 %), according to the manufacturer's instructions (Invitrogen). The culture was harvested after 95 hours (i.e., after induction with methanol for 67 hours). The final volume of the culture was approximately 13.5 liters.
Sample Preparation from Fermentation Culture The large cell. mass was removed by centrifugation. The cell free media collected (9 liters) was further clarified using a 0.2 ~m filtration unit (Pellicon). The remaining 8.5 liters containing secreted rHuPSP94 was tested for protein expression and stored at -20 °C for further isolation and puri.fi_cation of the protein.
Protein Estimation The amount of rHuPSP94 protein secreted in the culture supernatant from the flask shaken and the fermentation process was obtained based on estimates of band intensities of samples compared to band intensities of a standard curve obtained by loading known quantities of pure lyophilized PSP94 on a SDS-PAGE. The initial estimate for rHuPSP94 at each step of purification was determined by OD at 280 nm. Quantification of total protein content at the final steps of purification was done by the BCA (bicinchoninic acid) method, using bovine serum albumin (BSA) as standard.
Lyophilization Samples of purified rHuPSP94 were dialyzed against deionized water using a 3000 molecular weight cut-off membrane and were lyophilized.
SDS-PAGE
SDS-PAGE was performed using acrylamide at a final concentration of 15 °, for the separating portion of the gel and acrylamide at a final. concentration o.f 5 °s for the stacking portion of the gel. The gel contained 0.1 °s SDS and was performed under reducing conditions. Broad-range molecular weight markers were used for the estimation of molecular weight of the protein. Proteins were stained with Coomassie Brilliant Blue R-250.
Western Blotting For immunoblotting, Mini Trans-Blot Electrophoretic Transfer Cell (Bio Rad) was used with Hi bond-C super membrane (Amersham) and 85mm blotting papers. Protein samples (0.4 ug) were loaded and separated on SDS-PAGE, as described earlier. Proteins were transferred to the membrane for 2 hours at 4 °C, using transfer buffer (25 mM Tris, 1.92 mM Glycine, pH 8.3 and 20 o methanol) and a transfer unit set at 200 milliamperes (mAmp). Membranes were blocked overnight by incubation in 2 0 (w/v) non-fat dry milk (skim milk) disolved in tris buffer saline (TBS: 500 mM NaCl, 20 mM Tris-HCl, pH
7.5) at room temp (RT). Membranes were washed three times with TBS
containing 0.02 0 (v/v) Tween-20 (this buffer is named TTBS).
Membranes were subsequently incubated for 2 hours at RT with anti-PSP94 antibody (1:2060 dilution) diluted in TTBS containing 2 o skim milk. Membranes were washed twice with TTBS (5 minutes each washing), and incubated at RT with a secondary antibody (i.e., swine anti-rabbit antibody HRP conjugated) (1:5000 dilution) diluted in TTBS. Membranes were washed twice with 0.02 o TTBS (5 minutes each washing). Blots were developed using the ECL detection system, according to manufacturer's instructions, using the Super Signal Substrate, and exposed to a Hyperfilm ECL from Amersham LS for 5 to 20 seconds. Pre-stained molecular weight markers were used for molecular weight estimation.
Purification of rHuPSP94 using DE52 Column Chromatography Following remc>val of P. pastoris cells from the fermentation culture, supernatant was concentrated approximately ten fold, dialyzed and subjected to anion exchange chromatography. A DE52 column having a bed volume of approximately 40 ml (2.5 cm internal diameter (id) X 8 cm height(h)) was equilibrated with 0.05 M Tris-HC1, pH 8.0 (equilibrating buffer). The sample (25 ml) containing 15 to 20 mg of rHuPSP94 protein was applied to the DE52 column at a flow rate of 1 ml/minute.
Impurities were removed from the column by washing it with 40 to 50 ml of the equilibrating buffer, and monitoring the absorbance at 280 nm. This step was followed by the addition of 100 to 150 ml of 0.05 M Tris-HC1, 1>H 6.5 to the column until the pH of the wash reached approximately 6.5. The column was further washed with 100 to 150 ml of 0.05 M MES-acetate buffer, pH 6.5, until the absorbance at 280nm approached zero. Finally rHuPSP94 was eluted from the column with 0.05 M MES-acetate buffer, pH 5Ø Peak fractions were characterized by absorbance at 280 nm, followed by SDS-PAGE and Western blot analysis as described above. Fractions with high absorbance at 280 nm values (0.5 to 1.8) were pooled and dialyzed against water or PBS for storage at -20 °C and/or lyophilization.
Amino acid Composition Amino acid analysis of the DE52 purified flask shaken culture and fermentation cultures was carried out. The Perkin Elmer Biosystems Derivatizer-Analysis system was used with Spheri-5 PTC C-18 5~ column and UV detection at OD254.
Mass Spectral analysis PSP94 derived polypeptides were synthesized, were found to be in accordance with the required specifications and were analyzed by Mass Spectral Analysis. Mass spectrometry analysis of polypeptide 7-21 (SEQ ID N0: 4), PCK3145 (SEQ ID N0: 5) and polypeptide 76-94 (SEQ
ID N0: 6) are represented in figures 1, 2 and 3 respectively.
Polypeptide samples were analyzed using the PerSeptive Biosystems (Framingham, MA), with Voyager-DE MALDI-TOF mass spectrometer using 337 nm light from a nitrogen laser. About 12 to 50 scans were averaged for each analysis.
Purified samples from the flask shaken culture and fermentation culture were analyzed using the PerSeptive Biosystems (Framingham, MA), with Voyager-DE MALDI:-TOF mass spectrometer using 337 nm light from a nitrogen laser. About 50 scans were averaged for each analysis. A sample from the native PSP94 was also analyzed under similar conditions for comparison.
IN-VITRO EFFECT OF rHuPSP94 ON PC-3 CELLS
(MTS ASSAY) The biological activity of the rHuPSP94 was determined by its growth inhibitory effect on human prostate cancer cells PC-3. Cell proliferation was monitored on PC-3 cells using the MTS/PMS
(phenazine methosulfate) kit (Promega), which primarily measures mitochondrial activity of live cells. The basic principle of this method involves the fact that the mitochondrial enzymes of the live cells metabolize the MTS/PMS dyes forming a brown colored precipitate which can be measured as optical density (OD) by absorption at 490 nm in a spectrophotometer. Therefore, the OD values are proportional to the number of living cells. In addition, monitoring of cell morphology was also performed. Cell morphology would be indicative of their health status. For example, viable cells would appear adherent and spread out whereas dead cells would be in suspension in the media and would appear granular and round.
Results of in vitro effect of rHuPSP94 on PC-3 cells measured by MTS assay are summarized in table 2, below. PC-3 cells (ATCC, Lot AT06) used in these experiments were at: a passage number lower or equal to 70 (n >_ 70). Cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~g/ml of bovine serum albumin (BSA) and 0.1 ~M FeS09. Peptide was diluted in the same media. Cells were continuously exposed to the polypeptides of the present invention for 72 hours without changing media. Native PSP94 or rHuPSP99 concentrated two fold were directly added to wells and diluted to 1X in order to minimize cell manipulation and avoid detachment.
The evaluation of growth inhibitory effect of rHuPSP94 on PC-3 cells indicated a substantial reduction in cell numbers (i.e., viability) ranging from 37 % to 57 % reduction at concentrations of 80 and 120 ~g/ml of rHuPSP94 respectively. This effect was observed in 3 out of 4 experiments (Table 2). Results of trypan blue exclusion test demonstrated a cell viability of 62 o at 80 ~g/ml.
ExperimentSample ~ Viability (control = 100 0 (~g/ml) no. 40 60 80 120 1 rHuPSP94 72 78 58 43 2 rHuPSP94 63 63 63 68 3 rHuPSP94 95 85 78 ND
4 rHuPSP94 100 52 62 60 5 rHuPSP94 100 98 90 52 Sample ~ Viability (control = 100 0 (~g/ml) rHuPSP94 98 84 78 70 55 rHuPSP94 92 95 80 71 59 rHuPSP94 89 69 79 68 65 IN-VITRO EFE'ECT OF rHuPSP94 ON PC-3 CELLS
([3H]-THYMIDINE UPTAKE ASSAY) The in vitro growth inhibition effect of rHuPSP94 was assessed using [3H]-Thymidine uptake assay. [3H]-Thymidine uptake assay involves [3H]-Thymidine incorporation into cellular DNA of actively proliferating cells. It measures the proliferative index of the cells versus the MTS assay, which quantifies the number of lived cells following treatment. Cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~tg/ml of bovine serum albumin (BSA) and 0.1 ~tM E'eS09. PC-3 cells were exposed to various concentrations of rHuPSP94 for 72 hours and during the final 16 hours of incubation cells were pulsed with 1 ~tCi of [3H]-Thymidine. The radioactivity in each well of the plate is counted by a beta-counter and is expressed as total counts per minutes (cpm).
Results of in vitro effect of rHuPSP94 on PC-3 cells using the ~[H]-Thymidine uptake assay are summarized in Table 3 and are expressed as percentage of radioactivity measured for treated-cells relative to the radioactivity measured for non-treated cells (for which [3H]-thymidine uptake value was set at 100 °).
Results indicated a 65 o reduction in the percentage of cells incorporating [3H]-thymidine following treatment with rHuPSP94 at a concentration of 80 ~g/ml for 72hrs, compared to the non-treated control. Results of a 65 ~ reduction _in [3H]-thymidine uptake may also be an indication of a 65 o reduction in cell. proliferation.
Comparison was performed between [3H]-Thymidine uptake assay and the MTS assay, in order to evaluate their relative sensitivity.
An additional plate was set aside for MTS assay and treated in parallel with the same lot (i.e., batch) of rHuPSP94 as the one used for the [3H]-thymidine uptake assay. Result obtained for the MTS
assay demonstrated a 35 % reduction in cell viability (65 % cells remaining viable) following treatment with rHuPSP94 at a concentration of 80 ~tg/ml, indicating that the [3H]-Thymidine uptake assay, which was able to measure a 65 °. reduction in cell proliferation, may be more sensitive than the MTS assay.
ExperimentSample 3[H]-Thymidine no. Uptake ($
of control) (~g~ml) 5 1.0 20 40 80 1 rHuPSP94 94 101 98 79 35 1 native PSP94 97 98 100 98 77 IN-VITRO EFFECT OF DECAPEPTIDE AND OTHER POLYPEPTIDE ON
The synthetic decapeptide (SEQ ID N0: 3) has been shown herein to mimic the biological activity of native PSP94 (nPSP94)(SEQ ID NO:
1) and therefore its effect on the PC-3 cells was studied in clonogenicity assay (colony formation). Cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~tg/ml of bovine serum albumin (BSA) and 0.1 ~M FeS09.
Clonogenicity was evaluated for PC-3 cells grown in the presence of various concentration of the decapeptide after 9 days of culture (Figure 4a). A parallel experiment was performed with various concentration of nPSP94 using the same experimental conditions (Figure 4b). Other experiments evaluating clonogenicity was performed with the decapeptide (Figure 5a) or nPSP94 (Figure 5b) after 21 days of culture as well as after 10 days of culture (Figure 6a: Decapeptide and figure 6b: nPSP94).
Referring to Figures 4 to 6, the decapeptide (SEQ ID N0: 3) had a similar inhibitory action as nPSP94 (SEQ ID NO: 1) on in-vitro PC-3 cells studied. Results indicated a 40 % decrease in colony number for cells incubated with the decapeptide (SEQ ID N0: 3) at a concentration of 1 ~g/ml. A decrease in colony number of up to 60 $
was observed for the decapeptide (SEQ ID N0: 3) at a concentration of 10 ~tg/ml.
DNA FRAGMENTATION ASSAY
Cell apoptosis result in DNA fragmentation can be evaluated by the presence of a DNA ladder visualized when DNA is run on a 1.2 °s agarose gel. DNA ladder assay (apoptosis assay) was performed following exposure of PC-3 to various concentrations of the polypeptides for 72 hours. The polypeptides that were used in this particular experiment are polypeptide 7-21 (SEQ ID NO: 4), polypeptide PCK3145 (SEQ ID N0: 5) and polypeptide 76-94 (SEQ ID N0:
6). Visualization of DNA isolated and run on 1.2 o agarose gel, demonstrated that every polypeptides tested induced a DNA laddering effect characteristic. of apoptosis. This effect was especially evident following treatment with PCK3145 (SEQ ID N0: 5), which is illustrated by figure 7. Lane 1 of the gel illustrated in figure 7 represents a lambda FiindIII digest standard. Lane 2 of the gel illustrated in figure 7 represents DNA laddering effect obtained for doxorubicin-treated cells. Lane 3 of the gel illustrated in figure 7 represents DNA laddering effect obtained for cells incubated with 40 ~g of nPSP94. Lane 4 of the gel illustrated in figure 7 represents DNA laddering effect obtained for cel:Ls incubated with 20 ~tg of nPSP94. Lane 5 of the gel illustrated in figure 7 represents DNA
laddering effect obtained for cells incubated with 22.5 ~M of PCK3145 (SEQ ID N0: 5). Lane 6 of the gel illustrated in figure 7 represents DNA laddering effect obtained for cells incubated with 45~M of PCK3145 (SEQ ID N0: 5).
APOPTOSIS ASSAY BY ELISA PLUS
The three polypeptides (SEQ ID N0: 4, SEQ ID NO: 5 and SEQ ID
NO 6) and native PSP94 used here as a positive control were tested in ELISA plus assay to measure cell death through apoptosis. Briefly, the ELISA plus assay is a sandwich enzyme immunoassay able to measure mono- and oligonucleosomes present in the cytoplasmic fraction of cell lysate using two antibodies, one directed against DNA and the other directed against histones. The apoptotic cell death is characterized by activation of endogenous endonucleases (e. g., calcium- and magnesium-dependant), which cleave double-stranded DNA
at the most accessible internucleosomal_ linker region, generating mono- and oligonucleosomes. The enrichment of mono- and oligonucleosomes in the cytoplasm of the apoptotic cells is due to the fact that DNA degradation occurs several hours before plasma membrane breakdown.
Four thousand cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~g/ml of bovine serum albumin (BSA) and 0.1 ~tM FeS09. The PC-3 cells were treated with various concentrations (22.5 ~M to 90 ~M) of polypeptides for 72 hours. Apoptosis assay was done as per manufacturer's instructions using the ApopTag kit (Boeringher Mannheim).
Results presented in figure 8, indicate a dose dependent increase in the apoptotic cell death effect was observed for every polypeptides used (SEQ ID N0: 4, SEQ ID N0: 5 and SEQ ID NO 6).
Polypeptide PCK3145 (SEQ ID N0: 5) was more potent than the other polypeptides at 90 ~M concentration (Figure 8).
(Figures 9 to 11) Biological activity of the polypeptides as set forth in SEQ ID
N0: 4, SEQ ID NO: 5 and SEQ ID NO 6 was determined by their growth inhibitory effect on human prostate cancer cells PC-3. Native PSP94, rHuPSP94, polypeptide 22-36 and PB111 polypeptide (scrambled polypeptide) were also included in this experiment as controls. Cell proliferation assay was performed on either PC-3 cells or normal fibroblasts (used here as control) using the MTS/PMS kit (Promega).
Four thousand cells (Figure 9 and 10) or three thousand (figure 11) cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~g/ml of bovine serum albumin (BSA) and 0.1 ~M FeS09. In addition, monitoring of cell morphology was also ~>erformed.
Results of these experiments are shown in figures 9 to 11. No cell inhibitory effe<-:t was observed following incubation of fibroblasts with various polypeptide concentrations (from 10 to 90 ~tM) for 72 hours (Figure 9). However, a significant growth inhibition was observed for polypeptides as set forth in SEQ ID N0: 4 and SEQ ID N0: 6 and more importantly with polypeptide PCK3145 (SEQ
ID N0: 5) (Figure 10). Another experiment was performed using PCK3145 and polypeptide 22-36 at various concentrations on PC-3 cells, grown in OPTI-MEM media. In figures 9 to 1:1, the percentage of growth inhibition given for treated cells is evaluated relative to non-treated control cells for which a value of 100 % cell survival is given.
EXAMPLES 8 & 9 IN-VIVO EXPERIMENTS (Figures 12 & 13) Studies MLL-1 and MLL-2 were performed as follows; on day 0, male Copenhagen rats were injected subcutaneously with 5 x 105 Mat LyLu cells per rat. These cells were derived from cultures of Mat LyLu cell line grown in RPMI media containing 10 0 (v/v) of fetal calf serum in logarithmic phase of growth. Cells were harvested from the culture flasks by trypsinization, were centrifuged at 1200 rotation per minute (rpm) and washed three timed with Hanks balanced salt solution (HBSS). Following washing, cells were counted and adjusted to a concentration of 5 x 10'' cells/ml in HBSS. A 0.1 ml volume of tumor cell inoculum containing 5 x 105 cells was administered subcutaneously into the flank region of each rat. Three days after tumor cell implantation (i.e., inoculation), animals were treated daily by a subcutaneous injection of the desired polypeptide until day 13.
Experiments illustrated in figure 12 show the anti-tumor efficacy validation cf rHuPSP94 against Mat LyLu (MLL) tumor implanted in nude mice (Protocol based on S. Garde et al.; The Prostate, 22: 225-233, 1993).
For study MLL-1 (Figure 12), tumor-implanted nude mice were separated in different groups, each receiving various amount of rHuPSP94 or control reagents. The different groups used in these experiments are illustrated below. Each group contained 8 mice.
Group 1: Negative control: PBS subcutaneously (s. c.) Group 2: Positive control: Doxorubicin at 5mg/kg intraveanously (i.v.) single bolus on day 3 Group 3: rHuPSP94 at lltg/kg/day (s. c.) Group 4: rHuPSP94 at l0~tg/kg/day (s. c.) Group 5: rHuPSP94 at 100~g/kg/day (s.c.) A schematic of inoculation is illustrated below;
(Tumor cell implantation (T.C.I.), treatment (Tx), measurement (M), day (D)).
M M M M
D~0 ~3 L57 ~9 D11 D13 D14 T.C.I. Tx daily Tx Terminate Experiments illustrated in study MLL-2 show the anti-tumor efficacy validation of rHuPSP94 against Mat Ly Lu (MLL) tumor implanted in severe combined immunode.ficiency (SCID) mice (Protocol based on S. Garde et al.; The Prostate, 22: 225-233, 1993).
For study MLL-2 (figure 13), tumor-implanted Scid mice were separated in different groups each receiving various amounts of rHuPSP94 or control reagents. The different groups used in these experiments are illustrated below. Each group contained 8 mice.
Group 1: Negative control: PBS (s. c.) Group 2: Positive control: Doxorubicin at 5mg/kg i.v. single bolus on day 3 Group 3: rHuPSP94 at l~g/kg/day (s. c.) Group 4: rHuPSP94 at 10~g/kg/day (s. c.) Group 5: rHuPSP94 at 100~g/kg/day (s. o.) A schematic of inoculation is illustrated below;
(Tumor cell implantation (T.C.I.), treatment (Tx), measurement (M), day (D) ) .
M M M M
DO 3 ~7 D9 D11 D D
~ ~
T.C.I. Tx daily Tx Terminate Results of those two studies indicate a difference in tumor size and growth in Nude vs SCID mice. The tumors grew slower and were smaller in SLID mice, This may be due to some specific factors controlling tumor growth in this mouse strain. Results also show a significant tumor reduction in mice injected with Doxorubicin (positive control). For example, tumor weight reduction in Nude mice (study MLL-1) injected with Doxorubici.n was 48 % (p=0.006)(p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
Tumor weight reduction in SCID mice (study MLL-2) inoculated with Doxorubicin was 82 0 (p=0.002) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Results indicate also a significant tumor reduction in mice treated with rHuPSP94 at a concentration of 1 ~g/kg/day. For example, tumor weight reduction in Nude mice (study MLL-1) treated with rHuPSP94 at a concentration of 1 ~tg/kg/day was 26 % (p=0.042) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Tumor weight reduction in SLID
mice (study MLL-2) treated with rHuPSP94 at a concentration of 1 ~tg/kg/day was 65 0 (p=0.010) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
(Figure 14) PC-3 human prostate tumor was obtained from ATCC (ATCC
1435). PC-3 cells were grown in RPMI media containing 10 % (v/v) of fetal calf serum and were harvested in the logarithmic phase of growth by trypsinization. Cells were centrifuged at 1200 rotation per minute (rpm) and washed three timed with Hanks balanced salt solution (HBSS). Following washing, cells were counted and adjusted to a concentration of 1 x 10~~ cells/ml in HBSS. A 0.1 ml volume of tumor cell inoculum containing 1 x 106 cells was administered subcutaneously into the two opposite flank region of each Nude mouse (Nu/Nu, BALB/c background). Tumor growth was monitored for approximately 18 days. Once tumor growth has been established (volume of tumor reached a volume of 50 mm3) treatment with rHuPSP94 (SEQ ID N0: 2) was initiated and was performed once a day for 14 days by the subcutaneous route. Based on the assigned treatment groups illustrated in table 4.
Treatment Test controlDose Level Dose No. of group articles (~g/kg/day) concentrationanimal (wg/mg) 1 Negative PBS 0 0 8 control 2 Positive Doxorubicin 5000 2500 8 control 3 rHuPSP94 1 0.5 8 4 rHuPSP94 10 5 8 5 rHuPSP94 100 50 8 6 rHuPSP94 1000 ( 500 ~ 8 ~
Results of this experiment (Figure 14) demonstrated tumor growth reduction in the group of mice treated with rHuPSP94 at a dosage level of 1 ~g/kg body weight per day. This reduction was similar to that observed for Doxorubicin (given at 5 mg/kg/day) which is a chemotherapeutic agent used as reference gold standard.
(Figures 15-17) PC-3 human prostate tumor (ATCC 1435) obtained from ATCC was implanted bilateraly into nude mice and tumor growth was monitored for approximately 18 days. PC-3 cells were injected once subcutaneously into each flank of the mice. Once tumor growth has been established (i.e., volume of tumor reached 0.25 to 0.50 cm~) the treatment with decapeptide (SEQ ID NO: 3), native PSP94 (SEQ ID
N0: 1) and control scrambled polypept:ide PB111 was initiated and was performed once a day for 14 days by the subcutaneous route based on the treatment groups (randomly assigned) illustrated in table 5.
Treatment Test and control Dose Level Dose No. of groups articles (~g/kg/day)concentrationanimal (~g/mg) 1(NegativePBS 0 0 4 control) 3 Decapeptide 1 0.5 4 (SEQ ID N0: 3) 4 Decapeptide 10 5 4 (SEQ ID N0: 3) Decapeptide 100 50 4 (SEQ ID N0: 3) 6 Decapeptide 1000 500 4 (SEQ ID NO: 3) 7 Native PSP94 1 0.5 4 (SEQ ID N0: 1) 8 Native PSP94 10 5 4 (SEQ ID N0: 1) Native PSP94 100 50 4 (SEQ ID N0: 1) 11 Native PSP94 1000 500 4 (SEQ ID NO: 1) 12 Scrambled 1 0.5 4 polypeptide(PB111) 13 Scrambled 10 5 4 polypeptide(PB111) 14 Scrambled 100 50 4 polypeptide(PB111) Scrambled ~ 1000 500 4 polypeptide(PB111) Figure 15 represents results obtained for tumor-implanted nude 5 mice treated with the decapeptide (SEQ ID N0: 3) compared to a non-treated control. Figure 16 represents results obtained for tumor-implanted nude mice treated with scrambled polypeptide PB111 compared to a non-treated control. Figure 17 represents results obtained for tumor-implanted nude mice treated with native PSP94 (SEQ ID N0: 1) 10 compared to a non-treated control. Results of these experiments (Figures 15-17) indicate a significant (p<0.05) tumor growth reduction in mice treated with the decapeptide (SEQ ID N0: 3) at a dosage level of 10 ~g/kg body weight per day.
MANUFACTURING AND PREPARATION OF POLYPEPTIDES
PSP94 derived polypeptides including PCK3145 (SEQ ID N0: 5) were synthesized using the FMOC and BOC solid phase polypeptide synthesis method (Merrifield, B., Science, 232: 341-347, 1986).
Polypeptides were analyzed in order to determine their identity by Mass Spectral Analysis. Polypeptide samples were analyzed using the PerSeptive Biosystems (Framingham, MA), with Voyager-DE MALDI-TOF
mass spectrometer using 337 nm light from a nitrogen laser. About 50 scans were averaged for each analysis. A sample from the native PSP94 was also analyzed under similar conditions for comparison.
Polypeptides were weighed on a Mett.ler AE 163 micro-balance. The measurements were to nearest 0.1 mg. 'rhe polypeptides were reconstituted in 10 mM PBS pH 7.3 to <~ final concentration of 1 and 5 mg/ml. The polypeptides dissolved relatively well and were filter sterilized through a 0.2 ~M syringe filter. Aliquots of 2 ml/tube were made and stored at -80 °C.
The pH of the polypeptides was measured after reconstitution to ensure that possible differences in pH would not be a factor of variation. The pH values of each solution were taken at three concentrations: neat, 100 ~g/ml and 12.5 ~g/ml. The pH range was approximately from 7.0 to 7.5. This did not make a significant difference in the outcome of the test as cells survive very well within this pH range. To change the concentrations to molar values, the approximate volume of the 1 mg/ml stocks were diluted in PBS pH
7.3. All stocks were made to contain 450 ~M polypeptide solutions.
When fresh stocks of polypeptide were to be reconstituted, it was done directly to 450 ~M concentration in PBS pH 7.3.
After our initial screening and confirmation of the inhibitory activity of the polypeptide on the growth of the PC-3 cells, a GMP
manufactured polypeptide was tested. This polypeptide was weighed and dissolved in PBS and 2 mg/ml stock solution was prepared, sterile filtered through a 0,2 ~m syringe filter and stored at in -80 °C.
(MTS ASSAY (Figures 18-21)) PCK3145, manufactured as set forth in example 12, was evaluated as a lead candidate product in tumor growth inhibition.
The biological activity of PCK3145 was determined by its growth inhibitory effect on the human prostate cancer cell line PC-3 using the MTS/PMS kit (Promega). This assay measures the mitochondria) activity of the live cells. The basic principle of this method involves the fact that the mitochondria) enzymes of the live cells metabolize the MTS/PMS dyes forming a brown colored precipitate which can be measured as optical density (OD) by absorption at 490 nm in a spectrophotometer. 'Therefore, the OD values are proportional to the number of living cells.
In addition, a visual observation of the cells was also done to check the cell morphology, which could also be indicative of cell growth. The following conditions for MTS assay were used: PC-3 (ATCC, Lot AT06), passage number n >_ 70, cell line adapted to grow in serum-free OPTI-MEM and in RPMI supplemented with BSA (50 ~g/ml) and Ferrous Sulfate (0.1 ~tM), continuous exposure for up to 72 hours without changing media (i.e., adding PCK3145 at 2X concentration directly to wells and diluting it 1:2 to 1X to minimize cell manipulation and avoid detachment). As indicated in Figure 18, PCK3145 was assessed at the following concentrations: 12.5, 25, 50, 100, 200, 300 and 400 ~tg/ml on PC-3 cells (ATCC) grown in supplemented media. The MTS tests were repeated 5 times and a dose dependent inhibitory effect on the growth of PC-3 cells was consistently reproducible demonstrating approximately 40 s cell growth inhibition at the highest PCK3145 concentration of 400 ~g/ml.
With the availability of GMP (good manufacturing practice) grade polypeptide the MTS assays were repeated to check the reproducibility and cytotoxicity against PC-3 cells. In parallel PC-3 cells were also treated with the native PSP94 as a reference positive control and with no treatment (negative control, i.e., cont.). Figure 19 shows the results of the MTS assay where 4000 cells were seeded and exposed to PCK3145 (GMP grade) for 48 hours. A
30 o growth inhibitory effect was observed following treatment with PCK3145 at 500 ~tg/ml. This effect was increased to approximately 40 °s after 72 hours of exposure (Figure 20). In a repeat experiment a 48 hours exposure to the polypeptide at 500 ~g/ml resulted in only 20-22 o growth inhibition, however this effect increased to 30 o after 72 hours exposure (figure 21). Despite assay to assay variability reflected by the state of cell growth in vitro, polypeptide PCK3145 exhibited a significant cell growth inhibition.
[3H]-THYMIDINE UPTAKE ASSAY (Figures 22-24) [3H]-Thymidine uptake assay involves [3H]-Thymidine incorporation into cellular DNA of actively proliferating cells.
[3H]-Thymidine uptake assay measures the proliferative index of the cells versus the MTS assay, which quantifies the number of lived cells following treatment. The anti-proliferative effects of PCK3145 and two other synthetic polypeptides derived from the amino and carboxy terminus ends of PSP94 (SEQ ID N0: 4 and N0: 6, respectively) as well as the decapeptide (SEQ ID N0: 3) previously shown to mimic the biological action of native PSP94 were assessed in [H3]-Thymidine uptake assay on PC-3 cells. Two separate experiments were conducted with GMP-grade PCK3145.
As shown in the Figures 22 and 23, polypeptide PCK3145 exhibited a significant proliferation inhibition activity reflected in the percentage of [H3]-Thymidine uptake. In the first experiment, a reduction of nearly 40 o in [3H]-Thymidine uptake was observed at PCK3145 concentration of 200 ~tg/ml. In the second experiment, although a two fold higher concentration of the PCK3145 was used (i.e., 400 ~g/ml) only a 25 o inhibition was observed. Despite assay to assay variation the overall degree of proliferative inhibitory effect against PC-3 cell was markedly evident with the GMP grade material. Treatment of PC-3 cells with the native PSP94 used as a positive reference standard, exhibited a significant dose dependent reduction in cell proliferation with almost 50 o reduction in the [H3]-Thymidine uptake following 72 hours exposure (Figure 24).
(APOPTOSIS-Figure 25) Apoptosis of PC-3 cells, following a 72 hours exposure to PCK3145 at 500 ~g/ml concentration, was evaluated in supplemented media by DNA fragmentation assay. Doxorubicin was used as a reference positive control. Unt=reated cells and PCK3145-treated cells were harvested and the DNA was isolated. Isolated DNA was run on a 1.2 $
agarose gel containing Ethidium Bromide (EtBr). As shown in Figure 25 treatment of PC-3 cells with polypept_ide PKC3145 resulted in DNA
fragmentation evidenced by the ladder formation seen for fragmented DNA. Lane 1 of the gel illustrated in figure 25 represents the DNA
marker (100 base pair DNA ladder). Lane 2 of the gel illustrated in figure 25 represents a control of untreated PC-3 cells. Lane 3 of the gel illustrated in figure 25 represents DNA laddering effect observed for cells treated with doxorubicin at a concentration of 2 ~g/ml.
Lane 4 of the gel illustrated in figure 25 represents DNA laddering effect observed for cells treated with PCK3145 (SEQ ID N0: 5).
(Figures 26-27) Studies PC3-6 and PC3-12 (Figures 26 - 27) are consecutive group experiments designed to characterize the in vivo activity of PCK3145 in the human PC-3 prostate cancer nude mouse xenograft model and to explore relationships between dose, route and schedule of administration and the efficacy parameters of tumor growth (volume).
PC-3 cells harvested in mid-log phase were inoculated at 5 x 106 cells per mice via the subcutaneous route in the mice's back area. Tumors grown from this inoculum were excised at approximately day 32 to 35 post-tumor implantation (p.t.i) when tumor volume reached 200-300 mm3 (i.e., cu mm). The necrotic tissue was removed and the viable tumor mass cut into small pieces (approximately 1 to 3 mm3) were implanted SC in the flank region at two opposite sites of the mouse. Treatment with various concentrations of PCK3145 was initiated at day 3 post-tumor implantation (p.t.i) and was continued daily for 21 days. Subcutaneous injections were done below tumor growth sites. Intra-peritoneal injections were performed in the abdominal region. Intra-venous injections were performed via the lateral tail vein. 'Che experiment was terminated 24 hours after the last treatment. Tumor measurements were taken at Days 11, 14, 16, 18, 20, 22 and 24 post-tumor implantation (p.t.i). Tumor volumes were calculated according to formula (axb2 x 0.5), where a - is the length of the long diameter, and b-is the width of the perpendicular small diameter.
Study No: PC3-6 illustrates the efficacy of PCK3145, injected subcutaneously, in tumor growth retardation in Nude mice, which have received PC-3 implants. Mice were separated in different group each receiving various amounts of PCK3145 (SEQ ID N0: 5) or control reagents. The differernt groups used in these experiments are illustrated in table 6 below. Each group contained 10 mice.
Doxorubicin was administered as single bolus intra-venous injection on days 3 and 11 post-tumor implantation (p.t.i).
Treatment Test and Dose Level No. of No. of group cont=rol (~g/kg/day) animals tumors articles 1 Negative PBS 0 10 20 control 2 Positive Doxorubicin 10000 10 20 control 3 PCK3145 0.1 10 20 Results of this study (Figure 26) demonstrated a significant PC-3 tumor growth retardation following treatment with PCK3145 at 10 ~g/kg/day. This anti-tumor effect was evidenced by a statistically significant decrease in percentage of tumor growth observed at days 11, 14, 16, 18 , 21 and 24 after tumor implantation with respective p-values ranging from p=0.001 to 0.002, in comparison to the control PBS-treated group (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Doxorubicin, a potent chemotherapeutic agent, was used as reference gold standard and demonstrated a highly significant anti-tumor therapeutic effect. ANOVA analysis of variance, Dunnett's test, Kruskal-Wallis and Dunn's test analysis of data confirmed statistical significance of the observed anti-tumor effect.
Study No: PC3-12 illustrates the efficacy of PCK3145 in tumor growth retardation in Nude mice, which have received PC-3 implants.
Mice were separated in different group each receiving various amounts of PCK3145 (SEQ ID N0: 5) or control reagents. PCK3145 was injected either through intra-venous or intra-peritoneal route. The different groups used in these experiments are illustrated in table 7 below.
Each group contained 9 mice.
Treatment Test and Dose level No. of No. of groups control (~g/kg/day) animals tumors articles 1 Negative PBS 0 9 18 control Results of this experiment (Figure 27) demonstrated a significant tumor grc.>wth retardation following treatment with PCK3145 at 100 ~g/kg/day via the intra-venous route. This effect was statistically significant at days 13, 17 and 20 after tumor implantation when compared by Student's t-test (p-values were p=0.005, 0.025 and 0.011, respectively for each time-point) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). No significant anti-tumor effect was observed following PCK3145 treatment at the other dosage levels of 10, 500 and 1000 ~g/kg/day injected via the intra-venous route. However a trend towards significance was observed following treatment with 500 and 1000 ~g/kg/day doses of PCK3145. Treatment of mice with PCK3145 at 100 and 1000 ~g/kg/day administered via the intra-peritoneal route showed a similar tumor growth retardation trend with statistically less significant difference observed at day 13 p.t.i (p=0.056) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit) at the highest dose of 1000 ~g/kg/day (Figure 27).
During the course of experimentation using the human PC-3 prostate cancer nude mouse xenograft model, results obtained have suggested that subcutaneous PCK3145 injection of mice at a site (i.e., scruff of the neck) distant from tumor site, might not be efficacious enough and will unlikely may unlikely result in an anti-tumor effect, at least in the experimental conditions tested (doses S of PCK3145 tested: 10 ug/kg/day and 100 ug/kg/day). The use of the scruff of the neck as a subcutaneous injection site represents an optimal site for immune response induction rather than a route for therapeutic product administration and as such, selection of this site is expected to be a sub-optimal site for tumor efficacy evaluation.
IN VIVO EXPERIMENTS USING DUNNING RAT MAT LY LU PROSTATE CANCER
LINE
(Figures 28-30) Anti-tumor efficacy evaluation of PCK3145 against Mat Ly Lu (MLL) tumor implanted in Copenhagen rats was performed. (Protocol based on S. Garde et al.; The Prostate, 22: 225-233, 1993). Mat LyLu tumor cells were harvested in mid-log phase from the culture flasks by trypsinization, were centrifuged at 1200 rotation per minute (rpm) and washed three timed with Hanks balanced salt solution (HBSS).
Following washing, cells were counted and adjusted to a concentration of 5 x 106 cells/ml in HBSS. A 0.1 ml volume of tumor cell inoculum containing 5 x 105 cells was administered subcutaneously into the flank region of each rat. Treatment started at day 3 post-tumor implantation (p.t.i) by local subcutaneous injection (i.e., in the shaved back area just= below tumor implantation site) of various PCK3145 concentrations. This treatment was continued daily for 16 days. Experiments were terminated 24 hours after the last treatment.
Tumor measurements were taken at days 7, 9, 11, 14, 16 and 18. Tumor volumes are calculated according to formula (axb2 x 0.5), where a -is the length of the long diameter, b-width of the perpendicular small diameter. At day 19 tumors of individual rats were excised and weighed.
Study No: MLL-5 illustrates the efficacy of PCK3145 (SEQ ID N0:
5) compared with polypeptide 7-21 (SEQ ID N0: 4) and polypeptide 76-94 (SEQ ID NO: 6) in tumor growth retardation in Copenhagen rats, which have received Mat Ly Lu implants. Mice were separated in different groups, each receiving various amount of PCK3145 (SEQ ID
NO: 5) or control reagents. PCK3145 was injected through the _6g_ subcutaneous route. The different groups used in these experiments are illustrated in table 8 below. Each group contained 8 mice.
Treatment Test and Dose Level No. of No. of groups control. (~g/kg/day) animals tumors articles 1 Negative PBS 0 8 8 control 2 Polypeptide 10 8 8 3 Polypeptide 1 8 8 6 Polypeptide 10 8 8 7 Polypeptide 1 8 8 Results of this study (Figure 28) demonstrated a significant anti-tumor effect following administration of PCK3145 at 10 ~tg/kg/day. This was evidenced by a significant tumor volume reduction at days 11 (p=0.006), 13 (p=0.00001), 16 (p=0.002) and 18(p=0.004), post-tumor cell implantation compared to control PBS-treated group (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). No significant effect was detectable following PCK3145 treatment at 1 ~g/kg/day. It was of interest to note that the amino-terminus polypeptide 7-21 also demonstrated comparable anti-tumor effect, which was also observed in the PC-3 nude mouse xenograft model, indicating the possibility of an overlapping active site between the N-terminus and the central regions of the PSP94 protein. This was evidenced by a significant tumor volume reduction observed at day 13 (p=0.05), 16 (p=0.00005), and 18 (p=0.01) in mice treated with polypeptide 7-21) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
Study No: MLL-6 illustrates the efficacy of PCK3145 (SEQ ID NO:
5) in tumor growth retardation in Copenhagen rats, which have received Mat Ly Lu implants. Mice were separated in different group each receiving various amounts of PCK3145 (SEQ ID NO: 5) or control reagents. PCK3145 was injected through the subcutaneous route. The different groups used in these experiments are illustrated in table 9 below. Each group contained 8 mice. Doxorubicin was administered as single bolus via intra-venous injection on day 3 p.t.i.
Treatment Test and Dose level No. of No. of groups control (~tg/kg/day)animals tumors articles 1 (Negative PBS 0 8 8 control) 2 Doxorubicin 5000 8 8 5 Scrambled 10 8 8 polypeptide 6 Scrambled 100 8 8 polypeptide Results of this study (Figures 29 and 30) demonstrated a significant dose-dependent anti-tumor effect following administration of PCK3145 at 10 and 100 ~g/kg/day. This was evidenced by a significant tumor volume reduction (31 % over control) following PCK3145 treatment especially with 100 ~tg/kg/day at days 14, 16 and 18 post-tumor cell implantation (Figure 29). The p-value versus negative control-treated group (i.e., scrambled polypeptide (PB111)) was highly significant at p=0.0000062 (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). A moderate extent of growth retardation (marginal statistical significance at p=0.03 versus control PBS-treated group) was also observed following treatment with scrambled polypeptide at a concentration of 100 ~g/kg/day (Figure 29) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Doxorubicin treatment was highly significant resulting in over 80 o reduction in tumor volumes. This anti-tumor effect of PCK3145 at 100 ~g/kg/day was also reproduced following analysis of the tumor weights data. As shown in figure 30, (tumor weight data) a significant reduction in tumor weights (p=0.0003) was observed on day 18 p.t.i. (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). This represented a 34 o reduction in tumor mass, a 20 gram difference between the control (56.6 g) and PCK3:L45-treated at 100 ~g/kg/day group (37.2 g). This difference in tumor weights was also statistically significant when it was compared to the tumor weights of the control scrambled polypeptide-treated rats given the same dose of 100~g/kg/day (p=0.003) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Comparison of the scrambled polypeptide treated tumor weights with that of control PBS-untreated tumor weights was not statistically significant (p=0.06) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
In order to test for the efficacy of combination treatment, in tumor growth retardation, PCK3145 and taxotere (i.e., docetaxel) were co-administered in Nude mice previously inoculated with PC-3 tumor cells. Mice were separated in different groups each receiving PCK3145 alone or PCK3145 in combination with taxotere (administered by separate routes) or control reagent (i.e., PBS). In this experiment, the combination treatment was initiated against relatively large tumor burdens. Tumors were allowed to grow beyond the 50 to 60 mm3 size at which PCK3145 treatment usually becomes inefficient. PCK3145 was injected through intravenous route every other day for 28 days starting from day 1 when 50 to 60 mm3 size subcutaneous tumors were apparent. Taxotere was injected by intra-peritoneal route at a sub-optimal concentration of 2 mg/kg on days 4 and 11 after subcutaneous tumors were evident. The different groups used in this experiment are illustrated in table 10 below. Each group contained 11 mice.
Treatment Test and Dose level No. of No of tumors groups control. (~g/kg) animals articles 1. Negative PBS 0 11 11 control 2. Positive Taxotere 2000 11 11 control 3. PCK3145 100 11 11 4. PCK3145 + 100 + 11 11 taxotere 2000 Results of this experiment (Figure 31) demonstrate a significant tumor growth retardation following combination treatment of PCK3145 and taxotere. This effect is statistically significant at days 19 and 22 post-tumor cell inoculation when compared by Student's t-test (p=0.02 at day 19 and p=0.047 at day 22), (p-values are measured by unpaired Student's t-test at p<0.05 as a cut-off limit) and was markedly better than taxotere administered alone at the same dose of 2 mg/kg (suboptimal dose).
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: PROCYON BIOPHARMA INC.
(ii) TITLE OF INVENTION: PHARMACEUTICAL PREPARATIONS AND
METHODS E'OR INHIBITING TUMORS
(iii) NUMBER OF' SEQUENCES: 92 (iv) CORRESPONDENCE ADDRESS:
(A) ADRESSEE: BROULLETTE KOSIE
(B) STREET: 1100 RENE-LESVEQUE BLVD WEST
(C) PROV/STATE: QUEBEC
(D) COUNTRY: CANADA
(E) POSTAL/ZIP CODE: H3B 5C9 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: FLOPPY DISK
(B) COMPUTER: IBM PC COMPATIBLE
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (TEXT) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 2,321,256 (B) FILING DATE: 2000-10-16 (C) CLASSIFICATION: A61K-38/17 (A) APPLICATION NUMBER: 2,355,334 (B) FILING DATE: 2001-08-20 (viii)ATTORNEY/PATENT AGENT INFORMATION:
(A) NAME: BROULLETTE KOSIE
(B) REGISTRATION NO.: 3939 (C) REFERENCE/DOCKET NO.:
(D) TEL. NO.: (514) 397 8500 (E) FAX NO.: (514) 397 8515 (2) INFORMATION FOR SEQ ID N0: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(iii)HYPOTHETICAL:
(iv)ANTI-SENSE:
(v) FRAGMENT TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(vii)IMMEDIATE SOURCE:
(viii)POSITION IN GENOME
(A) CHROMOSOME/SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMATION:
(x) PUBLICATION INFORMATION:
(A) AUTHORS:
(B) TITLE:
(C) JOURNAL:
(D) VOLUME:
(E) ISSUE:
(F) PAGES:
(G) DATE:
(H) DOCUMENT NO.:
(I;I FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES IN SEQ ID N0:1:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: l:
Ser Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys H:is Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys 35 Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile (2) INFORMATION FOR SEQ ID N0: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 102 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Glu Ala Glu Ala Tyr Val Glu Phe Ser Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile (2) INFORMATION FOR SEQ ID N0: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 3:
Tyr Thr Cys Ser Val Ser Glu Pro Gly Ile (2) INFORMATION FOR SEQ ID N0: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 4:
Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu (2) INFORMATION FOR SEQ ID N0: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (2) INFORMATION FOR SEQ ID N0: 6:
(i) SEQLJENCE CHARACTERISTICS:
(A) LENGTH: 19 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGI:NAL SOURCE:
(A) ORGANISM:
(xi) SEQLJENCE DESCRIPTION: SEQ ID N0: 6:
Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile (2) INFORMATION FOR SEQ ID N0: 7:
(i) SEQL.1ENCE CHARACTERISTICS:
(A) LENGTH: 26 (B) TYPE: NUCLEOTIDES
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'.ULE TYPE : DNA
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 7:
(2) INFORMATION FOR SEQ ID N0: 8:
(i) SEQCJENCE CHARACTERISTICS:
(A) LENGTH: 21 (B) TYPE: NUCLEOTIDES
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: DNA
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 8:
2) INFORMATION FOR SEQ ID N0: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: P85r (B) TYPE: NUCLEOTIDES
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
TCATGCTATT TCATACCTA~1 TGAGGGAGTT CCAGGAGATT CAACCAGGAA ATGCATGGAT 60 AAAGACAACT GCCAAAGAA'I' CTTCAAGAAG GAGGACTGCA AGTATATCGT GGTGGAGAAG 240 AAGGACCCAA AAAAGACCTC~ TTCTGTCAGT GAATGGATAA TCTAA 285 2) INFORMATION FOR SEQ ID N0: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'LJLE TYPE
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQCJENCE DESCRIPTION: SEQ ID NO: 10:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu 1 ' 5 10 15 2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGLNAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 11:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile 2) INFORMATION FOR SEQ ID N0: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
_77_ (A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 12:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser 2) INFORMATION FOR SEQ ID N0: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC',ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQL)ENCE DESCRIPTION: SEQ ID N0: 13:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys 2) INFORMATION FOR SEQ ID N0: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 14:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys 2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 (B) TYPE: AMINO ACID
55 (C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
60 (A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
_78_ Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr 2) INFORMATION FOR SEQ ID N0: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC',ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu 2) INFORMATION FOR SEQ ID N0: 17:
(i) SEQCIENCE CHARACTERISTICS:
(A) LENGTH: 23 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC;ULE TYPE:
(vi)ORIG:INAL SOURCE:
(A) ORGANISM:
(xi) SEQCIENCE DESCRIPTION: SEQ ID N0: 17:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val 2) INFORMATION FOR SEQ ID N0: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser 2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQL7ENCE CHARACTERISTICS:
(A) LENGTH: 25 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLE(:ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 19:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr 2) INFORMATION FOR SEQ ID N0: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC"ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 20:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr P:ro 2) INFORMATION FOR SEQ ID N0: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC.ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 21:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val 2) INFORMATION FOR SEQ ID N0: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 22:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly 2) INFORMATION FOR SEQ ID N0: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( i i ) MOLECULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCIENCE DESCRIPTION: SEQ ID N0: 23:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val. Ser Thr Pro Val Gly Tyr 2) INFORMATION FOR SEQ ID N0: 24:
(i) SEQCJENCE CHARACTERISTICS:
(A) LENGTH: 30 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC:ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCJENCE DESCRIPTION: SEQ ID NO: 24:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp 2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQCIENCE CHARACTERISTTCS:
(A) LENGTH: 31 (Bl TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D1 TOPOLOGY: LINEAR
(ii)MOLE(:ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val. Ser Thr Pro Val Gly Tyr Asp Lys 20 2) INFORMATION FOR SEQ ID N0: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLE(:ULE T~'PE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 26:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp 2) INFORMATION FOR SF;Q ID N0: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'.ULE TYPE
(vi)ORIGI:NAL SOURCE:
(A) ORGANISM:
(xi) SEQTTENCE DESCRIPTION: SEQ ID NO: 27:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn 2) INFORMATION FOR SEQ ID N0: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 2) INFORMATION FOR SEQ ID N0 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 28:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly 'I'yr Asp Lys Asp Asn Cys 2) INFORMATION FOR SEQ ID NO: 29:
20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(Dj TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys ~Pyr Glu Thr Glu Ile Ser Cys Cys Thr I~eu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln 2) INFORMATION )~OR SEQ ID N0: 30:
(i) SEQCJENCE CHARACTERISTICS:
(A) LENGTH: 36 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( i i ) MOLEC'.ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg 2) INFORMATION FOR SEQ ID NO: 31:
NO: 91) 82) EWQTDNCETCTCYETEEWQTDNCETCTCYETEEWQTDNCETCTCYETEEWQTDNCE
TCTCYETE (SEQ ID NO: 92) Heterologous fusion includes new polypeptides made by the fusion of polypeptides of the present invention with heterologous polypeptides. Such polypeptides may include but are not limited to bacterial polypeptides (e.g., betalactamase, glutathione-S-transferase, or an enzyme encoded by the E.coli trp locus), yeast protein, viral proteins, phage prot=eins, bovine serum albumin, chemotactic polypeptides, immunoglobulin constant region (or other immunoglobulin regions), albumin, or ferritin.
Other type of polypeptide modification includes amino acids sequence deletions (e. g., truncations). Those generally range from about 1 to 30 residues, more preferably about 1 to 10 residues and typically about 1 to 5 residues.
A host cell transformed or transfected with nucleic acids encoding the polypeptides of the present invention (i.e., vector containing the DNA sequence of the polypeptides of the present invention) or chimeric proteins formed with the polypeptides of the present invention are also encompassed by the invention. Any host cell, which produces a polypeptide analog, mutant, variant, fragment, or chimera having at least one of the biological properties of the present invention is encompassed by the present invention. For example, such host cell may include bacterial, yeast, plant, insect or mammalian cells. In addition, the polypeptides of the present invention may be produced in transgenic animals. Transformed or transfected host cells and transgenic animals may be obtained using materials and methods that are routinely available to one skilled in the art.
T17: L'TT7T~PTlIATC
General Molecular Biology Unless otherwise indicated, the recombinant DNA techniques utilized in the present invention are standard procedures, known to those skilled in the art. Example of such techniques are explained in the literature in sources such as J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al ., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), T.A. Brown (editor), Essential Molecular Biology: A
Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present) and are incorporated herein by reference.
"Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA
that is a mixture of single- and doub:Le-stranded regions, hybrid molecules comprising DNA and RNA that may be sin_qle-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "po.lynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus "polynucleotide"
embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic o.f viruses and cells.
"Polynucleotide" includes but is not limited to linear and end-closed molecules. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
"Polypeptides" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds (i.e., peptide isosteres). "Polypeptide" refers to both short chains, commonly referred as peptides, oligopeptides or oligomers, and to longer chains generally referred to as proteins.
As described above, polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
As used herein the term "polypeptide analog" relates to mutants, variants, chimeras, fusions, deletions, additions and any other type of modifications made relative to a given polypeptide.
As used herein, the term "homologous" sequence relates to nucleotide or amino acid sequence derived from the rHuPSP94 DNA
sequence or polypeptide.
As used herein, the term "heterologous" sequence relates to DNA
sequence or amino acid sequence of a heterologous polypeptide and includes sequence other than that of PSP94.
As used herein, the term "tumor" relates to solid or non-solid tumors, metastasic or non-metastasic tumors, tumors of different tissue origin including, but not limited to, tumors originating in the liver, lung, brain, lymph node, bone marrow, adrenal gland, breast, colon, pancreas, prostate, stomach, or reproductive tract (cervix, ovaries, endometrium etc.). The term "tumor" as used herein, refers also to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
As used herein, the term "polysaccharide" refers to a substance made of two or more saccharide unit and comprise, for example, chitosan, pectin, chondroitin sulfate, cyclodextrin, dextrans, guar gum, inulin, amylose, and locust bean gum.
As used herein, the term "vector" refers to an autonomously replicating DNA or RNA molecule into which foreign DNA or RNA
fragments are inserted and then propagated in a host cell for either expression or amplification of the foreign DNA or RNA molecule. The term « vector » comprises and is not limited to a plasmid (e. g., linearized or not) that can be used to transfer DNA sequences from one organism to another.
As used herein, the term "time-release encapsulation means"
refers to controlled or sustained release obtained when a pharmaceutical composition is formulai:ed, for example, with polysaccharides, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, dry powders, or transdermal delivery systems. Other controlled release compositions of the present invention include liquids that, upon administration to a mammal, form a solid or a gel in situ. Furthermore, the term "time-s release encapsulation means" or "time-release means" comprises a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycol.ic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crossli.nked or amphipathic block copolymers of hydrogels.
As used herein, "pharmaceutical composition" means therapeutically effective amounts o.f the agent together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or carriers. A "therapeutically effective amount" as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen.
Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e. g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e. g., Tween 20, Tween 80, Pluronic F68, bile acid salts).
Solubilizing agents (e. g., glycerol, polyethylene glycerol), anti-oxidants (e. g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance. Controlled or sustained release compositions include formulation in lipophilic depots (e. g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral routes. In one embodiment the pharmaceutical composition is administered parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally.
Further, as used herein "pharmaceutically acceptable carrier"
or "pharmaceutical carrier" are known in the art and include, but are not limited to, 0.01-0.1 M and preferably 0.05 M phosphate buffer or 0.8 a saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions.
Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's orfixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the 1_Lke. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and t:he like.
Mutants, variants and analogs proteins Mutant polypeptides will possess one or more mutations, which are deletions (e.g., truncations), insertions (e.g., additions), or substitutions of amino acid residues. Mutants can be either naturally occurring (that is to say, purified or isolated from a natural source) or synthetic (for example, by performing site directed mutagenesis on the encoding DNA or made by other synthetic methods such as chemical synthesis). It is thus apparent that the polypeptides of the invention can be either naturally occurring or recombinant (that is to say prepared from the recombinant DNA
techniques).
A protein at least 50 o identical, as determined by methods known to those skilled in the art (for example, the methods described by Smith, T.F. and Waterman M.S. (198:L) Ad. Appl.Math., 2:482-489, or Needleman, S.B. and Wunsch, C.D. (1970) J.Mol.Biol., 48: 443-453), to those polypeptides of the present invention are included in the invention, as are proteins at least 70 °s or 80 o and more preferably at least 90 % identical to the protein of the present invention.
This will generally be over a region of at least 5, preferably at least 20 contiguous amino acids.
"Variant" as the term used herein, is a polynucleotide or polypeptide that differs from reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusion and truncations in the polypeptide encoded by the reference sequence, as discussed herein. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequence of t:he reference polypeptide and the variant are close:Ly similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid by one or more substitutions, additions, deletions, or any combination therefore. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant polynuclotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenes:is techniques or by direct synthesis.
Amino acid sequence variants may be prepared by introducing appropriate nucleotide changes into DNA, or by in vitro synthesis of the desired polypeptide. Such variant include, for example, deletions, insertions, or substitutions of residues within the amino acid sequence. A combination of deletion, insertion and substitution can be made to arrive at the final construct, provided that the final protein product possesses the desired characteristics. The amino acid changes also may alter posttranslational processes such as changing the number or position of the glycocylation sites, altering the membrane anchoring characteristics, altering the intra-cellular location by inserting, deleting or otherwise affecting the transmembrane sequence of the native protein, or modifying its susceptibility to proteolytic cleavage.
It is to be understood herein, that if a "range" or "group" of substances (e.g. amino acids), substitutents" or the like is mentioned or if other- types of a particular characteristic (e. g.
temperature, pressure, chemical structure, time, etc.) is mentioned, the present invention relates to and explicitly incorporates herein each and every specific member and combination of sub-ranges or sub-groups therein whatsoever. Thus, any specified range or group is to be understood as a shorthand way of referring to each and every member of a range or group individually as well as each and every possible sub-ranges or sub-groups encompassed therein; and similarly with respect to any sub-ranges or sub-groups therein. Thus, for example, - with respect to a pressure greater than atmospheric, this is to be understood as specifically incorporating herein each and every individual pressure state, as well as sub-range, above atmospheric, such as for example 2 psig, 5 psig, 20 psig, 35.5 psig, 5 to 8 psig, 5 to 35, psig 10 to 25 psig, to 40 psig, 35 to 50 psig, 2 to 100 psig, etc..;
with respect to a temperature greater than 100° C, this is 15 to be understood as specifically incorporating herein each and every individual temperature state, as well as sub-range, above 100° C, such as for example 101° C, 105° C
and up, 110° C and up, 115° C and up, 110 to 135° C, 115° c to 135° C, 102° C to 150° C, up to 210° C, etc.;
- with respect to a temperature lower than 100° C, this is to be understood as specifically incorporating herein each and every individual temperature state, as well as sub-range, below 100° C, such as for example 15° C and up, 15° C to 40°
C, 65° C to 95° C, 95° C and lower, etc.;
- with respect to residence or reaction time, a time of 1 minute or more is to be understood as specifically incorporating herein each and every individual time, as well as sub-range, above 1 minute, such as for example 1 minute, 3 to 15 minutes, 1 minute to 20 hours, 1. to 3 hours, 16 hours, 3 hours to 20 hours etc.;
- with respect to polypeptides, a polypeptide analog consisting of at least two contiguous amino acids of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog consisting of amino acid 1 and 2, a polypeptide analog consisting of amino acids 2 and 3, a polypeptide analog consisting of amino acids 3 and 4, a polypeptide analog consisting of amino acids 6 and 7, a polypeptide analog consisting of amino acids 9 and 10, a polypeptide analog consisting of amino acids 36 and 37, a _3~_ polypeptide analog consisting of amino acids 93 and 94, etc.
- with respect to polypeptides, a polypeptide analog consisting of at least five contiguous amino acids of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog consisting of amino acids 1 to 5, a polypeptide analog consisting of amino acids 2 to 6, a polypeptide analog consisting of amino acids 3 to 7, a polypeptide analog consisting of amino acids 6 to 10, a polypeptide analog consisting of amino acids 9 to 13, a polypeptide analog consisting of amino acids 36 to 40, a polypeptide analog consisting of amino acids 90 to 94, etc.
- with respect to polypeptides, a polypeptide analog comprising a particular sequence and having an addition of at least one amino acid to its amino-terminus is to be understood as specifically incorporating each and every individual ~>ossibility, such as for example, a polypeptide analog having an addition of one amino acid to its amino-terminus, a polypeptide analog having an addition of two amino acid to its amino-terminus, a polypeptide analog having an addition of three amino acid to its amino-terminus, a polypeptide analog having an addition of ten amino acid to its amino-terminus, a polypeptide analog having an addition of eighteen amino acid to its amino-terminus, a polypeptide analog having an addition of forty amino acid to its amino-terminus, a polypeptide analog having an addition of two hundred amino acid to its amino-terminus, etc.
- with respect to polypeptides, a polypeptide analog comprising a particular sequence and having an addition of at least one amino acid to its carboxy-terminus is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog having an addition of one amino acid to its carboxy-terminus, a polypeptide analog having an addition of two amino acid to its carboxy-terminus, a polypeptide analog having an addition of five amino acid to its carboxy-terminus, a polypeptide analog having an addition of twenty amino acid to its carboxy-terminus, a polypeptide analog having an addition of fifty-three amino acid to its carboxy-terminus, a polypeptide analog having an addition of three hundred amino acid to its carboxy-terminus, etc.
- with respect to polypeptides, a polypeptide analog comprising two to fifty units of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog comprising two units of that particular sequence, a polypeptide analog comprising three units of that particular sequence, a polypeptide analog comprising six units of that particular sequence, a polypeptide analog comprising thirteen units of that particular sequence, a polypeptide analog comprising thirty-five units of that particular sequence, a polypeptide analog comprising fifty units of that particular sequence, etc.
- with respect to polypeptides, a polypeptide analog comprising two to ten units of a particular sequence is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog comprising two units of that particular sequence, a polypeptide analog comprising three units of that particular sequence, a polypeptide analog comprising four units of that particular sequence, a polypeptide analog comprising five units of that particular sequence, a pol.ypeptide analog comprising six units of that particular sequence, a polypeptide analog comprising seven units of that particular sequence, a polypeptide analog comprising eight units of that particular sequence, a polypeptide analog comprising nine units of that particular sequence, and a polypeptide analog comprising ten units of that particular sequence.
- with respect to polypeptides, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID N0: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), is to be understood as specifically incorporating each and every individual possibility, such as for example, a polypeptide analog of two amino acid units wherein the amino acids are sequentially; Glu and Trp, a polypeptide analog of two amino acid units wherein the amino acids are sequentially; Trp and Glu, a polypeptide analog of three amino acid units wherein the amino acids are sequentially; Trp, Glu, Trp, a polypeptide analog of three amino acid units wherein the amino acids are sequentially; Trp, Trp, Trp, a polypeptide analog of three amino acid units wherein the amino acids are sequentially; Glu, Glu, Trp, a polypeptide analog of three amino acid units wherein the amino acids are, independently of the order; Tyr, Asp, Glu, a polypepti.de analog of three amino acid units wherein the amino acids are, independently of the order; Thr, Asp, Asn, a polypepti.de analog of three amino acid units wherein the amino acids are, independently of the order; Thr, Thr, Asn, a polypepti.de analog of four amino acid units wherein the amino acids are, independently of the order; Glu, Gln, Cys, Asn, a polypeptide analog of four amino acid units wherein the amino acids are, independently of the order; Gl.n, Gln Cys, Trp, a polypeptide analog of four amino acid units wherein the amino acids are, Cys, Cys, Cys, Cys, a polypeptide analog of fourteen amino acid units wherein the amino acids are, independently of the order; Asn, Asp, Glu, Gln, Trp, Cys, Tyr, Thr, Thr, Asp, Asn, Gln, Thr, Cys, a polypeptide analog of fourteen amino acid units wherein the amino acids are, independently of the order; Asp, Asp, Asp, Asp, Trp, Cys, Cys, Trp, Thr, Thr, Thr, Thr, Thr, Cys, a polypeptide analog of fourteen amino acid units wherein the amino acids are, independently of the order; Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, Tyr, etc.
with respect to polypeptides, a polypeptide analog having at least 90 0 of its amino acid sequence identical to a particular amino acid sequence is to be understood as specifically incorporating each and every individual possibility (excluding 100 ~), such as for example, a polypeptide analog having 90 °; of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 91 ° of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 93 °. of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 97 ~ of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 99 ° of its amino acid sequence identical to that particular amino acid sequence, etc.
- with respect to polypeptides, a polypeptide analog having at least 70 0 of its amino acid sequence identical to a particular amino acid sequence is to be understood as specifically incorporating each and every individual possibility (excluding 100 oj, such as for example, a polypeptide analog having 70 ~ of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 71 0 of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 73 °, of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 88 ° of its amino acid sequence identical to that particular amino acid sequence, a polypeptide analog having 97 °. of its amino acid sequence identical tc: that particular amino acid sequence, a polypeptide analog having 99 ° of its amino acid sequence identical to that particular amino acid sequence, etc.
with respect to polypeptides, a polypeptide analog having at least 50 s of sequence its amino acid identical to a particular a mino acid sequence to be understood as is specifically incorporating d every individual each an possibility (excluding , h as for example, a 100 ~) suc polypeptide analog having of its amino sequence 50 acid identical to that particularaminoacid sequence,a polypeptide analog having of its amino sequence 51 acid identical to that particularaminoacid sequence,a polypeptide analog having of its amino sequence 54 acid identical to that particularaminoacid sequence,a polypeptide analog having . its amino sequence 66 of acid identical to that particularaminoacid sequence,a polypeptide analog having % its amino sequence 70 of acid identical to that particularaminoacid sequence,a polypeptide analog having a its amino sequence 79 of acid identical to that particularaminoacid sequence,a polypeptide analog having . its amino sequence 82 of acid identical to that particularaminoacid sequence,a polypeptide analog having of its amino sequence 99 acid identical to that particularaminoacid sequence,etc.
and similarly with respect to other parameters such as low pressures, concentrations, elements, etc...
It is also to be understood herein that "g" or "gm" is a reference to the gram weight unit; that "C" is a reference to the Celsius temperature unit; and "psig" is a reference to "pounds per square inch gauge".
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts mass spectrometry analysis of polypeptide 7-21 (SEQ
ID N0: 4).
Figure 2 depicts mass spectrometry analysis of polypeptide PCK3145 (SEQ ID N0: 5).
Figure 3 depicts mass spectrometry analysis of polypeptide 76-94 (SEQ
ID NO: 6) .
Figure 4a is a graph depicting the in-vitro inhibitory activity of the decapeptide of SEQ ID N0: 3 on PC-3 cells after 9 days of culture.
Figure 4b is a graph depicting the in-vitro inhibitory activity of the native PSP94 (nPSP94) on PC-3 cells after 9 days of culture.
Figure 5a is a graph depicting the in-vitro inhibitory activity of the decapeptide of SEQ ID N0: 3 on PC-3 cells after 21 days of culture.
Figure 5b is a graph depicting the in-vitro inhibitory activity of the native PSP94 (nPSP94) on PC-3 cells after 21 days of culture.
Figure 6a is a graph depicting the in-vitro inhibitory activity of the decapeptide of SEQ ID N0: 3 on PC-3 cells after 10 days of culture.
Figure 6b is a graph depicting the in-vitro inhibitory activity of the native PSP94 (nPSP94) on PC-3 cel:Ls after 10 days of culture.
Figure 7 depicts a gel showing DNA fragmentation following treatment of PC-3 cells with polypeptide PCK3145 as set forth in SEQ ID N0: 5.
Figure 8 is a graph depicting the results of an apoptosis assay with an ELISA plus kit following polypeptide treatment of PC-3 cells for 72 hours with various concentration of polypeptide 7-21 (SEQ ID N0:
4), polypeptide PCK3145 (SEQ ID N0: 5), polypeptide 76-94 (SEQ ID NO:
6) or native PSP94 (SEQ ID NO: 1).
Figure 9 is a graph depicting in vitro fibroblast cell growth when exposed for 72 hours to various concentration of native PSP94 (nPSP94) (SEQ ID N0: 1) or various concentration of rHuPSP94 (SEQ ID
NO: 2) or polypeptide 7-21 (SEQ ID N0: 4), polypeptide PCK3145 (SEQ
ID N0: 5), or polypeptide 76-94 (SEQ ID NO: 6).
Figure 10 is a graph depicting the effect of polypeptide 7-21 (SEQ ID
N0: 4), polypeptide PCK3145 (SEQ ID N0: 5), polypeptide 76-94 (SEQ ID
N0: 6), and polypeptide 61-75 on the in vitro growth of PC-3 cells after 72 hours.
Figure 11 is a graph depicting the effect of polypeptide 22-36 and polypeptide PCK3145 (SEQ ID N0: 5) on i.n vitro growth of PC-3 cells after 72 hours.
Figure 12 is a graph depicting results of study no. MLL-1 on the anti-tumor efficacy validation of rHuPSP94 (rPSP99) (SEQ ID N0: 2) against Mat Ly Lu (MLL) tumor implanted in nude mice.
Figure 13 is a graph depicting results of study no. MLL-2 on the anti-tumor efficacy validation of rHuPSP94 (rPSP94) (SEQ ID N0: 2) against Mat Ly Lu (MLL) tumor implanted in nude mice.
Figure 14 is a graph depicting tumor volume (tumor growth reduction) in rHuPSP94-treated nude mice.
Figure 15 is a graph depicting tumor volume (tumor growth reduction) in decapeptide (SEQ ID N0: 3)-treated nude mice.
Figure 16 is a graph depicting tumor volume (tumor growth reduction) in control scrambled polypeptide (PB111)-treated mice.
Figure 17 is a graph depicting tumor volume (tumor growth reduction) in native-PSP94 (nPSP94)-treated mice.
Figure 18 is a graph depicting the in vitro inhibitory activity of PCK3145 (SEQ ID N0: 5) on PC-3 cells, after a 72 hours treatment, as measured by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny_L)-2H-tetrazolium,inner salt) assay.
Figure 19 is a graph depicting the in vitro inhibitory activity of native PSP94 (SEQ ID N0: 1) and PCK3145 (SEQ ID NO: 5) (GMP grade) on PC-3 cells, after 48 hours of treatment, as measured by MTS assay.
Figure 20 is a graph depicting the in vitro inhibitory activity of PCK3145 (SEQ ID N0: 5) (GMP grade) on PC-3 cells (ATCC), after 72 hours of treatment, as measured by the MTS assay.
Figure 21 is a graph depicting the in vitro inhibitory activity of PCK3145 (SEQ ID NO: 5)(GMP grade) on PC:-3 cells (ATCC), after a 48 or 72 hours treatment, as measured by the MTS assay.
Figure 22 is a graph depicting the .in vitro inhibitory activity of decapeptide as set forth in SEQ ID N0: 3, polypeptide 7-21 as set forth in SEQ ID N0: 4, polypeptide PCK3145 as set forth in SEQ ID N0:
5, or polypeptide 76-94 as set forth in SEQ ID N0: 6 on PC-3 cells, measured by [3H]-Thymidine uptake assay.
Figure 23 is a graph depicting the in vitro inhibitory activity of decapeptide as set forth in SEQ ID N0: 3, polypeptide 7-21 as set forth in SEQ ID NO: 4, polypeptide PCK3145 as set forth in SEQ ID N0:
5, or polypeptide 76-94 as set forth in SEQ ID NO: 6 on PC-3 cells, measured by [3H]-Thymidine uptake assay.
Figure 24 is a graph depicting the in vitro inhibitory activity of native PSP94 (SEQ ID NO: 1) on PC-3 cells after 72 hours treatment, measured by [3H]-Thymidine uptake assay.
Figure 25 depicts a gel showing DNA fragmentation following treatment of PC-3 cells with PCK3145 (SEQ ID N0: 5) or doxorubicin.
Figure 26 is a graph depicting the in vivo inhibitory activity of PCK3145 (SEQ ID N0: '.>) (0.1 ~g/kg/day and 10 ~g/kg/day) against human PC-3 tumor xenografted in nude mice.
Figure 27 is a graph depicting the in vivo inhibitory activity of PCK3145 (SEQ ID N0: 5) (10 ~g/kg/day to 1000 ~g/kg/day, administered either via the intra-venous or intra-peritoneal route) against human PC-3 tumor xenografted in nude mice.
Figure 28 is a graph depicting the in vivo inhibitory activity of polypeptide 7-21 (:>EQ ID N0: 4), PCK3145 (SEQ ID N0: 5) or polypeptide 76-94 (SE:Q ID N0: 6), given at doses of 1 ~g/kg/day or 10 ~g/kg/day, in Copenhagen rats implanted with Dunning Mat Ly Lu tumors.
Figure 29 is a graph depicting the in vivo inhibitory activity of PCK3145 (SEQ ID N0: 5) or the scrambled polypeptide given at doses of ~tg/kg/day or 100 ~g/kg/day, in Copenhagen rats implanted with Dunning Mat Ly Lu tumors.
Figure 30 is a graph depicting tumor weight at day 18 following PCK3145 (SEQ ID N0: 5) or scrambled polypeptide treatment (10 ~tg/kg/day or 100~tg/kg/day), in Copenhagen rats implanted with Dunning Mat Ly Lu tumors.
Figure 31 is a graph depicting the efficacy of PCK3145 and taxotere (i.e. docetaxel) combination treatment in Nude mice implanted with PC-3 tumor cells in tumor growth retardation.
DETAILED DESCRIPTION OF THE INVENTION
The recombinant human rHuPSP94 expressed in yeast is non-glycosylated and has 10 cystein residues. The molecular weight of rHuPSP94 was determined to be 11.5 kDa, compared to 10.7 kDa for its native counterpart.
Various experimental studies have been carried out in order to determine the efficacy of rHuPSP94 (SEQ ID N0: 2) relative to the native PSP94 secreted by the diseased prostate as tumor suppressive agent. Studies have also been carried out to determine the efficacy of the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID N0: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID N0: 5 (PCK3145), and the polypept:ide as set forth in SEQ ID N0: 6 (polypeptide 76-94), as tumor suppressive agents. The tumor suppression activity of the polypeptides of the present invention has been monitored by their ability to reduce or inhibit the growth of prostatic adenocarcinoma both in-vivo and in-vitro.
Those results are sununarized below.
Studies were carried out using PC-3 human prostate adenocarcinoma line, which can be maintained both in vivo as a xenograft in nude mice and in vitro as a cell line. In addition, a rat Dunning Mat LyLu prostate tumor, which is a pre-eminent animal model for the study of CaP, was also used. The Dunning tumor is a fast growing, poorly differentiated, transplantable tumor, which can be maintained both in-vivo in the Copenhagen rat and in-vitro as a cell line.
The following examples are offered by way of illustration and not by way of limitation.
PREPARATION OF rHuPSP94 (SEQ ID NO: 2) and polypeptides (SEQ ID NO:
3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6) Recombinant HuPSP94 was cloned and expressed in Pichia pastoris, and then purified and characterized as follows.
Materials DEAF-cellulose (DE52) was purchased from Whatman (Fairfield, New-Jersey). Dialysis membranes and the electro chemiluminescence (ECL) detection kit were purchased from Biolynx Canada(Pierce Inc.).
Broad-range molecular weight markers and Econo-pack columns fitted with flow adapters were purchased from Bio-Rad Labs Ltd (California).
Pellicon device was purchased from Millipore (Massachusetts). Tris-HC1 was obtained from ICN. MES ((2-[N-Morpholino]ethanesulfonic acid) hydrate)was obtained from Sigma. Swine anti-rabbit IgG alkaline-phosphatase conjugates was purchased from DAKO (Denmark). Pichia Pastoris expression Kit version G was from Invitrogen(Carlsbad, California). Non-Radioactive High Prime DIG labeling kit~ was purchased from Boehringer Mannheim (Indianapolis, Indiana). The MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assays were performed using Cell Titer Aqueous Non radioactive cell proliferation assay kit from Promega (Madison, Wisconsin). MRX microtiter plate reader was from Dynex technologies (Chantillly, Virginia). Rabbit polyclonal antiserum against PSP94 was a gift from the late Dr. A. Sheth. All primers were synthesized by Procyon B:iopharma Inc. London, Ontario, Canada.
Cell line and cell culture P. pastoris host strain GS115 (hiss) and all Pichia related products were obtained from Invitrogen. PC-3 (ATCC-# CRL 1435) cell line was obtained from the American Type Cell Culture (ATCC) and maintained in OPTI MEM (minimum essential media) with 10 o fetal bovine serum (FBS). All cell culture products were obtained from GIBCO BRL.
Cloning TA cloning vector (pCR TM 2.1) containing human PSP94 cDNA
including a 20 amino acid leader sequence described previously (Baijal-Gupta, M., et. al., J. Endocr:inol., 165:425-433, 2000) was used to amplify human PSP94 without its leader sequence using appropriate primers. The primers for the polymerase chain reaction (PCR) were designed to contain an EcoRI restriction sites at either end. The 5' primer used was 5'-GGG AAG AAT TCT CAT GCT ATT TCA TA-3' (SEQ ID NO: 7) and the 3' primer, 5'-TGG ATA TCT GCA GAA TTC GGC-3' (SEQ ID N0: 8). The +1 start site for PSP94 (at a Serine residue) has been underlined in the 5' primer described above.
The PCR included 1 cycle of 12 minutes at 94 °C, followed by 25 cycles of 1 minute at 94 °C, 1 minute at 55 °C, 1 minute at 72 °C and a final step of 1 cycle of 10 minutes at 72 °C. PCR amplification of the product was performed using BM ExpandTM High Fidelity PCR System.
The product was run on a 1.5 o agarose gel and the appropriate PCR
product was isolated using Pharmacia Sehphaglass Kit (Bandprep).
Subcloning of the PSF94 insert was performed in pPIC9 vector (Invitrogen). The EcoRI enzyme was used for the restriction digestion of both the plasmid and the PCR products (thus removing PSP94 signal sequence) followed by ligation and transformation, using DHSa cells. The isolated clones were selected for by ampicillin resistance and inserts were identified by restriction mappings. The constructs were sequenced (Robart's sequencing service, London, Ontario) to identify PSP94 insert with a correct sequence as well as proper orientation and reading frame.
Screening for Clones Expressing rHuPSP94 For Pichia pastoris transformation, the spheroplast method was used according to manufacturer's instructions (Invitrogen) using GS115 and KM71 yeast strains. Plasmid pPIC9 with or without the PSP94 insert were linearized using SalI restriction enzyme. Transformed colonies were screened and selected for their ability to produce their own histidine, hence survived on media without histidine. All GS115 transformants scored as Mut+, whereas all KM71 colonies, which did not grow well in the liquid culture, scored as Muts. Hence a number of GS115 clones were screened for production of the highest levels of rHuPSP94 expression.
About a hundred clones were selected and grown into 2 ml of culture media until an optical density at 600 nm (OD600) of approximately 6 was reached. Total DNA was isolated for rapid dot blot analysis in order to detect multiple integrations by Southern blot that would possibly correspond to high rHuPSP94 expressing clones. Two hundred microliters of each culture specimens were denatured and blotted (in duplicate) to a positively charged nylon membrane, placed in a dot blot apparatus. The membrane was subsequently air-dried. The membrane was soaked between two sheets of Whatman 3MM paper for 15 minutes in a solution containing 50mM
ethylenediaminetetraacetic acid(EDTA), 2.5 % beta-mercaptoethanol (BME), pH 9, followed by an incubation of 24 hours at 37 °C with 1 mg/ml Zymolyase 100T, 5 minutes in O.:L N NaOH, 1.5 M NaCl, 0.015 M
sodium citrate pH 7 and two 5 minutes incubation in 2x saline-sodium citrate (SSC). Finally the membrane was baked at 80 °C for 45 minutes and exposed to ultraviolet light (UV) for 15 minutes. Human PSP94 cDNA probe was labeled with the non-radioactive High Prime DIG
labeling kit~ (Boehringer Mannheim) and was used for hybridization.
Hybridization with digoxigenin labeled cDNA probe (25ng/Ltl) was done for 2 days at 42 °C in Sodium dodecyl sulfate(SDS) buffer (SDS 7 0 (w/v); formamide 50 ='', (v/v); 5 X SSC; 50 mM sodium phosphate, pH 7.0;
N-lauroyl-sarcosine 0.1 % (w/v)) and blocking reagent, CSPD~ 2 (w/v) (Boehringer Mannheim) was used as the chemi.luminescence substrate. All digoxigenin (DIG) labeling procedures were performed according to the manufacturer's instruction. Detection was performed using the Hyper film-ECL product (Amersham Life Science Inc.
Arlington Hts, Illinois).
The clone with the highest signal intensity was used for all flasks shaken cultures.
timization of the Expression of the Protein in Flask Shaken Cultures A clone containing the PSP94 construct was selected for high expression of the protein. Colony was grown in 25m1 of basal minimum growth media (BMG) until an OD600 between 2 and 6 was obtained. This clone was further amplified in Baffled Erlenmeyer flasks in a volume of 1 liter of BMG media until the OD600 reached approximately between 2.0 to 6Ø The culture was centrifuged for 15 minutes at 2500 X g and the pellet was collected. The induction phase (i.e., induction of expression of rHuPSP94) was carried out by inoculating the cell pellet in basal minimum media (BMM). Growth was performed in Baffled flasks for 6 days, as recommended by :Cnvitrogen. The volume of BMM
added varied according to the size of the pellet collected. Five milliliters of 100 °s methanol were added for each liter of culture.
This was performed each day, around the same time, to a final concentration of 0.1 °s of methanol. A plasmid without the PSP94 insert served as a negative control.
To determine the optimum time for harvesting rHuPSP94 secreted in the cell culture media, aliquots were taken every 24 hours for 6 days, starting from the first day of induction. Levels of rHuPSP94 protein expression were determined by measuring OD600 and by performing a 15 o SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) stained with Coomassie Brilliant. blue or by Western blot analysis using polyclonal antibody against PSP94.
Sample Preparation Culture supernatant of clone showing the highest rHuPSP94 expression, post-induction (e.g., after 96 hours), was centrifuged at 2500 X g for 20 minutes. The supernatant was filtered through a 0.8 um filter and concentrated approximately 10-fold using a Pellicon unit (Millipore). The filtered supernatant was dialyzed against 0.05 mM Tris-HCl buffer, pH 8.0, using a 3500 molecular weight cut-off membrane. An aliquot of the dialyzed supernatant was analyzed by SDS-PAGE and Western blot analysis and the rest was submitted to further purification.
Culture Conditions for Fermentation Fermentation was carried out at the Institute for Biological Sciences, National Research Council (NRC) (Ottawa, Ontario Canada), following manufacturer's instruction (Invitrogen). For example, a fermentation procedure was initiated by inoculating 7.5 liter of media with 625 ml of a starting culture. The growth phase was carried out for approximately 2 days :in BMG media until the OD600 reached approximately 0.5. The induction phase was initiated by the addition of methanol (100 %), according to the manufacturer's instructions (Invitrogen). The culture was harvested after 95 hours (i.e., after induction with methanol for 67 hours). The final volume of the culture was approximately 13.5 liters.
Sample Preparation from Fermentation Culture The large cell. mass was removed by centrifugation. The cell free media collected (9 liters) was further clarified using a 0.2 ~m filtration unit (Pellicon). The remaining 8.5 liters containing secreted rHuPSP94 was tested for protein expression and stored at -20 °C for further isolation and puri.fi_cation of the protein.
Protein Estimation The amount of rHuPSP94 protein secreted in the culture supernatant from the flask shaken and the fermentation process was obtained based on estimates of band intensities of samples compared to band intensities of a standard curve obtained by loading known quantities of pure lyophilized PSP94 on a SDS-PAGE. The initial estimate for rHuPSP94 at each step of purification was determined by OD at 280 nm. Quantification of total protein content at the final steps of purification was done by the BCA (bicinchoninic acid) method, using bovine serum albumin (BSA) as standard.
Lyophilization Samples of purified rHuPSP94 were dialyzed against deionized water using a 3000 molecular weight cut-off membrane and were lyophilized.
SDS-PAGE
SDS-PAGE was performed using acrylamide at a final concentration of 15 °, for the separating portion of the gel and acrylamide at a final. concentration o.f 5 °s for the stacking portion of the gel. The gel contained 0.1 °s SDS and was performed under reducing conditions. Broad-range molecular weight markers were used for the estimation of molecular weight of the protein. Proteins were stained with Coomassie Brilliant Blue R-250.
Western Blotting For immunoblotting, Mini Trans-Blot Electrophoretic Transfer Cell (Bio Rad) was used with Hi bond-C super membrane (Amersham) and 85mm blotting papers. Protein samples (0.4 ug) were loaded and separated on SDS-PAGE, as described earlier. Proteins were transferred to the membrane for 2 hours at 4 °C, using transfer buffer (25 mM Tris, 1.92 mM Glycine, pH 8.3 and 20 o methanol) and a transfer unit set at 200 milliamperes (mAmp). Membranes were blocked overnight by incubation in 2 0 (w/v) non-fat dry milk (skim milk) disolved in tris buffer saline (TBS: 500 mM NaCl, 20 mM Tris-HCl, pH
7.5) at room temp (RT). Membranes were washed three times with TBS
containing 0.02 0 (v/v) Tween-20 (this buffer is named TTBS).
Membranes were subsequently incubated for 2 hours at RT with anti-PSP94 antibody (1:2060 dilution) diluted in TTBS containing 2 o skim milk. Membranes were washed twice with TTBS (5 minutes each washing), and incubated at RT with a secondary antibody (i.e., swine anti-rabbit antibody HRP conjugated) (1:5000 dilution) diluted in TTBS. Membranes were washed twice with 0.02 o TTBS (5 minutes each washing). Blots were developed using the ECL detection system, according to manufacturer's instructions, using the Super Signal Substrate, and exposed to a Hyperfilm ECL from Amersham LS for 5 to 20 seconds. Pre-stained molecular weight markers were used for molecular weight estimation.
Purification of rHuPSP94 using DE52 Column Chromatography Following remc>val of P. pastoris cells from the fermentation culture, supernatant was concentrated approximately ten fold, dialyzed and subjected to anion exchange chromatography. A DE52 column having a bed volume of approximately 40 ml (2.5 cm internal diameter (id) X 8 cm height(h)) was equilibrated with 0.05 M Tris-HC1, pH 8.0 (equilibrating buffer). The sample (25 ml) containing 15 to 20 mg of rHuPSP94 protein was applied to the DE52 column at a flow rate of 1 ml/minute.
Impurities were removed from the column by washing it with 40 to 50 ml of the equilibrating buffer, and monitoring the absorbance at 280 nm. This step was followed by the addition of 100 to 150 ml of 0.05 M Tris-HC1, 1>H 6.5 to the column until the pH of the wash reached approximately 6.5. The column was further washed with 100 to 150 ml of 0.05 M MES-acetate buffer, pH 6.5, until the absorbance at 280nm approached zero. Finally rHuPSP94 was eluted from the column with 0.05 M MES-acetate buffer, pH 5Ø Peak fractions were characterized by absorbance at 280 nm, followed by SDS-PAGE and Western blot analysis as described above. Fractions with high absorbance at 280 nm values (0.5 to 1.8) were pooled and dialyzed against water or PBS for storage at -20 °C and/or lyophilization.
Amino acid Composition Amino acid analysis of the DE52 purified flask shaken culture and fermentation cultures was carried out. The Perkin Elmer Biosystems Derivatizer-Analysis system was used with Spheri-5 PTC C-18 5~ column and UV detection at OD254.
Mass Spectral analysis PSP94 derived polypeptides were synthesized, were found to be in accordance with the required specifications and were analyzed by Mass Spectral Analysis. Mass spectrometry analysis of polypeptide 7-21 (SEQ ID N0: 4), PCK3145 (SEQ ID N0: 5) and polypeptide 76-94 (SEQ
ID N0: 6) are represented in figures 1, 2 and 3 respectively.
Polypeptide samples were analyzed using the PerSeptive Biosystems (Framingham, MA), with Voyager-DE MALDI-TOF mass spectrometer using 337 nm light from a nitrogen laser. About 12 to 50 scans were averaged for each analysis.
Purified samples from the flask shaken culture and fermentation culture were analyzed using the PerSeptive Biosystems (Framingham, MA), with Voyager-DE MALDI:-TOF mass spectrometer using 337 nm light from a nitrogen laser. About 50 scans were averaged for each analysis. A sample from the native PSP94 was also analyzed under similar conditions for comparison.
IN-VITRO EFFECT OF rHuPSP94 ON PC-3 CELLS
(MTS ASSAY) The biological activity of the rHuPSP94 was determined by its growth inhibitory effect on human prostate cancer cells PC-3. Cell proliferation was monitored on PC-3 cells using the MTS/PMS
(phenazine methosulfate) kit (Promega), which primarily measures mitochondrial activity of live cells. The basic principle of this method involves the fact that the mitochondrial enzymes of the live cells metabolize the MTS/PMS dyes forming a brown colored precipitate which can be measured as optical density (OD) by absorption at 490 nm in a spectrophotometer. Therefore, the OD values are proportional to the number of living cells. In addition, monitoring of cell morphology was also performed. Cell morphology would be indicative of their health status. For example, viable cells would appear adherent and spread out whereas dead cells would be in suspension in the media and would appear granular and round.
Results of in vitro effect of rHuPSP94 on PC-3 cells measured by MTS assay are summarized in table 2, below. PC-3 cells (ATCC, Lot AT06) used in these experiments were at: a passage number lower or equal to 70 (n >_ 70). Cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~g/ml of bovine serum albumin (BSA) and 0.1 ~M FeS09. Peptide was diluted in the same media. Cells were continuously exposed to the polypeptides of the present invention for 72 hours without changing media. Native PSP94 or rHuPSP99 concentrated two fold were directly added to wells and diluted to 1X in order to minimize cell manipulation and avoid detachment.
The evaluation of growth inhibitory effect of rHuPSP94 on PC-3 cells indicated a substantial reduction in cell numbers (i.e., viability) ranging from 37 % to 57 % reduction at concentrations of 80 and 120 ~g/ml of rHuPSP94 respectively. This effect was observed in 3 out of 4 experiments (Table 2). Results of trypan blue exclusion test demonstrated a cell viability of 62 o at 80 ~g/ml.
ExperimentSample ~ Viability (control = 100 0 (~g/ml) no. 40 60 80 120 1 rHuPSP94 72 78 58 43 2 rHuPSP94 63 63 63 68 3 rHuPSP94 95 85 78 ND
4 rHuPSP94 100 52 62 60 5 rHuPSP94 100 98 90 52 Sample ~ Viability (control = 100 0 (~g/ml) rHuPSP94 98 84 78 70 55 rHuPSP94 92 95 80 71 59 rHuPSP94 89 69 79 68 65 IN-VITRO EFE'ECT OF rHuPSP94 ON PC-3 CELLS
([3H]-THYMIDINE UPTAKE ASSAY) The in vitro growth inhibition effect of rHuPSP94 was assessed using [3H]-Thymidine uptake assay. [3H]-Thymidine uptake assay involves [3H]-Thymidine incorporation into cellular DNA of actively proliferating cells. It measures the proliferative index of the cells versus the MTS assay, which quantifies the number of lived cells following treatment. Cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~tg/ml of bovine serum albumin (BSA) and 0.1 ~tM E'eS09. PC-3 cells were exposed to various concentrations of rHuPSP94 for 72 hours and during the final 16 hours of incubation cells were pulsed with 1 ~tCi of [3H]-Thymidine. The radioactivity in each well of the plate is counted by a beta-counter and is expressed as total counts per minutes (cpm).
Results of in vitro effect of rHuPSP94 on PC-3 cells using the ~[H]-Thymidine uptake assay are summarized in Table 3 and are expressed as percentage of radioactivity measured for treated-cells relative to the radioactivity measured for non-treated cells (for which [3H]-thymidine uptake value was set at 100 °).
Results indicated a 65 o reduction in the percentage of cells incorporating [3H]-thymidine following treatment with rHuPSP94 at a concentration of 80 ~g/ml for 72hrs, compared to the non-treated control. Results of a 65 ~ reduction _in [3H]-thymidine uptake may also be an indication of a 65 o reduction in cell. proliferation.
Comparison was performed between [3H]-Thymidine uptake assay and the MTS assay, in order to evaluate their relative sensitivity.
An additional plate was set aside for MTS assay and treated in parallel with the same lot (i.e., batch) of rHuPSP94 as the one used for the [3H]-thymidine uptake assay. Result obtained for the MTS
assay demonstrated a 35 % reduction in cell viability (65 % cells remaining viable) following treatment with rHuPSP94 at a concentration of 80 ~tg/ml, indicating that the [3H]-Thymidine uptake assay, which was able to measure a 65 °. reduction in cell proliferation, may be more sensitive than the MTS assay.
ExperimentSample 3[H]-Thymidine no. Uptake ($
of control) (~g~ml) 5 1.0 20 40 80 1 rHuPSP94 94 101 98 79 35 1 native PSP94 97 98 100 98 77 IN-VITRO EFFECT OF DECAPEPTIDE AND OTHER POLYPEPTIDE ON
The synthetic decapeptide (SEQ ID N0: 3) has been shown herein to mimic the biological activity of native PSP94 (nPSP94)(SEQ ID NO:
1) and therefore its effect on the PC-3 cells was studied in clonogenicity assay (colony formation). Cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~tg/ml of bovine serum albumin (BSA) and 0.1 ~M FeS09.
Clonogenicity was evaluated for PC-3 cells grown in the presence of various concentration of the decapeptide after 9 days of culture (Figure 4a). A parallel experiment was performed with various concentration of nPSP94 using the same experimental conditions (Figure 4b). Other experiments evaluating clonogenicity was performed with the decapeptide (Figure 5a) or nPSP94 (Figure 5b) after 21 days of culture as well as after 10 days of culture (Figure 6a: Decapeptide and figure 6b: nPSP94).
Referring to Figures 4 to 6, the decapeptide (SEQ ID N0: 3) had a similar inhibitory action as nPSP94 (SEQ ID NO: 1) on in-vitro PC-3 cells studied. Results indicated a 40 % decrease in colony number for cells incubated with the decapeptide (SEQ ID N0: 3) at a concentration of 1 ~g/ml. A decrease in colony number of up to 60 $
was observed for the decapeptide (SEQ ID N0: 3) at a concentration of 10 ~tg/ml.
DNA FRAGMENTATION ASSAY
Cell apoptosis result in DNA fragmentation can be evaluated by the presence of a DNA ladder visualized when DNA is run on a 1.2 °s agarose gel. DNA ladder assay (apoptosis assay) was performed following exposure of PC-3 to various concentrations of the polypeptides for 72 hours. The polypeptides that were used in this particular experiment are polypeptide 7-21 (SEQ ID NO: 4), polypeptide PCK3145 (SEQ ID N0: 5) and polypeptide 76-94 (SEQ ID N0:
6). Visualization of DNA isolated and run on 1.2 o agarose gel, demonstrated that every polypeptides tested induced a DNA laddering effect characteristic. of apoptosis. This effect was especially evident following treatment with PCK3145 (SEQ ID N0: 5), which is illustrated by figure 7. Lane 1 of the gel illustrated in figure 7 represents a lambda FiindIII digest standard. Lane 2 of the gel illustrated in figure 7 represents DNA laddering effect obtained for doxorubicin-treated cells. Lane 3 of the gel illustrated in figure 7 represents DNA laddering effect obtained for cells incubated with 40 ~g of nPSP94. Lane 4 of the gel illustrated in figure 7 represents DNA laddering effect obtained for cel:Ls incubated with 20 ~tg of nPSP94. Lane 5 of the gel illustrated in figure 7 represents DNA
laddering effect obtained for cells incubated with 22.5 ~M of PCK3145 (SEQ ID N0: 5). Lane 6 of the gel illustrated in figure 7 represents DNA laddering effect obtained for cells incubated with 45~M of PCK3145 (SEQ ID N0: 5).
APOPTOSIS ASSAY BY ELISA PLUS
The three polypeptides (SEQ ID N0: 4, SEQ ID NO: 5 and SEQ ID
NO 6) and native PSP94 used here as a positive control were tested in ELISA plus assay to measure cell death through apoptosis. Briefly, the ELISA plus assay is a sandwich enzyme immunoassay able to measure mono- and oligonucleosomes present in the cytoplasmic fraction of cell lysate using two antibodies, one directed against DNA and the other directed against histones. The apoptotic cell death is characterized by activation of endogenous endonucleases (e. g., calcium- and magnesium-dependant), which cleave double-stranded DNA
at the most accessible internucleosomal_ linker region, generating mono- and oligonucleosomes. The enrichment of mono- and oligonucleosomes in the cytoplasm of the apoptotic cells is due to the fact that DNA degradation occurs several hours before plasma membrane breakdown.
Four thousand cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~g/ml of bovine serum albumin (BSA) and 0.1 ~tM FeS09. The PC-3 cells were treated with various concentrations (22.5 ~M to 90 ~M) of polypeptides for 72 hours. Apoptosis assay was done as per manufacturer's instructions using the ApopTag kit (Boeringher Mannheim).
Results presented in figure 8, indicate a dose dependent increase in the apoptotic cell death effect was observed for every polypeptides used (SEQ ID N0: 4, SEQ ID N0: 5 and SEQ ID NO 6).
Polypeptide PCK3145 (SEQ ID N0: 5) was more potent than the other polypeptides at 90 ~M concentration (Figure 8).
(Figures 9 to 11) Biological activity of the polypeptides as set forth in SEQ ID
N0: 4, SEQ ID NO: 5 and SEQ ID NO 6 was determined by their growth inhibitory effect on human prostate cancer cells PC-3. Native PSP94, rHuPSP94, polypeptide 22-36 and PB111 polypeptide (scrambled polypeptide) were also included in this experiment as controls. Cell proliferation assay was performed on either PC-3 cells or normal fibroblasts (used here as control) using the MTS/PMS kit (Promega).
Four thousand cells (Figure 9 and 10) or three thousand (figure 11) cells were seeded in Costar 96 well cell culture flat bottom plates in RPMI supplemented media containing 50 ~g/ml of bovine serum albumin (BSA) and 0.1 ~M FeS09. In addition, monitoring of cell morphology was also ~>erformed.
Results of these experiments are shown in figures 9 to 11. No cell inhibitory effe<-:t was observed following incubation of fibroblasts with various polypeptide concentrations (from 10 to 90 ~tM) for 72 hours (Figure 9). However, a significant growth inhibition was observed for polypeptides as set forth in SEQ ID N0: 4 and SEQ ID N0: 6 and more importantly with polypeptide PCK3145 (SEQ
ID N0: 5) (Figure 10). Another experiment was performed using PCK3145 and polypeptide 22-36 at various concentrations on PC-3 cells, grown in OPTI-MEM media. In figures 9 to 1:1, the percentage of growth inhibition given for treated cells is evaluated relative to non-treated control cells for which a value of 100 % cell survival is given.
EXAMPLES 8 & 9 IN-VIVO EXPERIMENTS (Figures 12 & 13) Studies MLL-1 and MLL-2 were performed as follows; on day 0, male Copenhagen rats were injected subcutaneously with 5 x 105 Mat LyLu cells per rat. These cells were derived from cultures of Mat LyLu cell line grown in RPMI media containing 10 0 (v/v) of fetal calf serum in logarithmic phase of growth. Cells were harvested from the culture flasks by trypsinization, were centrifuged at 1200 rotation per minute (rpm) and washed three timed with Hanks balanced salt solution (HBSS). Following washing, cells were counted and adjusted to a concentration of 5 x 10'' cells/ml in HBSS. A 0.1 ml volume of tumor cell inoculum containing 5 x 105 cells was administered subcutaneously into the flank region of each rat. Three days after tumor cell implantation (i.e., inoculation), animals were treated daily by a subcutaneous injection of the desired polypeptide until day 13.
Experiments illustrated in figure 12 show the anti-tumor efficacy validation cf rHuPSP94 against Mat LyLu (MLL) tumor implanted in nude mice (Protocol based on S. Garde et al.; The Prostate, 22: 225-233, 1993).
For study MLL-1 (Figure 12), tumor-implanted nude mice were separated in different groups, each receiving various amount of rHuPSP94 or control reagents. The different groups used in these experiments are illustrated below. Each group contained 8 mice.
Group 1: Negative control: PBS subcutaneously (s. c.) Group 2: Positive control: Doxorubicin at 5mg/kg intraveanously (i.v.) single bolus on day 3 Group 3: rHuPSP94 at lltg/kg/day (s. c.) Group 4: rHuPSP94 at l0~tg/kg/day (s. c.) Group 5: rHuPSP94 at 100~g/kg/day (s.c.) A schematic of inoculation is illustrated below;
(Tumor cell implantation (T.C.I.), treatment (Tx), measurement (M), day (D)).
M M M M
D~0 ~3 L57 ~9 D11 D13 D14 T.C.I. Tx daily Tx Terminate Experiments illustrated in study MLL-2 show the anti-tumor efficacy validation of rHuPSP94 against Mat Ly Lu (MLL) tumor implanted in severe combined immunode.ficiency (SCID) mice (Protocol based on S. Garde et al.; The Prostate, 22: 225-233, 1993).
For study MLL-2 (figure 13), tumor-implanted Scid mice were separated in different groups each receiving various amounts of rHuPSP94 or control reagents. The different groups used in these experiments are illustrated below. Each group contained 8 mice.
Group 1: Negative control: PBS (s. c.) Group 2: Positive control: Doxorubicin at 5mg/kg i.v. single bolus on day 3 Group 3: rHuPSP94 at l~g/kg/day (s. c.) Group 4: rHuPSP94 at 10~g/kg/day (s. c.) Group 5: rHuPSP94 at 100~g/kg/day (s. o.) A schematic of inoculation is illustrated below;
(Tumor cell implantation (T.C.I.), treatment (Tx), measurement (M), day (D) ) .
M M M M
DO 3 ~7 D9 D11 D D
~ ~
T.C.I. Tx daily Tx Terminate Results of those two studies indicate a difference in tumor size and growth in Nude vs SCID mice. The tumors grew slower and were smaller in SLID mice, This may be due to some specific factors controlling tumor growth in this mouse strain. Results also show a significant tumor reduction in mice injected with Doxorubicin (positive control). For example, tumor weight reduction in Nude mice (study MLL-1) injected with Doxorubici.n was 48 % (p=0.006)(p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
Tumor weight reduction in SCID mice (study MLL-2) inoculated with Doxorubicin was 82 0 (p=0.002) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Results indicate also a significant tumor reduction in mice treated with rHuPSP94 at a concentration of 1 ~g/kg/day. For example, tumor weight reduction in Nude mice (study MLL-1) treated with rHuPSP94 at a concentration of 1 ~tg/kg/day was 26 % (p=0.042) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Tumor weight reduction in SLID
mice (study MLL-2) treated with rHuPSP94 at a concentration of 1 ~tg/kg/day was 65 0 (p=0.010) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
(Figure 14) PC-3 human prostate tumor was obtained from ATCC (ATCC
1435). PC-3 cells were grown in RPMI media containing 10 % (v/v) of fetal calf serum and were harvested in the logarithmic phase of growth by trypsinization. Cells were centrifuged at 1200 rotation per minute (rpm) and washed three timed with Hanks balanced salt solution (HBSS). Following washing, cells were counted and adjusted to a concentration of 1 x 10~~ cells/ml in HBSS. A 0.1 ml volume of tumor cell inoculum containing 1 x 106 cells was administered subcutaneously into the two opposite flank region of each Nude mouse (Nu/Nu, BALB/c background). Tumor growth was monitored for approximately 18 days. Once tumor growth has been established (volume of tumor reached a volume of 50 mm3) treatment with rHuPSP94 (SEQ ID N0: 2) was initiated and was performed once a day for 14 days by the subcutaneous route. Based on the assigned treatment groups illustrated in table 4.
Treatment Test controlDose Level Dose No. of group articles (~g/kg/day) concentrationanimal (wg/mg) 1 Negative PBS 0 0 8 control 2 Positive Doxorubicin 5000 2500 8 control 3 rHuPSP94 1 0.5 8 4 rHuPSP94 10 5 8 5 rHuPSP94 100 50 8 6 rHuPSP94 1000 ( 500 ~ 8 ~
Results of this experiment (Figure 14) demonstrated tumor growth reduction in the group of mice treated with rHuPSP94 at a dosage level of 1 ~g/kg body weight per day. This reduction was similar to that observed for Doxorubicin (given at 5 mg/kg/day) which is a chemotherapeutic agent used as reference gold standard.
(Figures 15-17) PC-3 human prostate tumor (ATCC 1435) obtained from ATCC was implanted bilateraly into nude mice and tumor growth was monitored for approximately 18 days. PC-3 cells were injected once subcutaneously into each flank of the mice. Once tumor growth has been established (i.e., volume of tumor reached 0.25 to 0.50 cm~) the treatment with decapeptide (SEQ ID NO: 3), native PSP94 (SEQ ID
N0: 1) and control scrambled polypept:ide PB111 was initiated and was performed once a day for 14 days by the subcutaneous route based on the treatment groups (randomly assigned) illustrated in table 5.
Treatment Test and control Dose Level Dose No. of groups articles (~g/kg/day)concentrationanimal (~g/mg) 1(NegativePBS 0 0 4 control) 3 Decapeptide 1 0.5 4 (SEQ ID N0: 3) 4 Decapeptide 10 5 4 (SEQ ID N0: 3) Decapeptide 100 50 4 (SEQ ID N0: 3) 6 Decapeptide 1000 500 4 (SEQ ID NO: 3) 7 Native PSP94 1 0.5 4 (SEQ ID N0: 1) 8 Native PSP94 10 5 4 (SEQ ID N0: 1) Native PSP94 100 50 4 (SEQ ID N0: 1) 11 Native PSP94 1000 500 4 (SEQ ID NO: 1) 12 Scrambled 1 0.5 4 polypeptide(PB111) 13 Scrambled 10 5 4 polypeptide(PB111) 14 Scrambled 100 50 4 polypeptide(PB111) Scrambled ~ 1000 500 4 polypeptide(PB111) Figure 15 represents results obtained for tumor-implanted nude 5 mice treated with the decapeptide (SEQ ID N0: 3) compared to a non-treated control. Figure 16 represents results obtained for tumor-implanted nude mice treated with scrambled polypeptide PB111 compared to a non-treated control. Figure 17 represents results obtained for tumor-implanted nude mice treated with native PSP94 (SEQ ID N0: 1) 10 compared to a non-treated control. Results of these experiments (Figures 15-17) indicate a significant (p<0.05) tumor growth reduction in mice treated with the decapeptide (SEQ ID N0: 3) at a dosage level of 10 ~g/kg body weight per day.
MANUFACTURING AND PREPARATION OF POLYPEPTIDES
PSP94 derived polypeptides including PCK3145 (SEQ ID N0: 5) were synthesized using the FMOC and BOC solid phase polypeptide synthesis method (Merrifield, B., Science, 232: 341-347, 1986).
Polypeptides were analyzed in order to determine their identity by Mass Spectral Analysis. Polypeptide samples were analyzed using the PerSeptive Biosystems (Framingham, MA), with Voyager-DE MALDI-TOF
mass spectrometer using 337 nm light from a nitrogen laser. About 50 scans were averaged for each analysis. A sample from the native PSP94 was also analyzed under similar conditions for comparison.
Polypeptides were weighed on a Mett.ler AE 163 micro-balance. The measurements were to nearest 0.1 mg. 'rhe polypeptides were reconstituted in 10 mM PBS pH 7.3 to <~ final concentration of 1 and 5 mg/ml. The polypeptides dissolved relatively well and were filter sterilized through a 0.2 ~M syringe filter. Aliquots of 2 ml/tube were made and stored at -80 °C.
The pH of the polypeptides was measured after reconstitution to ensure that possible differences in pH would not be a factor of variation. The pH values of each solution were taken at three concentrations: neat, 100 ~g/ml and 12.5 ~g/ml. The pH range was approximately from 7.0 to 7.5. This did not make a significant difference in the outcome of the test as cells survive very well within this pH range. To change the concentrations to molar values, the approximate volume of the 1 mg/ml stocks were diluted in PBS pH
7.3. All stocks were made to contain 450 ~M polypeptide solutions.
When fresh stocks of polypeptide were to be reconstituted, it was done directly to 450 ~M concentration in PBS pH 7.3.
After our initial screening and confirmation of the inhibitory activity of the polypeptide on the growth of the PC-3 cells, a GMP
manufactured polypeptide was tested. This polypeptide was weighed and dissolved in PBS and 2 mg/ml stock solution was prepared, sterile filtered through a 0,2 ~m syringe filter and stored at in -80 °C.
(MTS ASSAY (Figures 18-21)) PCK3145, manufactured as set forth in example 12, was evaluated as a lead candidate product in tumor growth inhibition.
The biological activity of PCK3145 was determined by its growth inhibitory effect on the human prostate cancer cell line PC-3 using the MTS/PMS kit (Promega). This assay measures the mitochondria) activity of the live cells. The basic principle of this method involves the fact that the mitochondria) enzymes of the live cells metabolize the MTS/PMS dyes forming a brown colored precipitate which can be measured as optical density (OD) by absorption at 490 nm in a spectrophotometer. 'Therefore, the OD values are proportional to the number of living cells.
In addition, a visual observation of the cells was also done to check the cell morphology, which could also be indicative of cell growth. The following conditions for MTS assay were used: PC-3 (ATCC, Lot AT06), passage number n >_ 70, cell line adapted to grow in serum-free OPTI-MEM and in RPMI supplemented with BSA (50 ~g/ml) and Ferrous Sulfate (0.1 ~tM), continuous exposure for up to 72 hours without changing media (i.e., adding PCK3145 at 2X concentration directly to wells and diluting it 1:2 to 1X to minimize cell manipulation and avoid detachment). As indicated in Figure 18, PCK3145 was assessed at the following concentrations: 12.5, 25, 50, 100, 200, 300 and 400 ~tg/ml on PC-3 cells (ATCC) grown in supplemented media. The MTS tests were repeated 5 times and a dose dependent inhibitory effect on the growth of PC-3 cells was consistently reproducible demonstrating approximately 40 s cell growth inhibition at the highest PCK3145 concentration of 400 ~g/ml.
With the availability of GMP (good manufacturing practice) grade polypeptide the MTS assays were repeated to check the reproducibility and cytotoxicity against PC-3 cells. In parallel PC-3 cells were also treated with the native PSP94 as a reference positive control and with no treatment (negative control, i.e., cont.). Figure 19 shows the results of the MTS assay where 4000 cells were seeded and exposed to PCK3145 (GMP grade) for 48 hours. A
30 o growth inhibitory effect was observed following treatment with PCK3145 at 500 ~tg/ml. This effect was increased to approximately 40 °s after 72 hours of exposure (Figure 20). In a repeat experiment a 48 hours exposure to the polypeptide at 500 ~g/ml resulted in only 20-22 o growth inhibition, however this effect increased to 30 o after 72 hours exposure (figure 21). Despite assay to assay variability reflected by the state of cell growth in vitro, polypeptide PCK3145 exhibited a significant cell growth inhibition.
[3H]-THYMIDINE UPTAKE ASSAY (Figures 22-24) [3H]-Thymidine uptake assay involves [3H]-Thymidine incorporation into cellular DNA of actively proliferating cells.
[3H]-Thymidine uptake assay measures the proliferative index of the cells versus the MTS assay, which quantifies the number of lived cells following treatment. The anti-proliferative effects of PCK3145 and two other synthetic polypeptides derived from the amino and carboxy terminus ends of PSP94 (SEQ ID N0: 4 and N0: 6, respectively) as well as the decapeptide (SEQ ID N0: 3) previously shown to mimic the biological action of native PSP94 were assessed in [H3]-Thymidine uptake assay on PC-3 cells. Two separate experiments were conducted with GMP-grade PCK3145.
As shown in the Figures 22 and 23, polypeptide PCK3145 exhibited a significant proliferation inhibition activity reflected in the percentage of [H3]-Thymidine uptake. In the first experiment, a reduction of nearly 40 o in [3H]-Thymidine uptake was observed at PCK3145 concentration of 200 ~tg/ml. In the second experiment, although a two fold higher concentration of the PCK3145 was used (i.e., 400 ~g/ml) only a 25 o inhibition was observed. Despite assay to assay variation the overall degree of proliferative inhibitory effect against PC-3 cell was markedly evident with the GMP grade material. Treatment of PC-3 cells with the native PSP94 used as a positive reference standard, exhibited a significant dose dependent reduction in cell proliferation with almost 50 o reduction in the [H3]-Thymidine uptake following 72 hours exposure (Figure 24).
(APOPTOSIS-Figure 25) Apoptosis of PC-3 cells, following a 72 hours exposure to PCK3145 at 500 ~g/ml concentration, was evaluated in supplemented media by DNA fragmentation assay. Doxorubicin was used as a reference positive control. Unt=reated cells and PCK3145-treated cells were harvested and the DNA was isolated. Isolated DNA was run on a 1.2 $
agarose gel containing Ethidium Bromide (EtBr). As shown in Figure 25 treatment of PC-3 cells with polypept_ide PKC3145 resulted in DNA
fragmentation evidenced by the ladder formation seen for fragmented DNA. Lane 1 of the gel illustrated in figure 25 represents the DNA
marker (100 base pair DNA ladder). Lane 2 of the gel illustrated in figure 25 represents a control of untreated PC-3 cells. Lane 3 of the gel illustrated in figure 25 represents DNA laddering effect observed for cells treated with doxorubicin at a concentration of 2 ~g/ml.
Lane 4 of the gel illustrated in figure 25 represents DNA laddering effect observed for cells treated with PCK3145 (SEQ ID N0: 5).
(Figures 26-27) Studies PC3-6 and PC3-12 (Figures 26 - 27) are consecutive group experiments designed to characterize the in vivo activity of PCK3145 in the human PC-3 prostate cancer nude mouse xenograft model and to explore relationships between dose, route and schedule of administration and the efficacy parameters of tumor growth (volume).
PC-3 cells harvested in mid-log phase were inoculated at 5 x 106 cells per mice via the subcutaneous route in the mice's back area. Tumors grown from this inoculum were excised at approximately day 32 to 35 post-tumor implantation (p.t.i) when tumor volume reached 200-300 mm3 (i.e., cu mm). The necrotic tissue was removed and the viable tumor mass cut into small pieces (approximately 1 to 3 mm3) were implanted SC in the flank region at two opposite sites of the mouse. Treatment with various concentrations of PCK3145 was initiated at day 3 post-tumor implantation (p.t.i) and was continued daily for 21 days. Subcutaneous injections were done below tumor growth sites. Intra-peritoneal injections were performed in the abdominal region. Intra-venous injections were performed via the lateral tail vein. 'Che experiment was terminated 24 hours after the last treatment. Tumor measurements were taken at Days 11, 14, 16, 18, 20, 22 and 24 post-tumor implantation (p.t.i). Tumor volumes were calculated according to formula (axb2 x 0.5), where a - is the length of the long diameter, and b-is the width of the perpendicular small diameter.
Study No: PC3-6 illustrates the efficacy of PCK3145, injected subcutaneously, in tumor growth retardation in Nude mice, which have received PC-3 implants. Mice were separated in different group each receiving various amounts of PCK3145 (SEQ ID N0: 5) or control reagents. The differernt groups used in these experiments are illustrated in table 6 below. Each group contained 10 mice.
Doxorubicin was administered as single bolus intra-venous injection on days 3 and 11 post-tumor implantation (p.t.i).
Treatment Test and Dose Level No. of No. of group cont=rol (~g/kg/day) animals tumors articles 1 Negative PBS 0 10 20 control 2 Positive Doxorubicin 10000 10 20 control 3 PCK3145 0.1 10 20 Results of this study (Figure 26) demonstrated a significant PC-3 tumor growth retardation following treatment with PCK3145 at 10 ~g/kg/day. This anti-tumor effect was evidenced by a statistically significant decrease in percentage of tumor growth observed at days 11, 14, 16, 18 , 21 and 24 after tumor implantation with respective p-values ranging from p=0.001 to 0.002, in comparison to the control PBS-treated group (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Doxorubicin, a potent chemotherapeutic agent, was used as reference gold standard and demonstrated a highly significant anti-tumor therapeutic effect. ANOVA analysis of variance, Dunnett's test, Kruskal-Wallis and Dunn's test analysis of data confirmed statistical significance of the observed anti-tumor effect.
Study No: PC3-12 illustrates the efficacy of PCK3145 in tumor growth retardation in Nude mice, which have received PC-3 implants.
Mice were separated in different group each receiving various amounts of PCK3145 (SEQ ID N0: 5) or control reagents. PCK3145 was injected either through intra-venous or intra-peritoneal route. The different groups used in these experiments are illustrated in table 7 below.
Each group contained 9 mice.
Treatment Test and Dose level No. of No. of groups control (~g/kg/day) animals tumors articles 1 Negative PBS 0 9 18 control Results of this experiment (Figure 27) demonstrated a significant tumor grc.>wth retardation following treatment with PCK3145 at 100 ~g/kg/day via the intra-venous route. This effect was statistically significant at days 13, 17 and 20 after tumor implantation when compared by Student's t-test (p-values were p=0.005, 0.025 and 0.011, respectively for each time-point) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). No significant anti-tumor effect was observed following PCK3145 treatment at the other dosage levels of 10, 500 and 1000 ~g/kg/day injected via the intra-venous route. However a trend towards significance was observed following treatment with 500 and 1000 ~g/kg/day doses of PCK3145. Treatment of mice with PCK3145 at 100 and 1000 ~g/kg/day administered via the intra-peritoneal route showed a similar tumor growth retardation trend with statistically less significant difference observed at day 13 p.t.i (p=0.056) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit) at the highest dose of 1000 ~g/kg/day (Figure 27).
During the course of experimentation using the human PC-3 prostate cancer nude mouse xenograft model, results obtained have suggested that subcutaneous PCK3145 injection of mice at a site (i.e., scruff of the neck) distant from tumor site, might not be efficacious enough and will unlikely may unlikely result in an anti-tumor effect, at least in the experimental conditions tested (doses S of PCK3145 tested: 10 ug/kg/day and 100 ug/kg/day). The use of the scruff of the neck as a subcutaneous injection site represents an optimal site for immune response induction rather than a route for therapeutic product administration and as such, selection of this site is expected to be a sub-optimal site for tumor efficacy evaluation.
IN VIVO EXPERIMENTS USING DUNNING RAT MAT LY LU PROSTATE CANCER
LINE
(Figures 28-30) Anti-tumor efficacy evaluation of PCK3145 against Mat Ly Lu (MLL) tumor implanted in Copenhagen rats was performed. (Protocol based on S. Garde et al.; The Prostate, 22: 225-233, 1993). Mat LyLu tumor cells were harvested in mid-log phase from the culture flasks by trypsinization, were centrifuged at 1200 rotation per minute (rpm) and washed three timed with Hanks balanced salt solution (HBSS).
Following washing, cells were counted and adjusted to a concentration of 5 x 106 cells/ml in HBSS. A 0.1 ml volume of tumor cell inoculum containing 5 x 105 cells was administered subcutaneously into the flank region of each rat. Treatment started at day 3 post-tumor implantation (p.t.i) by local subcutaneous injection (i.e., in the shaved back area just= below tumor implantation site) of various PCK3145 concentrations. This treatment was continued daily for 16 days. Experiments were terminated 24 hours after the last treatment.
Tumor measurements were taken at days 7, 9, 11, 14, 16 and 18. Tumor volumes are calculated according to formula (axb2 x 0.5), where a -is the length of the long diameter, b-width of the perpendicular small diameter. At day 19 tumors of individual rats were excised and weighed.
Study No: MLL-5 illustrates the efficacy of PCK3145 (SEQ ID N0:
5) compared with polypeptide 7-21 (SEQ ID N0: 4) and polypeptide 76-94 (SEQ ID NO: 6) in tumor growth retardation in Copenhagen rats, which have received Mat Ly Lu implants. Mice were separated in different groups, each receiving various amount of PCK3145 (SEQ ID
NO: 5) or control reagents. PCK3145 was injected through the _6g_ subcutaneous route. The different groups used in these experiments are illustrated in table 8 below. Each group contained 8 mice.
Treatment Test and Dose Level No. of No. of groups control. (~g/kg/day) animals tumors articles 1 Negative PBS 0 8 8 control 2 Polypeptide 10 8 8 3 Polypeptide 1 8 8 6 Polypeptide 10 8 8 7 Polypeptide 1 8 8 Results of this study (Figure 28) demonstrated a significant anti-tumor effect following administration of PCK3145 at 10 ~tg/kg/day. This was evidenced by a significant tumor volume reduction at days 11 (p=0.006), 13 (p=0.00001), 16 (p=0.002) and 18(p=0.004), post-tumor cell implantation compared to control PBS-treated group (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). No significant effect was detectable following PCK3145 treatment at 1 ~g/kg/day. It was of interest to note that the amino-terminus polypeptide 7-21 also demonstrated comparable anti-tumor effect, which was also observed in the PC-3 nude mouse xenograft model, indicating the possibility of an overlapping active site between the N-terminus and the central regions of the PSP94 protein. This was evidenced by a significant tumor volume reduction observed at day 13 (p=0.05), 16 (p=0.00005), and 18 (p=0.01) in mice treated with polypeptide 7-21) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
Study No: MLL-6 illustrates the efficacy of PCK3145 (SEQ ID NO:
5) in tumor growth retardation in Copenhagen rats, which have received Mat Ly Lu implants. Mice were separated in different group each receiving various amounts of PCK3145 (SEQ ID NO: 5) or control reagents. PCK3145 was injected through the subcutaneous route. The different groups used in these experiments are illustrated in table 9 below. Each group contained 8 mice. Doxorubicin was administered as single bolus via intra-venous injection on day 3 p.t.i.
Treatment Test and Dose level No. of No. of groups control (~tg/kg/day)animals tumors articles 1 (Negative PBS 0 8 8 control) 2 Doxorubicin 5000 8 8 5 Scrambled 10 8 8 polypeptide 6 Scrambled 100 8 8 polypeptide Results of this study (Figures 29 and 30) demonstrated a significant dose-dependent anti-tumor effect following administration of PCK3145 at 10 and 100 ~g/kg/day. This was evidenced by a significant tumor volume reduction (31 % over control) following PCK3145 treatment especially with 100 ~tg/kg/day at days 14, 16 and 18 post-tumor cell implantation (Figure 29). The p-value versus negative control-treated group (i.e., scrambled polypeptide (PB111)) was highly significant at p=0.0000062 (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). A moderate extent of growth retardation (marginal statistical significance at p=0.03 versus control PBS-treated group) was also observed following treatment with scrambled polypeptide at a concentration of 100 ~g/kg/day (Figure 29) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Doxorubicin treatment was highly significant resulting in over 80 o reduction in tumor volumes. This anti-tumor effect of PCK3145 at 100 ~g/kg/day was also reproduced following analysis of the tumor weights data. As shown in figure 30, (tumor weight data) a significant reduction in tumor weights (p=0.0003) was observed on day 18 p.t.i. (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). This represented a 34 o reduction in tumor mass, a 20 gram difference between the control (56.6 g) and PCK3:L45-treated at 100 ~g/kg/day group (37.2 g). This difference in tumor weights was also statistically significant when it was compared to the tumor weights of the control scrambled polypeptide-treated rats given the same dose of 100~g/kg/day (p=0.003) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit). Comparison of the scrambled polypeptide treated tumor weights with that of control PBS-untreated tumor weights was not statistically significant (p=0.06) (p values measured by unpaired Student's t-test at p<0.05 as cut-off limit).
In order to test for the efficacy of combination treatment, in tumor growth retardation, PCK3145 and taxotere (i.e., docetaxel) were co-administered in Nude mice previously inoculated with PC-3 tumor cells. Mice were separated in different groups each receiving PCK3145 alone or PCK3145 in combination with taxotere (administered by separate routes) or control reagent (i.e., PBS). In this experiment, the combination treatment was initiated against relatively large tumor burdens. Tumors were allowed to grow beyond the 50 to 60 mm3 size at which PCK3145 treatment usually becomes inefficient. PCK3145 was injected through intravenous route every other day for 28 days starting from day 1 when 50 to 60 mm3 size subcutaneous tumors were apparent. Taxotere was injected by intra-peritoneal route at a sub-optimal concentration of 2 mg/kg on days 4 and 11 after subcutaneous tumors were evident. The different groups used in this experiment are illustrated in table 10 below. Each group contained 11 mice.
Treatment Test and Dose level No. of No of tumors groups control. (~g/kg) animals articles 1. Negative PBS 0 11 11 control 2. Positive Taxotere 2000 11 11 control 3. PCK3145 100 11 11 4. PCK3145 + 100 + 11 11 taxotere 2000 Results of this experiment (Figure 31) demonstrate a significant tumor growth retardation following combination treatment of PCK3145 and taxotere. This effect is statistically significant at days 19 and 22 post-tumor cell inoculation when compared by Student's t-test (p=0.02 at day 19 and p=0.047 at day 22), (p-values are measured by unpaired Student's t-test at p<0.05 as a cut-off limit) and was markedly better than taxotere administered alone at the same dose of 2 mg/kg (suboptimal dose).
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: PROCYON BIOPHARMA INC.
(ii) TITLE OF INVENTION: PHARMACEUTICAL PREPARATIONS AND
METHODS E'OR INHIBITING TUMORS
(iii) NUMBER OF' SEQUENCES: 92 (iv) CORRESPONDENCE ADDRESS:
(A) ADRESSEE: BROULLETTE KOSIE
(B) STREET: 1100 RENE-LESVEQUE BLVD WEST
(C) PROV/STATE: QUEBEC
(D) COUNTRY: CANADA
(E) POSTAL/ZIP CODE: H3B 5C9 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: FLOPPY DISK
(B) COMPUTER: IBM PC COMPATIBLE
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (TEXT) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 2,321,256 (B) FILING DATE: 2000-10-16 (C) CLASSIFICATION: A61K-38/17 (A) APPLICATION NUMBER: 2,355,334 (B) FILING DATE: 2001-08-20 (viii)ATTORNEY/PATENT AGENT INFORMATION:
(A) NAME: BROULLETTE KOSIE
(B) REGISTRATION NO.: 3939 (C) REFERENCE/DOCKET NO.:
(D) TEL. NO.: (514) 397 8500 (E) FAX NO.: (514) 397 8515 (2) INFORMATION FOR SEQ ID N0: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(iii)HYPOTHETICAL:
(iv)ANTI-SENSE:
(v) FRAGMENT TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(vii)IMMEDIATE SOURCE:
(viii)POSITION IN GENOME
(A) CHROMOSOME/SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMATION:
(x) PUBLICATION INFORMATION:
(A) AUTHORS:
(B) TITLE:
(C) JOURNAL:
(D) VOLUME:
(E) ISSUE:
(F) PAGES:
(G) DATE:
(H) DOCUMENT NO.:
(I;I FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES IN SEQ ID N0:1:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: l:
Ser Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys H:is Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys 35 Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile (2) INFORMATION FOR SEQ ID N0: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 102 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Glu Ala Glu Ala Tyr Val Glu Phe Ser Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile (2) INFORMATION FOR SEQ ID N0: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 3:
Tyr Thr Cys Ser Val Ser Glu Pro Gly Ile (2) INFORMATION FOR SEQ ID N0: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 4:
Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu (2) INFORMATION FOR SEQ ID N0: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (2) INFORMATION FOR SEQ ID N0: 6:
(i) SEQLJENCE CHARACTERISTICS:
(A) LENGTH: 19 AMINO ACIDS
(B) TYPE: AMINO ACIDS
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: PROTEIN
(vi)ORIGI:NAL SOURCE:
(A) ORGANISM:
(xi) SEQLJENCE DESCRIPTION: SEQ ID N0: 6:
Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile (2) INFORMATION FOR SEQ ID N0: 7:
(i) SEQL.1ENCE CHARACTERISTICS:
(A) LENGTH: 26 (B) TYPE: NUCLEOTIDES
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'.ULE TYPE : DNA
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 7:
(2) INFORMATION FOR SEQ ID N0: 8:
(i) SEQCJENCE CHARACTERISTICS:
(A) LENGTH: 21 (B) TYPE: NUCLEOTIDES
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE: DNA
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 8:
2) INFORMATION FOR SEQ ID N0: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: P85r (B) TYPE: NUCLEOTIDES
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
TCATGCTATT TCATACCTA~1 TGAGGGAGTT CCAGGAGATT CAACCAGGAA ATGCATGGAT 60 AAAGACAACT GCCAAAGAA'I' CTTCAAGAAG GAGGACTGCA AGTATATCGT GGTGGAGAAG 240 AAGGACCCAA AAAAGACCTC~ TTCTGTCAGT GAATGGATAA TCTAA 285 2) INFORMATION FOR SEQ ID N0: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'LJLE TYPE
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQCJENCE DESCRIPTION: SEQ ID NO: 10:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu 1 ' 5 10 15 2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGLNAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 11:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile 2) INFORMATION FOR SEQ ID N0: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
_77_ (A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 12:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser 2) INFORMATION FOR SEQ ID N0: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC',ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQL)ENCE DESCRIPTION: SEQ ID N0: 13:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys 2) INFORMATION FOR SEQ ID N0: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 14:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys 2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 (B) TYPE: AMINO ACID
55 (C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
60 (A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
_78_ Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr 2) INFORMATION FOR SEQ ID N0: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC',ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu 2) INFORMATION FOR SEQ ID N0: 17:
(i) SEQCIENCE CHARACTERISTICS:
(A) LENGTH: 23 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC;ULE TYPE:
(vi)ORIG:INAL SOURCE:
(A) ORGANISM:
(xi) SEQCIENCE DESCRIPTION: SEQ ID N0: 17:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val 2) INFORMATION FOR SEQ ID N0: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser 2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQL7ENCE CHARACTERISTICS:
(A) LENGTH: 25 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLE(:ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 19:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr 2) INFORMATION FOR SEQ ID N0: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC"ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 20:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr P:ro 2) INFORMATION FOR SEQ ID N0: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC.ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 21:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val 2) INFORMATION FOR SEQ ID N0: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 22:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly 2) INFORMATION FOR SEQ ID N0: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( i i ) MOLECULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCIENCE DESCRIPTION: SEQ ID N0: 23:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val. Ser Thr Pro Val Gly Tyr 2) INFORMATION FOR SEQ ID N0: 24:
(i) SEQCJENCE CHARACTERISTICS:
(A) LENGTH: 30 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC:ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCJENCE DESCRIPTION: SEQ ID NO: 24:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp 2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQCIENCE CHARACTERISTTCS:
(A) LENGTH: 31 (Bl TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D1 TOPOLOGY: LINEAR
(ii)MOLE(:ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val. Ser Thr Pro Val Gly Tyr Asp Lys 20 2) INFORMATION FOR SEQ ID N0: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLE(:ULE T~'PE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 26:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp 2) INFORMATION FOR SF;Q ID N0: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'.ULE TYPE
(vi)ORIGI:NAL SOURCE:
(A) ORGANISM:
(xi) SEQTTENCE DESCRIPTION: SEQ ID NO: 27:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn 2) INFORMATION FOR SEQ ID N0: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 2) INFORMATION FOR SEQ ID N0 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 28:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly 'I'yr Asp Lys Asp Asn Cys 2) INFORMATION FOR SEQ ID NO: 29:
20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(Dj TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys ~Pyr Glu Thr Glu Ile Ser Cys Cys Thr I~eu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln 2) INFORMATION )~OR SEQ ID N0: 30:
(i) SEQCJENCE CHARACTERISTICS:
(A) LENGTH: 36 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( i i ) MOLEC'.ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg 2) INFORMATION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 31:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile 2) INFORMATION
FOR
SEQ
ID
N0:
32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 25 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
30 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: ID N0: 32:
SEQ
GluTrp Thr Asp Asn Cys Glu Thr Cys Tyr Glu Thr Gln Cys Thr Glu IleSer Cys Thr Leu Val Ser Thr Gly Tyr Asp Lys Cys Pro Val Asp AsnCys Arg Ile Phe Gln 2) INFORMATION
FOR
SEQ
ID
N0:
33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: ID N0: 33:
SEQ
GluTrp Thr Asp Asn Cys Glu Thr Cys Tyr Glu Thr Gln Cys Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys 2) INFORMATION FOR SEQ ID N0: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pr_o Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys 2) INFORMATION FOR SEQ ID N0: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu 2) INFORMATION FOR SEQ ID N0: 36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 36:
(A) LENGTH: 37 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 31:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile 2) INFORMATION
FOR
SEQ
ID
N0:
32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 25 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
30 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: ID N0: 32:
SEQ
GluTrp Thr Asp Asn Cys Glu Thr Cys Tyr Glu Thr Gln Cys Thr Glu IleSer Cys Thr Leu Val Ser Thr Gly Tyr Asp Lys Cys Pro Val Asp AsnCys Arg Ile Phe Gln 2) INFORMATION
FOR
SEQ
ID
N0:
33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: ID N0: 33:
SEQ
GluTrp Thr Asp Asn Cys Glu Thr Cys Tyr Glu Thr Gln Cys Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys 2) INFORMATION FOR SEQ ID N0: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pr_o Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys 2) INFORMATION FOR SEQ ID N0: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu 2) INFORMATION FOR SEQ ID N0: 36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 36:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp 2) INFORMATION FOR SEQ ID N0: 37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 37:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys 2) INFORMATION FOR SEQ ID N0: 38:
35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 38:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys 2) INFORMATION FOR SEQ ID N0: 39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 37:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys 2) INFORMATION FOR SEQ ID N0: 38:
35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 38:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys 2) INFORMATION FOR SEQ ID N0: 39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC:ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 39:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr P:ro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr 2) INFORMATION FOR SEQ ID N0: 40:
(i) SEQUENCE CHARACTERISTICS:
20 (A) LENGTH: 46 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 40:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile 2) INFORMATION FOR SEQ ID N0: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 41:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val 2) INFORMATION FOR SEQ ID N0: 42:
_87_ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val 2) INFORMATION FOR SE;Q ID N0: 43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQLJENCE DESCRIPTION: SEQ ID NO: 43:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu 2) INFORMATION FOR SEQ ID N0: 44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 44:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu _88_ Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys 2) INFORMATION FOR SEQ ID N0: 45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 15 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
20 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 45:
25 Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys 2) INFORMATION FOR SEQ ID N0: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 52 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 46:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp 2) INFORMATION
FOR
SEQ
ID
N0:
47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 53 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LIN EAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: ID N0:
SEQ 47:
Glu Trp Thr Asp Asn Cys Cys Cys Tyr Thr Gln Glu Thr Thr Glu Glu Ile Ser Cys Thr Leu Val Pro Gly Tyr Lys Cys Ser Thr Val Asp Asp Asn Cys Arg Ile Phe Lys Asp Lys Tyr Val Gln Lys Glu Cys Ile Val Glu Lys Lys Asp Pro 2) INFORMATION FOR SEQ ID N0: 48:
(i) SEQUENCE CHARACTERIS'CICS:
(A) LENGTH: 54 (B) TYPE: AMINO ACID
30 (C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
35 (A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 48:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys 2) INFORMATION FOR SEQ ID NO: 49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 49:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro L~ys Lys 2) INFORMATION FOR SEQ ID N0: 50:
(i) SEQLiENCE CHARACTERISTICS:
(A) LENGTH: 56 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 50:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr 2) INFORMATION FOR SEQ ID N0: 51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 51:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys 2) INFORMATION FOR SEQ ID N0: 52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 52:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser 2) INFORMATION FOR SEQ ID N0: 53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 59 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu 1 5 lU 15 Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro hys Lys Thr Cys Ser Val 2) INFORMATION FOR SEQ ID N0: 54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'.ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr P:ro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro hys Lys Thr Cys Ser Val Ser 2) INFORMATION FOR SEQ ID N0: 55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 61 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 55:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pr_o Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu 50 2) INFORMATION FOR SEQ ID NO: 56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 56:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile the Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro hys Lys Thr Cys Ser Val Ser Glu Trp 2) INFORMATION FOR SEQ ID N0: 57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 (B) TYPE: AMINO AC;ID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC;ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 57:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu 1 5 11) 15 Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile 2) INFORMATION FOR SEQ ID N0: 58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 (Bj TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile 2) INFORMATION FOR SEQ ID N0: 59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 59:
Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr C',ys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 60:
Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 61:
Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr 1 5 1C) 15 Glu Thr 2) INFORMATION FOR SEQ ID N0: 62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'.ULE TYPE:
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 62:
Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID NO: 63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAL
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 63:
His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 64:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 45 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAL
(ii)MOLECULE TYPE:
50 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:
55 Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGI:NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 65:
Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu I'hr 2) INFORMATION FOR SEQ ID NO: 66:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 66:
Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 67:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:
Lys Gly Asn Lys His Pro Ile Asn Ser Gl.u Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID NO: 68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEO'ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 68:
Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 69:
(i) SEQUENCE CHARACTERIS'rICS:
(A) LENGTH: 26 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC.'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 69:
Asp Leu Lys Gly Asn hys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 70:
Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 71:
Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 20 2) INFORMATION FOR SEQ ID N0: 72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQL7ENCE DESCRIPTION: SEQ ID N0: 72:
Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 73:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 73:
Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 74:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( i i ) MOLECULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 74:
Thr Arg Lys Cys Met Rsp Leu Lys Gly Asn Lys His L?ro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SE;Q ID NO: 75:
20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 75:
Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 76:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:
Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 77:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC:LJLE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 77:
Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:
Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:
Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCJENCE DESCRIPTION: SEQ ID NO: 80:
Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 25 2) INFORMATION FOR SEQ ID N0: 81:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
30 (D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:
Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 50 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
55 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:
60 Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SF;Q ID N0: 83:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC;ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 83:
Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser G:Lu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys !'yr Glu Thr 2) INFORMATION FOR SEQ ID NO: 84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 84:
Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID NO: 85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 85:
Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn hys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 86:
Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 87:
Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 (C) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCIENCE DESCRIPTION: SEQ ID N0: 88:
Ser Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu L,ys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION
FOR SEQ ID
N0: 89:
(i) SEQUENCE CHARACTERIS'PICS:
(A) LENGTH: 15 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE
TYPE:
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 1 (D) OTHER INFORMATION : The residuen this i position is either glutamic acid,asparagine, or aspartic acid.
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 4 (D)OTHER INFORMATION : The residuethis position in is either threonine, or serine.
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 6 (D)OTHER INFORMATION : The residuethis position in is either glutamic acid, asparagine,or aspartic acid.
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 8 (D)OTHER INFORMATION : The residuethis position in is either glutamic acid, asparagine,or aspartic acid.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 9 (D)OTHER INFORMATION : The residuethis position in is either threonine, or serine.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 11 (D)OTHER INFORMATION : The residuethis position in is either threonine, or serine.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 13 (D)OTHER INFORMATION : The residue in this position is either tyrosine, or phenylalanine.
(ix) FEA'PURE
(A)NAME/KEY : Modified site (B)LOCATION : 14 (D)OTHER INFORMATION : The residue in this position is either glutamic acid, asparagine, or aspartic acid.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 15 (D)OTHER INFORMATION : The residue in this position is either threonine, or serine.
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 89:
Xaa Trp Gln Xaa Asp Xaa Cys Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa 2) INFORMATION FOR SEQ ID N0: 90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 90:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 92:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 39:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr P:ro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr 2) INFORMATION FOR SEQ ID N0: 40:
(i) SEQUENCE CHARACTERISTICS:
20 (A) LENGTH: 46 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 40:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile 2) INFORMATION FOR SEQ ID N0: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 41:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val 2) INFORMATION FOR SEQ ID N0: 42:
_87_ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val 2) INFORMATION FOR SE;Q ID N0: 43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQLJENCE DESCRIPTION: SEQ ID NO: 43:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu 2) INFORMATION FOR SEQ ID N0: 44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 44:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu _88_ Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys 2) INFORMATION FOR SEQ ID N0: 45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 15 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
20 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 45:
25 Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys 2) INFORMATION FOR SEQ ID N0: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 52 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 46:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp 2) INFORMATION
FOR
SEQ
ID
N0:
47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 53 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LIN EAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: ID N0:
SEQ 47:
Glu Trp Thr Asp Asn Cys Cys Cys Tyr Thr Gln Glu Thr Thr Glu Glu Ile Ser Cys Thr Leu Val Pro Gly Tyr Lys Cys Ser Thr Val Asp Asp Asn Cys Arg Ile Phe Lys Asp Lys Tyr Val Gln Lys Glu Cys Ile Val Glu Lys Lys Asp Pro 2) INFORMATION FOR SEQ ID N0: 48:
(i) SEQUENCE CHARACTERIS'CICS:
(A) LENGTH: 54 (B) TYPE: AMINO ACID
30 (C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
35 (A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 48:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys 2) INFORMATION FOR SEQ ID NO: 49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 49:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro L~ys Lys 2) INFORMATION FOR SEQ ID N0: 50:
(i) SEQLiENCE CHARACTERISTICS:
(A) LENGTH: 56 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 50:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr 2) INFORMATION FOR SEQ ID N0: 51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 51:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys 2) INFORMATION FOR SEQ ID N0: 52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 52:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser 2) INFORMATION FOR SEQ ID N0: 53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 59 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu 1 5 lU 15 Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro hys Lys Thr Cys Ser Val 2) INFORMATION FOR SEQ ID N0: 54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'.ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr P:ro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro hys Lys Thr Cys Ser Val Ser 2) INFORMATION FOR SEQ ID N0: 55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 61 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 55:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pr_o Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu 50 2) INFORMATION FOR SEQ ID NO: 56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 56:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile the Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro hys Lys Thr Cys Ser Val Ser Glu Trp 2) INFORMATION FOR SEQ ID N0: 57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 (B) TYPE: AMINO AC;ID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC;ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 57:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu 1 5 11) 15 Ile Ser Cys Cys Thr heu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile 2) INFORMATION FOR SEQ ID N0: 58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 (Bj TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Ile Ser Cys Cys Thr Leu Val Ser Thr Pro Val Gly Tyr Asp Lys Asp Asn Cys Gln Arg Ile Phe Lys Lys Glu Asp Cys Lys Tyr Ile Val Val Glu Lys Lys Asp Pro Lys Lys Thr Cys Ser Val Ser Glu Trp Ile Ile 2) INFORMATION FOR SEQ ID N0: 59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 59:
Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr C',ys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 60:
Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 61:
Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr 1 5 1C) 15 Glu Thr 2) INFORMATION FOR SEQ ID N0: 62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'.ULE TYPE:
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 62:
Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID NO: 63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAL
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 63:
His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 64:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 45 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAL
(ii)MOLECULE TYPE:
50 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:
55 Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGI:NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 65:
Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu I'hr 2) INFORMATION FOR SEQ ID NO: 66:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIG1NAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 66:
Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 67:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:
Lys Gly Asn Lys His Pro Ile Asn Ser Gl.u Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID NO: 68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEO'ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 68:
Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 69:
(i) SEQUENCE CHARACTERIS'rICS:
(A) LENGTH: 26 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC.'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 69:
Asp Leu Lys Gly Asn hys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 70:
Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 71:
Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 20 2) INFORMATION FOR SEQ ID N0: 72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQL7ENCE DESCRIPTION: SEQ ID N0: 72:
Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 73:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 73:
Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 74:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( i i ) MOLECULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 74:
Thr Arg Lys Cys Met Rsp Leu Lys Gly Asn Lys His L?ro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SE;Q ID NO: 75:
20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 75:
Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 76:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:
Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 77:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC:LJLE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 77:
Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:
Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:
Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCJENCE DESCRIPTION: SEQ ID NO: 80:
Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 25 2) INFORMATION FOR SEQ ID N0: 81:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
30 (D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:
Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 50 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
55 (vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:
60 Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SF;Q ID N0: 83:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
( ii ) MOLEC;ULE TYPE
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 83:
Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser G:Lu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys !'yr Glu Thr 2) INFORMATION FOR SEQ ID NO: 84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 84:
Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID NO: 85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 85:
Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn hys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: S:LNGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 86:
Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 87:
Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu Lys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 (C) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQCIENCE DESCRIPTION: SEQ ID N0: 88:
Ser Cys Tyr Phe Ile Pro Asn Glu Gly Val Pro Gly Asp Ser Thr Arg Lys Cys Met Asp Leu L,ys Gly Asn Lys His Pro Ile Asn Ser Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION
FOR SEQ ID
N0: 89:
(i) SEQUENCE CHARACTERIS'PICS:
(A) LENGTH: 15 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLEC'ULE
TYPE:
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 1 (D) OTHER INFORMATION : The residuen this i position is either glutamic acid,asparagine, or aspartic acid.
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 4 (D)OTHER INFORMATION : The residuethis position in is either threonine, or serine.
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 6 (D)OTHER INFORMATION : The residuethis position in is either glutamic acid, asparagine,or aspartic acid.
(ix) FEATURE
(A) NAME/KEY : Modified site (B) LOCATION : 8 (D)OTHER INFORMATION : The residuethis position in is either glutamic acid, asparagine,or aspartic acid.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 9 (D)OTHER INFORMATION : The residuethis position in is either threonine, or serine.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 11 (D)OTHER INFORMATION : The residuethis position in is either threonine, or serine.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 13 (D)OTHER INFORMATION : The residue in this position is either tyrosine, or phenylalanine.
(ix) FEA'PURE
(A)NAME/KEY : Modified site (B)LOCATION : 14 (D)OTHER INFORMATION : The residue in this position is either glutamic acid, asparagine, or aspartic acid.
(ix) FEATURE
(A)NAME/KEY : Modified site (B)LOCATION : 15 (D)OTHER INFORMATION : The residue in this position is either threonine, or serine.
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 89:
Xaa Trp Gln Xaa Asp Xaa Cys Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa 2) INFORMATION FOR SEQ ID N0: 90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 90:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr 2) INFORMATION FOR SEQ ID N0: 92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR
(ii)MOLECULE TYPE:
(vi)ORIGINAL SOURCE:
(A) ORGANISM:
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 92:
Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr
Claims (95)
1. A polypeptide selected from the group consisting of the polypeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4, the polypeptide as set forth in SEQ ID NO:
5, and the polypeptide as set forth in SEQ ID NO: 6.
5, and the polypeptide as set forth in SEQ ID NO: 6.
2. A polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO:
5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ
ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, said polypeptide analog being capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ
ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, said polypeptide analog being capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
3. A polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO:
5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ
ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, said polypeptide analog being capable of inhibiting the growth of a tumor.
5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ
ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, said polypeptide analog being capable of inhibiting the growth of a tumor.
4. The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID
NO: 6 (polypeptide 76-94) and mixture(s) thereof, for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID
NO: 6 (polypeptide 76-94) and mixture(s) thereof, for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
5. The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID
NO: 6 (polypeptide 76-94) and mixture(s) thereof, for inhibiting the growth of a tumor.
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID
NO: 6 (polypeptide 76-94) and mixture(s) thereof, for inhibiting the growth of a tumor.
6. The use of rHufSP94 as set forth in SEQ ID NO: 2 according to claim 4 or 5 wherein rHuPSP94 is used in a dosage range from about 10 micrograms/kg/day to about 4 milligrams/kg/day.
7. The use of rHuPSP94 as set forth in SEQ ID NO: 2 according to claim 4 or 5 wherein rHuPSP94 is used in a dosage range from about 500 picograms/kg/day to about 1 milligram/kg/day.
8. The use of rHuPSP94 as set forth in SEQ ID NO: 2 according to claim 4 or 5 wherein rHuPSP94 is used in a dosage range from about 5 nanograms/kg/day to about 10 micrograms/kg/day.
9. The use of rHuPSP94 as set forth in SEQ ID NO: 2 according to claim 4 or 5 wherein rHuPSP94 is used in a dosage range from about 5 nanograms/kg/day to about 500 nanograms/kg/day.
10.The use of a polypeptide according to claim 4 or 5 wherein said polypeptide is selected from the group consisting of the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4, the polypeptide as set forth in SEQ
ID NO: 5, the polypeptide as set forth in SEQ ID NO: 6, and mixtures thereof wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
ID NO: 5, the polypeptide as set forth in SEQ ID NO: 6, and mixtures thereof wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
11. The use of a polypeptide according to claim 4 or 5 wherein said polypeptide is used with an anticancer drug
12. The use of a polypeptide according to claim 11 wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
13.The use of a polypeptide as in one of claims 4 or 5 wherein said polypeptide is used with a pharmaceutically acceptable carrier.
14.The use of a polypeptide according to claim 11 wherein said polypeptide is used with a pharmaceutically acceptable carrier.
15.The use of a polypeptide as in one of claims 4 or 5 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
16.The use of a polypeptide according to claim 11 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
17.The use of a polypeptide according to claim 13 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
18.The use of a polypeptide according to claim 14 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
19.The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO:
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selects ed from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selects ed from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
20. The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO:
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected ed from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to t:he amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 for inhibiting the growth of a tumor.
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected ed from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to t:he amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 for inhibiting the growth of a tumor.
21.The use of a polypeptide analog according to claim 19 or 20 wherein said polypeptide analog is used with an anticancer drug.
22.The use of a polypeptide analog according to claim 21, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
23.The use of a polypeptide analog according to claim 19 or 20 wherein said polypeptide analog is used with a pharmaceutically acceptable carrier.
24.The use of a polypeptide analog according to claim 21 wherein said polypeptide analog is used with a pharmaceutically acceptable carrier.
25.The use of a polypeptide analog according to claim 19 or 20, wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
26.The use of a polypeptide analog according to claim 21 wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
27.The use of a polypeptide analog according to claim 23 wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
28.The use of a polypeptide analog according to claim 24 wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
29.A method for treating a patient with prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID
NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 5 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94) and mixtures thereof.
NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 5 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94) and mixtures thereof.
30.A method for treating a patient with a tumor, the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94) and mixtures thereof.
31.The method according to claim 29 or 30 wherein rHuPSP94 (SEQ ID
NO: 2) is administered in a dosage range from about 10 micrograms/kg/day to about 4 milligrams/kg/day.
NO: 2) is administered in a dosage range from about 10 micrograms/kg/day to about 4 milligrams/kg/day.
32.The method according to claim 29 or 30 wherein rHuPSP94 (SEQ ID
NO: 2) is administered in a dosage range from about 25 picograms/kg/day to about 1 milligram/kg/day.
NO: 2) is administered in a dosage range from about 25 picograms/kg/day to about 1 milligram/kg/day.
33.The method according to claim 29 or 30 wherein human rHuPSP94 (SEQ ID NO: 2) is administered in a dosage range from about 5 nanograms/kg/day to about 10 micrograms/kg/day.
34.The method according to claim 29 or 30 wherein said polypeptide is selected from the group consisting of the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID
NO: 4, the polypeptide as set forth in SEQ ID NO: 5, the polypeptide as set forth in SEQ ID NO: 6, and mixtures thereof, wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
NO: 4, the polypeptide as set forth in SEQ ID NO: 5, the polypeptide as set forth in SEQ ID NO: 6, and mixtures thereof, wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
35.The method according to claim 29 or 30 wherein said polypeptide is used with an anticancer drug.
36.The method of claim 35 wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
37.The method according to claim 29 or 30 wherein said polypeptide is used with a pharmaceutically acceptable carrier.
38.The method according to claim 35 wherein said polypeptide is used with a pharmaceutically acceptable carrier.
39.The method according to claim 29 or 30 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
40.The method according to claim 35 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
41.The method according to claim 37 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
42.The method according to claim 38 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
43.A method for treating a patient with prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition including a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier.
44.A method for treating a patient with a tumor, the method comprising administering to the patient a pharmaceutical composition including a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier.
45.The method according to claim 43 or 44 wherein said vector is used with an anticancer drug.
46.The method according to claim 45, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
47.The method according to claim 43 or 44 wherein said vector is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said vector.
48.The method according to claim 45 wherein said vector is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said vector.
49.A method for treating a patient with prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition comprising a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID NO: 9, and a polynucleotide having at least 10 to 50 contiguous residues of SEQ ID NO: 9, and a pharmaceutically acceptable carrier.
50.A method for treating a patient with a tumor, the method comprising administering to the patient a pharmaceutical composition comprising a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID NO: 9, and a polynucleotide having at least= 10 to 50 contiguous residues of SEQ ID NO: 9, and a pharmaceutically acceptable carrier.
51. The method according to claim 49 or 50 wherein said polynucleotide is used with an anticancer drug.
52. The method according to claim 51, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
53. The method according to claim 49 or 50 wherein said polynucleotide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polynucleotide.
54.The method according to claim 51 wherein said polynucleotide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polynucleotide.
55.A method for treating a patient with prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO:
5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, said polypeptide analog being capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO:
5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, said polypeptide analog being capable of inhibiting the growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH).
56.A method for treating a patient with a tumor, the method comprising administering to the patient a pharmaceutical composition comprising a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ
ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID
NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ
ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least: 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, said polypeptide analog being capable of inhibiting the growth a tumor.
ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID
NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ
ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least: 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, said polypeptide analog being capable of inhibiting the growth a tumor.
57.The method according to claim 55 or 56 wherein said polypeptide analog is used with an anticancer drug.
58.The method according to claim 57, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
59.The method according to claim 55 or 56, wherein said polypeptide analog is used with a pharmaceutically acceptable carrier.
60.The method according to claim 57, wherein said polypeptide analog is used with a pharmaceutically acceptable carrier.
61. The method according to claim 55 or 56, wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
62.The method according to claim 57 wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
63. The method according to claim 59 wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
64. The method according to claim 60 wherein said polypeptide analog is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide analog.
65.A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:
a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (Polypeptide 76-94) and mixture(s) thereof, and;
b) an anticancer drug.
a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (Polypeptide 76-94) and mixture(s) thereof, and;
b) an anticancer drug.
66.A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:
a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (Polypeptide 76-94) and mixtures) thereof, and;
b) a pharmaceutically acceptable carrier.
a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (Polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (Polypeptide 76-94) and mixtures) thereof, and;
b) a pharmaceutically acceptable carrier.
67.A pharmaceutical composition comprising:
a) A polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94) and mixture(s) thereof in a therapeutically effective amount, and;
b) an anticancer drug in a therapeutically effective amount.
a) A polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94) and mixture(s) thereof in a therapeutically effective amount, and;
b) an anticancer drug in a therapeutically effective amount.
68.A pharmaceutical composition comprising:
a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94) and mixtures) thereof in a therapeutically effective amount, and;
b) a pharmaceutically acceptable carrier.
a) a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO: 6 (polypeptide 76-94) and mixtures) thereof in a therapeutically effective amount, and;
b) a pharmaceutically acceptable carrier.
69.A pharmaceutical composition as in one claim 65 to 68, wherein rHuPSP94 (SEQ ID NO: 2) is used in a dosage range from about 10 micrograms/kg/day to about 4 milligrams/kg/day.
70.A pharmaceutical composition as in one claim 65 to 68, wherein rHuPSP94 (SEQ ID NO: 2) is used in a dosage range from about 500 picograms/kg/day to about 1 milligram/kg/day.
71.A pharmaceutical composition as in one claim 65 to 68, wherein rHuPSP94 is used in a dosage range from about 5 nanograms/kg/day to about 10 micrograms/kg/day.
72.A pharmaceutical composition as in one claim 65 to 68, wherein rHuPSP94 is used in a dosage range from about 5 nanograms/kg/day to about 500 nanograms/kg/day.
73.A pharmaceutical composition as in one claim 65 to 68, wherein said polypeptide is selected from the group consisting of the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4, the polypeptide as set forth in SEQ
ID NO: 5, the polypeptide as set forth in SEQ ID NO:6 and mixture(s) thereof, wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
ID NO: 5, the polypeptide as set forth in SEQ ID NO:6 and mixture(s) thereof, wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
74.A pharmaceutical composition according to claim 66 or 68 further comprising an anticancer drug.
75.A pharmaceutical composition according to claim 65, 67 or 74 wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
76.A pharmaceutical composition as in one claim 65 to 68 or 74, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.
77.A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier.
78.A pharmaceutical composition for inhibiting the growth of a tumor in a patient, comprising a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier.
79.A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID NO: 9 and a polynucleotide having at least 10 to 50 contiguous residues of SEQ ID NO: 9, and a pharmaceutically acceptable carrier.
80.A pharmaceutical composition for inhibiting the growth of a tumor in a patient, comprising a polynucleotide selected from the group consisting of a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID NO: 9 and a polynucleotide having at least: 10 to 50 contiguous residues of SEQ ID NO: 9, and a pharmaceutically acceptable carrier.
81.A pharmaceutical composition as in one of claims 77-80 further comprising an anticancer drug.
82.A pharmaceutical composition according to claim 81 wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
83.A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO:
5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ
ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and mixture(s) thereof, and;
b) an anticancer drug.
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO:
5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ
ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and mixture(s) thereof, and;
b) an anticancer drug.
84.A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH), comprising:
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1, C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID
NO: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and mixture(s) thereof, and;
a) a pharmaceutically acceptable carrier.
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1, C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID
NO: 5 and having an addition of at least one amino acid to its amino-terminus wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and mixture(s) thereof, and;
a) a pharmaceutically acceptable carrier.
85.A pharmaceutical composition comprising:
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ
ID NO:5 is selected from the group consisting of SEQ ID
NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ
ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof in a therapeutically effective amount, and;
b) an anticancer drug in a therapeutically effective amount.
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ
ID NO:5 is selected from the group consisting of SEQ ID
NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ
ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof in a therapeutically effective amount, and;
b) an anticancer drug in a therapeutically effective amount.
86.A pharmaceutical composition comprising:
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID
NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof in a therapeutically effective amount, and;
b) a pharmaceutically acceptable carrier.
a) a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO:
89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID
NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID
NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof in a therapeutically effective amount, and;
b) a pharmaceutically acceptable carrier.
87. A pharmaceutical composition according to claim 84 or 86, further comprising an anticancer drug.
88.A pharmaceutical composition according to claim 83, 85 or 87 wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
89.A pharmaceutical composition as in one of claim 83 to 86, or 87 further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.
90.A method for treating patients with a disease characterized by elevated levels of FSH comprising administering a pharmaceutical composition in an appropriate dosage form, the pharmaceutical composition comprising a polypeptide selected from the group consisting of rHuPSP94 as set forth SEQ ID NO:
2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4, the polypeptide as set forth in SEQ ID NO: 5, and the polypeptide as set forth in SEQ ID NO: 6, and a pharmaceutically acceptable carrier.
2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4, the polypeptide as set forth in SEQ ID NO: 5, and the polypeptide as set forth in SEQ ID NO: 6, and a pharmaceutically acceptable carrier.
91.A method for treating patients with a disease characterized by elevated levels of FSH comprising administering a pharmaceutical composition in an appropriate dosage form, the pharmaceutical composition comprising a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO:
5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5 and mixture(s) thereof, and a pharmaceutically acceptable carrier, in a human dose.
NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO:
5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q X2 D X1 C X1 X2 C X2 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5 and mixture(s) thereof, and a pharmaceutically acceptable carrier, in a human dose.
92.The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID
NO: 6 (polypeptide 76-94) and mixtures) thereof, for treating patients with a disease characterized by elevated levels of FSH.
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), and the polypeptide as set forth in SEQ ID
NO: 6 (polypeptide 76-94) and mixtures) thereof, for treating patients with a disease characterized by elevated levels of FSH.
93.The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO:
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X3 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof, for treating patients with a disease characterized by elevated levels of FSH.
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X3 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2 is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof, for treating patients with a disease characterized by elevated levels of FSH.
94. The use of a polypeptide selected from the group consisting of rHuPSP94 as set forth in SEQ ID NO: 2, the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO:
6 (polypeptide 76-94) and mixtures thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.
NO: 4 (polypeptide 7-21), the polypeptide as set forth in SEQ
ID NO: 5 (PCK3145), the polypeptide as set forth in SEQ ID NO:
6 (polypeptide 76-94) and mixtures thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.
95. The use of a polypeptide analog selected from the group consisting of a polypeptide analog of at least five contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO: 3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog of at least two contiguous amino acids of SEQ ID NO: 2, of SEQ ID NO:
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X3 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2, is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.
3, of SEQ ID NO: 4, of SEQ ID NO: 5, or of SEQ ID NO: 6, a polypeptide analog consisting of the amino acid sequence X1 W Q
X2 D X1 C X1 X2 C X3 C X3 X1 X2 as set forth in SEQ ID NO: 89, wherein X1 is either glutamic acid (Glu), asparagine (Asn) or aspartic acid (Asp), X2, is either threonine (Thr) or serine (Ser), and X3 is either tyrosine (Tyr) or phenylalanine (Phe), a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its amino-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 59 to SEQ ID
NO: 88, a polypeptide analog comprising SEQ ID NO: 5 and having an addition of at least one amino acid to its carboxy-terminus, wherein said polypeptide analog comprising SEQ ID NO:5 is selected from the group consisting of SEQ ID NO: 10 to SEQ ID
NO: 58, a polypeptide analog comprising two to fifty units of SEQ ID NO: 5, a polypeptide analog comprising two to ten units of SEQ ID NO: 5, a polypeptide analog consisting of a sequence of from two to fourteen amino acid units wherein the amino acid units are selected from the group of amino acid units of SEQ ID
NO: 5 consisting of glutamic acid (Glu), tryptophan (Trp), glutamine (Gln), threonine (Thr), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), or tyrosine (Tyr), a polypeptide analog having at least 90 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ
ID NO: 5, a polypeptide analog having at least 70 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5, and a polypeptide analog having at least 50 % of its amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 5 and mixture(s) thereof for the manufacture of a medicament for the therapeutic treatment of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia (BPH) or a disease characterized by elevated levels of FSH.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2359650A CA2359650C (en) | 2000-10-16 | 2001-10-15 | Pharmaceutical preparations and methods for inhibiting tumors |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002321256A CA2321256A1 (en) | 2000-10-16 | 2000-10-16 | Pharmaceutical preparations and methods for inhibiting tumours |
CA2,321,256 | 2000-10-16 | ||
CA002355334A CA2355334A1 (en) | 2000-10-16 | 2001-08-20 | Pharmaceutical preparations and methods for inhibiting tumors |
CA2,355,334 | 2001-08-20 | ||
CA2359650A CA2359650C (en) | 2000-10-16 | 2001-10-15 | Pharmaceutical preparations and methods for inhibiting tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2359650A1 true CA2359650A1 (en) | 2002-04-16 |
CA2359650C CA2359650C (en) | 2013-02-12 |
Family
ID=27171367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2359650A Expired - Fee Related CA2359650C (en) | 2000-10-16 | 2001-10-15 | Pharmaceutical preparations and methods for inhibiting tumors |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2359650C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005033141A1 (en) * | 2003-09-26 | 2005-04-14 | Ambrilia Biopharma Inc. | Regulation of matrix metalloproteinases by psp94 family members |
-
2001
- 2001-10-15 CA CA2359650A patent/CA2359650C/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005033141A1 (en) * | 2003-09-26 | 2005-04-14 | Ambrilia Biopharma Inc. | Regulation of matrix metalloproteinases by psp94 family members |
Also Published As
Publication number | Publication date |
---|---|
CA2359650C (en) | 2013-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7655631B2 (en) | Pharmaceutical preparations and methods for inhibiting tumors | |
AU2002213691A1 (en) | Pharmaceutical preparations and methods for inhibiting tumors | |
KR101364374B1 (en) | Bioactive FUS1 peptides and nanoparticle-polypeptide complexes | |
JP5734865B2 (en) | Anti-cancer chimeric peptide with excellent selectivity | |
KR20040038982A (en) | Therapeutic agents comprising pro-apoptotic proteins | |
KR102606176B1 (en) | Atf5 peptide variants and uses thereof | |
JP7030934B2 (en) | Nanoparticle preparation | |
WO2005074521A2 (en) | C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF | |
JP2001520521A (en) | VP22 protein and uses thereof | |
Kadkhodayan et al. | Generation of GFP native protein for detection of its intracellular uptake by cell-penetrating peptides | |
CA2359650C (en) | Pharmaceutical preparations and methods for inhibiting tumors | |
US9238682B2 (en) | Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients | |
AU2007249137A1 (en) | Pharmaceutical preparations and methods for inhibiting tumors | |
HUT77263A (en) | Intracellular delivery of chemical agents to a specific cell type | |
ES2351783T3 (en) | PHARMACEUTICAL PREPARATIONS AND PROCEDURES FOR THE INHIBITION OF TUMORS. | |
KR102577502B1 (en) | Plasmid platform for stable expression and delivery of biomolecules | |
KR102504190B1 (en) | Cargo molecule transport domain RMMR1, variant thereof, recombinant cargo molecule containing thereof and cargo molecule transport method using the same | |
WO2023135264A1 (en) | Binding proteins specific for cd32a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20161017 |